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SUMMARY 
A large number of metabolic waste products accumulate in the blood of patients with renal 
failure. Since these solutes have deleterious effects on the biological functions, they are 
called uremic toxins and have been classified in three groups: 1) small water soluble solutes 
(MW < 500 Da), 2) small solutes with known protein binding (MW < 500 Da), and 3) middle 
molecules (500 Da < MW < 60 kDa). Protein bound uremic toxins are poorly removed by 
conventional hemodialysis treatments because of their high protein binding and high 
distribution volume. The prototypical protein bound uremic toxins indoxyl sulfate (IS) and p-
cresyl sulfate (pCS) are associated with the progression of chronic kidney disease, 
cardiovascular outcomes, and mortality of patients on maintenance hemodialysis. 
Furthermore, these two compounds are bound to albumin, the main plasma protein, via 
electrostatic and/or Van-der-Waals forces. The aim of the present thesis was to develop a 
dialysis strategy, based on the reversible modification of the ionic strength in the blood 
stream by increasing the sodium chloride (NaCl) concentration, in order to enhance the 
removal of protein bound substances, such as IS and pCS, with the ultimate goal to improve 
clinical patient outcomes. 
 
Enhancing the NaCl concentration ([NaCl]) in both human normal and uremic plasma was 
efficient to reduce the protein bound fraction of both IS and pCS by reducing their binding 
affinity to albumin. Increasing the ionic strength was feasible during modified pre-dilution 
hemodiafiltration (HDF) by increasing the [NaCl] in the substitution fluid. The NaCl excess 
was adequately removed within the hemodialyzer. This method was effective to increase the 
removal rate of both protein bound uremic toxins. Its ex vivo hemocompatibility, however, 
was limited by the osmotic shock induced by the high [NaCl] in the substituate. Therefore, 
modified pre-dilution HDF was further iterated by introducing a second serial cartridge, 
named the serial dialyzers (SDial) setup. This setting was validated for feasibility, 
hemocompatibility, and toxin removal efficiency. A better hemocompatibility at similar 
efficacy was obtained with the SDial setup compared with the modified pre-dilution HDF. 
Both methods were finally tested in an animal sheep model of dialysis to verify 
biocompatibility. Low hemolysis and no activation of both the complement and the 
coagulation systems were observed when increasing the [NaCl] in blood up to 0.45 and 0.60 
M with the modified pre-dilution HDF and the SDial setup, respectively. 
 
In conclusion, the two dialysis methods developed to transitory enhance the ionic strength 
in blood demonstrated adequate biocompatibility and improved the removal of protein 
bound uremic toxins by decreasing their protein bound fraction. The concepts require 
follow-on clinical trials to assess their in vivo efficacy and their impact on long-term clinical 
outcomes.  
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ZUSAMMENFASSUNG 
Eine große Zahl von Stoffwechselprodukten akkumuliert im Blut urämischer Patienten mit 
Nierenversagen. Da diese Moleküle schädliche Wirkungen auf die biologischen Funktionen 
haben, werden sie als Urämietoxine bezeichnet. Man teilt sie in drei Gruppen ein: 1) kleine 
wasserlösliche Substanzen (MG < 500 Da), 2) kleine, proteingebundene Substanzen (MG < 500 
Da), 3) Mittelmoleküle (500 Da < MG < 60 kDa). Proteingebundene Urämietoxine werden wegen 
ihrer starken Proteinbindung und ihres Verteilungsvolumen durch klassische 
Hämodialyseverfahrens nur schlecht entfernt. Die prototypischen proteingebundenen 
Urämietoxine Indoxylsulfat (IS) und p-Cresylsulfat (pCS) sind bei chronischen niereninsuffizienten 
Patienten mit dem Fortschreiten der Niereninsuffizienz, Herz-Kreislauf-Erkrankungen und der 
Mortalität verbunden. Außerdem sind diese beiden Toxine an Albumin, dem wichtigsten 
Plasmaprotein, durch elektrostatische und/oder Van-der-Waals-Kräfte gebunden. Das Ziel der 
vorliegenden Arbeit war es, ein Dialyseverfahren basierend auf einer reversiblen Modifikation 
der Ionenstärke im Blut durch Erhöhung der Natriumchlorid (NaCl)-Konzentration zu entwickeln, 
um die Entfernung von proteingebundenen Molekülen wie IS und pCS zu erhöhen und dadurch 
eine Verbesserung des klinischen Verlauf der Patienten zu erreichen. 
 
Die Erhöhung der NaCl-Konzentration ([NaCl]) sowohl in normalem als auch in urämischem 
menschlichem Plasma war geeignet, um den proteingebundenen Anteil von IS und pCS durch 
Schwächung ihrer Bindungsaffinität zu Albumin zu verringern. Die Erhöhung der Ionenstärke 
während einer modifizierten Prädilutions-Hämodiafiltration (HDF) konnte durch eine Erhöhung 
der [NaCl] in der Substitutionslösung umgesetzt werden; dabei wurde der NaCl-Überschuss 
innerhalb des Dialysators vollständig entfernt. Dieses Verfahren war effektiv, um die 
Entfernungsrate beider proteingebundenen Urämietoxine zu steigern; seine Ex-vivo-
Hämokompatibilität war allerdings aufgrund des osmotischen Schocks infolge der hohen [NaCl] 
im Substituat begrenzt. Deshalb wurde eine Iteration der modifizierten Prädilutions-HDF durch 
Einbau eines zweiten, seriellen Dialysators vorgenommen, bezeichnet als serielles Dialysator 
System (SDial). Diese letzte Methode wurde dann bezüglich der Durchführbarkeit, der 
Hämokompatibilität und Toxinentfernung validiert. Durch das SDial-System konnte, verglichen 
mit der modifizierten Prädilutions-HDF, eine bessere Hämokompatibilität bei ähnlicher 
Wirksamkeit erzielt werden. Beide Methoden, modifizierte Prädilutions-HDF und SDial System, 
wurden abschließend in ein Tierdialysemodell mit Schafen transferiert, wobei eine 
zufriedenstellende  Biokompatibilität demonstriert werden konnte. 
 
Beide, zur vorübergehenden Erhöhung der Ionenstärke im Blut entwickelten Dialyseverfahren 
zeigten bei zufriedenstellender Biokompatibilität eine verbesserte Entfernung 
proteingebundener Urämietoxine durch Reduktion ihrer proteingebundenen Fraktion. In einem 
nächsten Schritt sind klinische Studien erforderlich, die diese Konzepte bezüglich ihrer In-vivo-
Wirksamkeit und ihrer langfristigen Wirkung auf den Krankheitsverlauf untersuchen. 
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ABBREVIATIONS 
 
β2m β2-microglobulin 
γ removal rate 
λ wavelength 
[NaCl] sodium chloride 
concentration 
[NaCl]ART sodium chloride 
concentration in the arterial 
line 
[NaCl]blood sodium chloride 
concentration in blood 
[NaCl]BM sodium chloride 
concentration in blood 
downstream the first 
dialyzer / upstream the 
second one 
[NaCl]IN sodium chloride 
concentration in the first 
dialyzer dialysate inlet 
[NaCl]OUT sodium chloride 
concentration in the first 
dialyzer dialysate outlet 
[NaCl]SUB sodium chloride 
concentration in the 
substitution fluid 
[NaCl]VEN sodium chloride 
concentration in the venous 
line 
AGE advanced glycation end-
products 
ART arterial (septum) 
BGA blood gas analysis 
Bm number of binding sites 
BM between modules (septum) 
BR blood reservoir (septum) 
C5a complement component 5a 
Ca
2+ calcium ion 
CH3COOH acetic acid 
CH3COONa sodium acetate 
CH3COONH4 ammonium acetate 
CKD chronic kidney disease 
Cl
- chloride ion 
CMPF 3-carboxy-4-methyl-5-
propyl-2-furanpropionic 
acid 
COHb carboxyhemoglobin 
CVD cardiovascular disease 
D123 Dihydrorhodamine 123 
DMSO Dimethyl sulfoxide 
EDTA Titriplex® III 
ERA-EDTA european renal association 
- european dialysis and 
transplant association 
ESRD end-stage renal disease 
EtOH ethanol 
GFR glomerular filtration rate 
Hb hemoglobin 
HCO3
- hydrogenocarbonate ion 
Hct hematocrit 
HD hemodialysis 
HDF hemodiafiltration 
HEPES 4-(2-Hydroxyethyl) 
piperazine-1-ethanesulfonic 
acid N-(2-hydroxyethyl) 
piperazine-N′-(2-
ethanesulfonic acid) 
Hexapeptide N-Formyl-Nle-Leu-Phe-Nle-
Tyr-Lys 
HF hemofiltration 
HHb deoxyhemoglobin 
HSA human serum albumin 
IS indoxyl sulfate 
K
+ potassium ion 
K0A mass transfer area 
coefficient 
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K2HPO4 di-potassium hydrogen 
phosphate 
KA association constant 
KCl potassium chloride 
KD dissociation constant 
LDH lactate dehydrogenase 
LPS lipopolysaccharide 
MgCl2 magnesium chloride 
MetHb methemoglobin 
MW molecular weight 
Na
+ sodium ion 
NaCitrate sodium citrate 
NaCl sodium chloride 
NaOH sodium hydroxide 
NKF KDOQI kidney disease outcomes 
quality initiative guidelines 
of the national kidney 
foundation 
NH4COOH ammonium formate 
O2Hb oxyhemoglobin 
OD optical density 
PAA phenyl acetic acid 
PBF protein bound fraction 
PBS phosphate buffered saline 
pCO2 carbon dioxide partial 
pressure 
pCS para-cresyl sulfate 
PD peritoneal dialysis 
Phe phenylalanine 
PLT platelet (thrombocyte) 
Pmp per million population 
pO2 dioxygen partial pressure 
PTH parathyroid hormone 
pre-HDF pre-dilution 
hemodiafiltration 
QB blood flow rate 
QD dialysate flow rate 
Qex first dialyzer dialysate flow 
rate (serial dialysers setup 
only) 
Qinf substituate flow rate 
QNaCl sodium chloride solution 
infusion flow rate 
QUF ultrafiltration flow rate (also 
weight-loss) 
RBC red blood cell (erythrocyte) 
RP-HPLC reversed-phase high 
pressure liquid 
chromatography 
RR removal ratio 
RRT renal replacement 
therapies 
SDial serial dialyzers 
SDial pre-HDF serial dialyzers pre-dilution 
hemodiafiltration 
SDial-TM pre-HDF serial dialyzers with 
transmembrane pre-
dilution hemodiafiltration 
TAT thrombin-antithrombin III 
TBA tetrabutylammonium 
hydrogensulfate 
tHb total hemoglobin 
concentration 
TMP transmembrane pressure 
TP total protein concentration 
USRDS united states renal data 
system 
VEN venous (septum) 
WBC white blood cell (leucocyte) 
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INTRODUCTION 
I. Renal failure 
 
Kidneys are key organs responsible for the removal of metabolism waste products, 
regulation of the water and acid-base balance. Through their hormone secretion, they are 
also involved in the regulation of blood pressure, erythropoiesis and bone mass. Progressive 
renal failure leads to the deterioration of biochemical and physiologic functions and, finally, 
to the uremic syndrome characterized by multiple symptoms, such as nausea, changes in 
mental status, heart problems, etc., and in fine death (1) . The retention of substances that 
are normally cleared by healthy kidneys and the derangement of renal hormonal and 
enzymatic homeostasis affect several functional systems, most of all the cardiovascular (e.g. 
hypertension, atherosclerosis), neurological, hematological (e.g. anemia) and immunological 
systems (e.g. susceptibility to infections). Coagulation disturbances are also observed in 
uremic patients leading to bleeding tendency (1). 
Kidney failure may consist of either an acute and potentially temporary loss of function 
(acute kidney injury) or of a progressive loss of the renal function (chronic kidney disease, 
CKD). 
 
1) CKD stages 
 
A classification of CKD stages is proposed by the Kidney Disease Outcomes Quality Initiative 
guidelines of the National Kidney Foundation (NKF KDOQI) according to the kidney damage 
and function as estimated by the glomerular filtration rate (GFR) (2): 
 
Stage Description GFR (mL/min/1.73m²) 
1 Kidney damage with normal or increased GFR ≥ 90 
2 Kidney damage with mild decreased GFR 60 to 89 
3 Moderate decreased GFR 30 to 59 
4 Severe decreased GFR 15 to 29 
5 Kidney failure < 15 (or dialysis) 
Tab. 1: Stages of chronic kidney disease. 
CKD stage 3 has been divided in two: 3a with GFR between 45 and 59 mL/min/1.73m², and 3b with GFR 
between 30 and 44 mL/min/1.73m²; thus with different rankings of adjusted relative risk with albuminuria (3). 
Patients on maintenance hemodialysis are classified as CKD stage 5D (4). 
 
The renal function declines with time until being completely lost (CKD stage 5). This is called 
end-stage renal disease (ESRD) and requires treatment with any form of chronic dialysis or 
transplantation (1; 5). 
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2) Epidemiology of chronic renal failure 
 
Data on the incidence1 and prevalence2 of chronic renal failure are collected around the 
world by various registries, such as the United States Renal Data System (USRDS) and the 
European Renal Association - European Dialysis and Transplant Association (ERA-EDTA). 
The overall adjusted incident rate in Europe for the year 2010 (6) of the different countries 
ranged between 77 and 194 per million population (pmp) with diabetes mellitus, 
glomerulonephritis/-sclerosis, and hypertension being the main causes of renal failure. The 
incident rate per established therapy ranged from 55 to 153 pmp for hemodialysis, from 7.3 
to 34 pmp for peritoneal dialysis, and from 0.3 to 14.5 pmp for transplantation. Prevalent 
patients for all treatments on December 31st, 2010 in Europe ranged from 574 to 1262 pmp 
(adjusted values) (6). Thus, about 220 000 patients were treated by hemodialysis, about 
23 000 patients were treated by peritoneal dialysis, and 16 000 had been transplanted in 
Europe3 in 2010 (6).  
 
II. Uremic toxins 
 
1) Uremic toxin classification 
 
Uremic toxins are biological agents accumulating in renal failure. Their interactions with 
biological systems may produce biological responses deleterious to the human body (7). 
Other compounds have no proven direct toxicity, but may be useful markers of uremic 
retention (1). The European Uremic Toxin Working Group proposed in 2003 a classification 
of the uremic toxins and stratified them into three groups (8): 
• Small solutes (< 500 Da) with no protein binding, 
• Solutes with known or likely protein binding, 
• Middle molecules (≥ 500 Da). 
Molecules with a molecular weight (MW) exceeding 60 kDa (cutoff of the glomerular 
basement membrane) are excluded from the middle molecule group. Thus, this group 
should be understood as molecules with a MW between 500 Da and 60 kDa (8). The 
proposed classification has been updated in 2008 (9) and in 2012 (10). 
  
                                                      
1
 Definition: number of new cases of a condition during a specific period of time. 
2
 Definition: number of people in a given population with a particular disease at a given time. 
3
 Countries included are: Austria, Belgium, Bosnia and Herzegovina, Croatia, Czech Republic, Denmark, Estonia, 
Finland, France (23 of 26 regions), former Yugoslav Republic of Macedonia, Greece, Iceland, Italy (14 of 20 
regions), Latvia, Montenegro, Norway, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Spain (18 of 19 
regions), Sweden, The Netherlands, the United Kingdom, and Ukraine. 
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a. Free water-soluble small solutes 
 
Solute  CN CU Cmax MW Group 
1-methyladenosine µg/L 17.1 ± 5.1 / 10 104.0 ± 56.2 / 17 216.4 281 Ribonucleosides 
8-OH-2’Deoxyguanosine µg/L 0.64 ± 0.23  0.82 283 Purine 
1-methylguanosine µg/L 13.7 ± 16.9 / 10 41.6 ± 23.8 / 17 89.2 297 Ribonucleosides 
1-methylnosine µg/L 13.5 ± 3.9 / 10 620.4 ± 203.4 / 14 1027.2 282 Ribonucleosides 
ADMA mg/L 0.2 ± 0.06 / 6 1.6 ± 1.2 / 10 7.3 202 Guanidines 
α-keto-δ-guanidinovaleric acid µg/L < 30.2 / 66 - 140.4 151 Guanidines 
α-N-acetylarginine µg/L 18.1 ± 24.8 / 16 328.3 ± 142.6 / 13 4580.0 216 Guanidines 
Arab(in)itol mg/L < 0.6 / 33 15.0 ± 9.0 / 12 33.0 152 Polyols 
Argininic acid µg/L < 77.0 / 66 80.5 ± 56.0 / 11 197.8 175 Guanidines 
Benzylalcohol mg/L - 27.0 ± 50.7 / 17 187.9 108  
β-guanidinopropionic acid µg/L < 3.3 / 24 28.8 ± 18.3 / 29 65.4 131 Guanidines 
β-lipoprotein ng/L < 55.3 / 10 62.7 / 22 108.8 461 Peptides 
Creatine mg/L 9.7 ± 3.3 / 24 134.0 ± 30.3 / 29 235.8 131 Guanidines 
Creatinine mg/L < 12.0 / 23 136.0 ± 46.0 / 19746 240.0 113 Guanidines 
Cytidine µg/L < 468.0 683.3 ± 287.8 / 7 1263.6 234 Purines 
Dimethylglycine µg/L < 381.1 / 33 576.8 / 18 1040.3 103  
Dimethylguanosine       
Erythritol mg/L < 0.7 / 33 9.8 ± 14.0 / 12 37.0 122 Polyols 
γ-guanidinobutyric acid µg/L < 3.6 / 24 33.3 ± 16.0 / 30 1750.0 145 Guanidines 
Guanidine µg/L < 11.8 / 16 176.9 ± 83.8 / 13 800.0 59 Guanidines 
Guanidinoacetic acid µg/L 222.3 ± 79.6 / 24 383.8 ± 143.9 / 29 693.8 117 Guanidines 
Guanidonosuccinic acid mg/L 0.03 ± 0.01 / 16 6.5 ± 3.4 / 13 47.0 175 Guanidines 
Guanilin       
Hypowanthine mg/L 1.5 ± 0.5 / 145 2.0 ± 1.6 / 65 5.3 136 Purines 
Inosine       
Malondialdehydes µg/L 257.7 ± 81.7 / 30 428.8 ± 170.4 / 16 796.6 71  
Mannitol mg/L < 1.3 / 33 26.0 ± 25.0 / 12 76.0 182 Polyols 
Methylguanidine µg/L < 7.3 / 24 773.8 ± 508.8 / 5 1820.0 73 Guanidines 
Myoinositol mg/L < 10.0 / 8 94.0 ± 69.0 / 12 232.0 180 Polyols 
N
2
,N
2
-dimethylguanosine µg/L 9.0 ± 4.7 / 10 236.4 ± 89.7 / 14 415.8 311 Ribonucleosides 
N
4
 –acetylcytidine µg/L 57.0 ± 17.1 / 10 159.6 ± 30.8 / 14 221.2 285 Ribonucleosides 
N
6
 –methyladenosine µg/L 18.5 ± 8.4 / 10 70.3 ± 53.3 / 17 176.9 281 Ribonucleosides 
N
6
 –threonylcarbamoyladenosine µg/L 35.5 ± 27.2 / 10 378.0 ± 151.2 / 17 680.4 378 Ribonucleosides 
N-methyl-2-pyridone-5-carboxamide mg/L 1.37 ± 0.68 4.02 ± 3.28 7.80 152 Nicotinamide 
Nitrosodimethylamine       
Nitrosomethylamine       
Orotic acid mg/L 0.5 ± 1.4 / 30 6.7 ± 16.0 / 22 38.7 174 Pyrimidines 
Orotidine mg/L 1.2 ± 1.6 / 30 20.2 ± 13.5 / 22 47.2 288 Pyrimidines 
Oxalate mg/L 0.3 ± 0.1 / 8 4.9 ± 1.4 / 8 7.6 90  
Phenylacetylglutamine mg/L < 4.7 53.3 ± 44.7 / 6 120.6 264  
Phenylethylamine       
Pseudouridine mg/L 0.5 ± 5.8 / 30 13.1 ± 21.4 / 7 86.6 244 Ribonucleosides 
SDMA µg/L 76.1 ± 21.0 / 66 640.3 ± 212.1 / 38 1232.2 202 Guanidines 
Sorbitol mg/L < 0.4 / 33 3.1 ± 2.1 / 12 7.3 182 Polyols 
Taurocyamine µg/L < 52.2 / 24 - 121.8 174 Guanidines 
Thiocyanate       
Threitol µg/L < 319.6 / 33 990.0 ± 920.0 / 12 5697.4 122 Polyols 
Thymine mg/L - 2.8 ± 4.2 / 22 11.2 126 Pyrimidines 
Trimethylamine µg/L 24.7 ± 7.3  82.0 59 Amine 
Uracil µg/L < 224.0 252.0 ± 154.6 / 7 448.0 112 Purines 
Urea g/L < 0.4 / 23 2.3 ± 1.1 / 16 4.6 60  
Uric acid mg/L < 67.2 83.4 ± 44.5 / 7 146.7 168 Purines 
Uridine mg/L 1.5 ± 1.3 / 30 9.8 ± 11.4 / 22 32.6 244 Pyrimidines 
Xanthine mg/L 0.5 ± 1.4 / 180 1.5 ± 0.8 / 65 3.0 152 Purines 
Xanthosine µg/L 23.9 ± 12.8 / 10 96.6 ± 62.9 / 11 222.4 284 Ribonucleosides 
Tab. 2: Free water-soluble low-molecular-weight solute concentrations. 
The table was adapted from (8). Abbreviations are: CN, normal concentration; CU, mean/median uremic 
concentration; Cmax, maximal uremic concentration; MW, molecular weight; ADMA, asymmetrical 
dimethylarginine; SDMA, symmetrical dimethylarginine. The underlined numbers behind the slash point to the 
number of data on which the means or medians have been obtained. No underlined number indicates that no 
data about the number of samples were available. Normal values are reported as means ± SD, or in the case of 
a single value as a maximum; uremic values are reported as mean ± SD or as a median. 
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Urea and creatinine are highly soluble in water and are the most abundant solutes to 
accumulate in blood as a consequence of renal failure. Thus, they are used as marker 
molecules to quantify and compare dialysis treatment efficacy and hemodialyzer properties 
(11). 
 
b. Protein bound solutes 
 
Since the various hemodialysis strategies focused for a long time on the removal of small 
water soluble molecules, protein-bound uremic toxins were qualified in 2001 as the 
“forgotten toxins” (12). In spite of their small MW, they behave like larger molecules since 
the carrier proteins are unable to pass dialysis membranes and, therefore, are retained in 
blood. Only the free, unbound fraction is dialyzed. Consequently, they are poorly removed 
by standard hemodialysis treatments (5; 7). However, only the free fraction of these toxins 
has an effect on biological system (8). 
 
Solute  CN CU Cmax MW Group 
2-methoxyresorcinol µg/L - 19.6 ± 81.2 / 17 322.0 140 Phenols 
3-deoxyglucosone mg/L 0.3 ± 0.1 / 30 1.7 ± 1.0 / 27 3.5 162 AGE 
CMPF mg/L 7.7 ± 3.3 / 7 61.0 ± 16.5 / 15 94.0 240  
Fructoselysine mg/L - 58.1 ± 10.8 / 10 79.7 308 AGE 
Glyoxal µg/L 67.0 ± 20.0 / 7 221.0 ± 28.0 / 20 277.0 58 AGE 
Hippuric acid mg/L < 5.0 247.0 ± 112.0 / 7 471.0 179 Hippurates 
Homocysteine mg/L < 1.7 / 24 8.1 ± 1.6 / 7 26.4 135  
Hydroquinone µg/L - 50.6 ± 84.7 / 17 286.0 110 Phenols 
Indole-3-acetic acid µg/L 17.5 ± 17.5 / 7 875.0 ± 560.0 / 42 9076.9 175 Indoles 
Indoxyl sulfate mg/L 0.6 ± 5.4 / 40 53.0 ± 91.5 / 20 236.0 213 Indoles 
Kinurenine µg/L < 391 / 7 686.4 ± 178.9 / 21 952.6 208 Indoles 
Kynurenic acid mg/L < 1.0 - 9.5 189 Indoles 
Leptin µg/L 8.4 ± 6.7 / 56 72.0 ± 60.6 / 8 490.0 16000 Peptides 
Melatonin ng/L 26.5 ± 7.1 / 35 175.8 ± 130.2 / 13 436.2 126 Indoles 
Methylglyoxal µg/L 47.0 ± 12.0 / 15 110.0 ± 18.0 / 20 146.0 72 AGE 
Nε-(carboxymethyl)lysine mg/L 1.1 ± 0.3 / 24 4.3 ± 1.3 / 44 6.9 204 AGE 
p-cresol mg/L 0.6 ± 1.0 / 12 20.1 ± 10.3 / 20 40.7 108 Phenols 
Pentosidine µg/L 51.6 ± 18.8 / 19 896.0 ± 448.0 / 24 2964.0 342 AGE 
Phenyl acetic acid mg/L < 1.4 467.2 ± 10.6 474.6 136  
Phenols mg/L 0.6 ± 0.2 / 12 2.7 ± 3.9 / 10 10.5 94 Phenols 
P-OH-hippuric acid mg/L - 18.3 ± 6.6 / 13 31.5 195 Hippurates 
Putrescine µg/L 21.1 ± 7.9 / 10 77.4 ± 27.3 / 25 132.0 88 Polyamines 
Quinolinic acid mg/L 0.1 ± 0.05 / 10 1.5 ± 0.9 / 54 3.3 167 Indoles 
Retinol-binding protein mg/L < 80 192.0 ± 78.0 / 112 369.2 21200 Peptides 
Spermidine µg/L - 97.2 ± 45.0 / 25 187.2 145 Polyamines 
Spermine µg/L - 18.2 ± 16.2 / 25 66.7 202 Polyamines 
Tab. 3: Protein bound solute concentrations. 
The table was adapted from (8). Abbreviations are: CN, normal concentration; CU, mean/median uremic 
concentration; Cmax, maximal uremic concentration; MW, molecular weight; CMPF, 3-carboxy-4-methyl-5-
propyl-2-furanpropionic acid; AGE, advanced glycation end products; RCC, reactive carbonyl compound. The 
underlined numbers behind the slash point to the number of data on which the means or medians have been 
obtained. No underlined number indicates that no data about the number of samples were available. Normal 
values are reported as means ± SD, or in the case of a single value as a maximum; uremic values are reported 
as mean ± SD or as a median. 
 
Advanced glycation end-products (AGE) were classified among the protein-bound molecules; 
their binding to proteins is, however, different from that of other classical protein-bound 
solutes, such as indoxyl sulfate and p-cresol (8). AGE modifications are actually irreversible 
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modifications of proteins (covalent binding). Proteins form AGEs by different chemical steps 
(Schiff reaction, generation of Amadori products, carboxymethyllysin, pentosidine, pyrraline) 
when exposed to glucose or other carbohydrates (13). 
 
c. Middle molecules 
 
Solute  CN CU Cmax MW Group 
Adiponectin mg/L < 11.1  16.6 30000 Peptides 
Adrenomedullin ng/L 13.2 ± 4.6 / 17 41.8 ± 19.7 / 29 81.2 5729 Peptides 
Atrial natriuretic peptide ng/L 28.0 ± 12.2 / 23 202.0 ± 117.3 / 27 436.6 3080 Peptides 
β2-microglobulin mg/L < 2.0 55.0 ± 7.9 / 10 100.0 11818 Peptides 
β-endorphin ng/L < 173.3 / 10 301.5 / 22 492.0 3465 Peptides 
Basic FGF       
Calcitonin-gene related peptide ng/L < 20.0  21.8 3450 Peptides 
Cholecystokinin ng/L < 20.0 45.9 ± 32.3 / 38 131.5 3866 Peptides 
Clara cell protein mg/L < 0.1 3.3 ± 2.0 / 112 12.5 15800 Peptides 
Complement factor D mg/L 1.9 ± 0.5 / 5 19.8 ± 4.1 / 5 26.0 23750  
Cystatine C mg/L < 1.6 11.8 ± 3.0 / 112 20.0 13300 Peptides 
Degranulation inhibiting protein I µg/L 321.7 ± 59.7 / 23 713.7 ± 390.0 / 125 1631.4 14100 Peptides 
Delta-sleep inducing peptide µg/L - 1.5 ± 0.9 / 7 3.3 848 Peptides 
Desacylghrelin       
Dinucleoside polyphosphates       
Endothelin ng/L 20.8 ± 3.8 / 23 63.0 ± 33.2 / 12 129.4 4283 Peptides 
Ghrelin       
Hepcidin       
Hyaluronic acid µg/L < 124.0 / 86 215.0 ± 257.0 / 184 1843.0 25000 Peptides 
Interleukin-1β ng/L < 160.0 / 15 428.0 ± 134.0 / 29 1700.0 32000 Cytokines 
Interleukin-6 ng/L 13.3 ± 3.1 / 28 92.3 ± 117.9 / 230 328.1 24500 Cytokines 
Interleukin-18       
κ-Ig light chain mg/L 34.0 ± 15.0 / 15 70.0 ± 60.9 / 104 287.0 25000 Peptides 
λ-Ig light chain mg/L 31.0 ± 11.2 / 15 87.0 ± 60.9 / 104 328.0 25000 Peptides 
Leptin µg/L 8.4 ± 6.7 / 56 72.0 ± 60.6 / 8 490.0 16000 Peptides 
Methionine-enkephalin ng/L < 18.3 / 10 32.2 / 22 75.5 555 Peptides 
Motiline       
Neuropeptide ng/L < 80.0 64.9 ± 25.5 / 19 115.9 4272 Peptides 
Octopamine       
Orexin A       
Parathyroid hormone µg/L < 0.06 1.2 ± 0.6 / 10 2.4 9225 Peptides 
Retinol-binding protein mg/L < 80 192.0 ± 78.0 / 112 369.2 21200 Peptides 
Substance P       
Tumor necrosis factor-α ng/L 13.3 ± 3.0 / 28 114.0 ± 147.0 / 230 408.0 26000 Cytokines 
Up4A       
Uroguanylin       
Vasoactive intestinal peptide       
Tab. 4: Middle molecule concentrations. 
The table was adapted from (8). Abbreviations are: CN, normal concentration; CU, mean/median uremic 
concentration; Cmax, maximal uremic concentration; MW, molecular weight; FGF, fibroblast growth factor. The 
underlined numbers behind the slash point to the number of data on which the means or medians have been 
obtained. No underlined number indicates that no data about the number of samples were available. Normal 
values are reported as means ± SD, or in the case of a single value as a maximum; uremic values are reported 
as means ± SD or as a median. 
 
The prototype of the middle molecule group is β2-microglobulin (β2m). Historically, concerns 
on the retention of β2m rose when this protein was detected in a specific amyloid 
developing after several years of renal replacement therapy (14). As reviewed by Miyata and 
Drüeke (15; 16), β2m and AGE-modified β2m are implicated in dialysis-related amyloidosis, a 
disease recognized few decades ago characterized by carpal tunnel syndrome, arthropathy 
and the formation of bone cysts (13; 15; 16). β2m is a constituent of the major 
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histocompatibilty complex class I antigen and it accumulates with progression of renal 
disease (15; 16; 17). This protein has been also related to cardiovascular disease (CVD), 
cardiovascular complications, and overall and cardiovascular mortality in hemodialysis 
patients (17; 18; 19; 20). 
 
2) Uremic toxicity 
 
CKD progression leads to the accumulation of metabolism waste products, which have a 
negative effect on health. Since the present thesis was focused on protein bound uremic 
toxins, the relevance of the studied compounds is presented in this part according to their 
adverse effects in vivo and in vitro. 
 
a. Indoxyl sulfate 
 
Indoxyl sulfate (IS) results from the degradation of dietary protein in the large intestine. 
More precisely, the amino acid tryptophan is metabolized into indole by tryptophanase in 
intestinal bacteria, such as Escherichia coli. After entering the blood stream, indole is 
metabolized into IS in the liver (21). 
 
 
Fig. 1: Chemical structure of indoxyl sulfate. 
MW: 213 Da. 
 
With a protein binding of about 90% (22), this solute accumulates with progression of CKD 
(23) maybe due to a defect of organic anion transport and, thus, inducing renal cytotoxicity 
(24). In rats, IS is related to the progression of glomerular sclerosis (25).  In vitro experiments 
have shown its implication in bone disorders observed in uremic patients: IS inhibits 
osteoclast differentiation and function (26) and induces also resistance to parathyroid 
hormone (PTH) in osteoblasts (27). IS is also associated with all-cause and cardiovascular 
mortality, CVD, and CKD progression (23; 28). In vivo observations have confirmed the 
vascular toxicity of IS by inducing aortic calcification and aortic wall thickening in rats (29); in 
vitro experiments also have demonstrated that IS inhibits endothelial proliferation and 
wound repair (30) by inducing oxidative stress in endothelial cells (31). 
 
b. p-Cresol and p-cresyl sulfate 
 
p-Cresol results from the degradation of the amino acid tyrosine by intestinal bacteria (32). 
Initial research has focused on p-cresol itself; however, it has been shown that this 
 compound circulates mainly as 
about 95% bound to plasma proteins 
 
 
Fig. 2: Chemical structure of p-cresol
MW: 108 Da. 
 
In vivo, both p-cresol and pCS accumulate with decreasing renal function 
due to reduced uptake by organic anion transporters 
progression (28). The free concentration of both toxins is related to all
cardiovascular mortality in hemodialysis patients 
high free serum p-cresol concentrations have a higher prevalence of hospitalization because 
of infections. This may be explain
reactive oxygen species) to bacteria 
molecules and impaired monocyte adhesion to endothelial cells 
activates leukocyte free radical production (pro
in vascular disease of the uremic population 
serum concentration of p-cresol was associated with the number of circulating endothelial 
microparticles in hemodialysis
showing disruption of endothelial progenitor cell function 
microparticles shedding (44) and decrease of endothelial proliferation and wound repair 
by pCS.  
 
c. Phenyl acetic acid
 
Phenyl acetic acid (PAA) has been introduced in 2009 as a protein
Different to IS and pCS, the protein binding
largely accumulates in plasma of ESRD patients (
production – a signaling molecule mediating neurotransmission, vasodilata
defense – by mononuclear leucocytes 
role in bone disorder in CKD by affecting proliferation, differentiation, mineralization and 
responsiveness to PTH of oste
macrophage function (49). 
 
 
Fig. 4: Chemical structure of phenyl acetic acid
MW: 136 Da. 
 
 
25 
p-cresyl sulfate (pCS) in the blood stream 
(33; 35). 
. Fig. 3: Chemical structure of 
MW: 187 Da. 
(38). pCS is a predictor of CKD 
(37; 39; 40). Furthermore, patients with 
ed by an impaired leukocyte response (production of 
(41), reduced expression of endothelial adhesion 
(42). Unlike 
-inflammatory effect) which may be involved 
(43). Meijers et al. demonstrated that the free 
 patients (44). This is in accordance with in vitro
(45), induction of endothelial 
 
 in plasma is low (about 30%) 
see Tab. 3) and interferes with nitric oxide 
(47). Furthermore, this solute is suspected to play a 
oclasts (48) and in immunodeficiency by inhibiting 
. 
 
(33; 34). pCS is 
 
p-cresyl sulfate 
(36; 37) possibly 
-cause and 
p-cresol, pCS 
 experiments 
(30) 
-bound substance. 
(46). This molecule 
tion and cell 
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III. Renal replacement therapies 
 
The immediate goals of renal replacement therapies (RRT) are: i) to remove toxic waste 
products from blood (11), and ii) to correct the electrolyte, water and acid base 
abnormalities (5). RRT are hemodialysis (HD) and peritoneal dialysis (PD). During HD, blood is 
cleansed in an artificial kidney (hemodialyzer) made of a semi-permeable membrane (50), 
whereas during PD, the peritoneum is used as semi-permeable membrane (51). Therefore, 
both methods differ in terms of access: HD, vascular access; PD, peritoneal cavity access. As 
presented above, HD is much more common compared to PD (about 10 patients on HD for 1 
on PD) (6). 
Similarly to native kidneys, which combine filtration at the glomerulus with selective 
reabsorption across the tubule, artificial kidneys accomplish their role by dialyzing and 
filtering the blood across semi-permeable membranes driven by diffusion and convection 
(11). However, artificial kidneys are not able to correct the endocrine abnormalities of renal 
failure (5). 
 
1) Dialysis therapies 
 
Basic RRT were originally based either on purely diffusive – hemodialysis – or on purely 
convective principles – hemofiltration (HF). During convective treatment, the ultrafiltered 
plasma water is replaced by a substitution fluid with a composition similar to dialysate (52).  
This substitution can be performed upstream (pre-dilution) or downstream (post-dilution) 
from the hemofilter. Later, hemodiafiltration (HDF) was introduced, which cumulates both 
principles of HD and HF. 
 
2) Hemodialyzer and hemodialysis membranes 
 
Hemodialysis membranes are divided in three main categories according to materials: 
cellulose, modified cellulose, and synthetic polymers. Synthetic membranes are the gold 
standard for current hemodialyzers (53), which usually are hollow-fiber type and available as 
low- and high-flux membrane (13). 
High-flux membranes are highly permeable to water (ultrafiltration coefficient > 20 
mL/h/mmHg) and have larger pore sizes with a cut-off of about 50 kDa (low-flux membrane 
cut-off is about 10 kDa) (54) enabling the removal of middle molecules such as β2m (11; 13). 
The development of high-flux membranes was driven by the desire to reach solute removal 
characteristics for artificial kidneys similar to those of the native organ (50). However, an 
increase of the membrane pore size to more effectively remove larger solutes is limited by 
serum albumin loss; albumin is essential for solute transport and maintenance of blood 
oncotic pressure (11). However, no upper limit of albumin loss during RRT has been defined 
so far (55). 
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Low-flux membranes are rather used during purely diffusion-based strategies (i.e., HD) 
whereas high-flux membranes are used for convective strategies (i.e., HF and HDF) and HD. 
In 2006, the NKF KDOQI guidelines recommend the use of high-flux dialysis (56). 
Hemodialyzers can be characterized, amongst others, by the sieving coefficient and the mass 
transfer area coefficient (K0A). This last term is a property of both the solute and the 
membrane. It reflects the maximum clearance possible at infinite blood and dialysate flow 
rates. The K0A value may change during dialysis due to protein adsorbtion onto the 
membrane (decrease of permeability) or loss of membrane surface area due to coagulation 
of hollow fibers (11). 
 
3) Hemodialysis in practice 
 
Dialysis machines are designed to ensure patient safety during treatment. Ergonomic 
interfaces ensure their easy use by the medical staff. Dialysate, which is produced on-line by 
HD machines from reverse osmosis water and bicarbonate concentrates, is a buffered 
solution (physiologic pH) composed of sodium (Na+), potassium (K+), calcium (Ca2+), 
magnesium (Mg2+), chloride (Cl-), and bicarbonate (HCO3
-). During HD, blood and dialysate 
are pumped through the hemodialyzer. Weight-loss (or ultrafiltration flow rate, QUF) might 
be set by the staff and is automatically regulated during the dialysis session by dialysate 
affluent and effluent pumps (5). 
Typical blood and dialysate flow rates (QB and QD, respectively) range from 200 to 400 
mL/min and from 500 to 800 mL/min, respectively (57), depending on dialysis treatment and 
vascular access. Typical dialysis treatments are performed thrice a week during 4 h sessions 
and a QUF of about 10 mL/min (58). 
 
 
IV. Clinical challenges 
 
1) Inadequate removal of uremic toxins 
 
The clearance of uremic toxins differs between the three toxin groups. Although urea is 
easily removed during hemodialysis, protein-bound uremic toxins, such as IS and pCS, and 
middle molecules, such as β2m, are only poorly removed (22; 33; 59; 60; 61). Due to their 
high protein binding (90% to 95%) (22; 35) and high volume of distribution (33), both IS and 
pCS rather behave like middle molecules. Therefore, current dialysis strategies are not 
effective to remove such molecules (7). However, differences on the removal of uremic 
toxins between dialysis treatments have been reported. 
The dialysis membrane type (low-flux versus high-flux, cellulosic versus synthetic) has no 
substantial impact on the removal of IS and pCS (22; 61). In contrast, dialysis strategies show 
large differences. Higher clearances are obtained with high-flux HD compared to PD (62) and 
 with pre- or post-dilution HDF compared to pre
flow rate improves the clearance but no difference is found neither between pre
dilution HDF (60; 63) nor between HD and HDF on the short 
In the case of β2m, higher clearances and removal rates are reached by convective 
strategies, such as HDF and HF, as compared to HD 
increases proportionally during HDF while increasing the ultrafiltration flow rate 
Furthermore, high-flux HD more effectively removes 
results are contradictory. Compared with HD, 
HDF (59; 65; 67) but clinical outcomes, as assessed by all
events are not significantly improved with HDF
clinical outcomes with high-
compared to HD and low-efficiency HDF (substitution volume < 17 L per sess
Nocturnal dialysis, characterized by longer and more frequent dialysis sessions (8
6 nights per week), significantly reduces 
session, thrice a week) (70). 
 
2) Worse clinical outcome in ESRD 
 
As reported by the ERA-EDTA registry in 2010 
RRT patients is low: 95.8%, 87.7%, 79.0%, and 57.1%, after 90 days, 1, 2, and 5 years, 
respectively. The survival probability is strongly depend
have a largely higher long term survival rate as compared to patients on hemodialysis 
peritoneal dialysis (about 80% 
life expectancy of ESRD patients is largely decreased when compared to the general 
population (see Fig. 5). The two main causes of death for ESRD patients is 
and infection (about 10%), as reported in 2012 by the USRDS 
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-dilution HF (60). Increasing the ultrafi
(64) and the long term 
(60; 63; 64; 66). T
β2m compared to PD 
β2m levels seem to be greater reduced with 
-cause mortality and cardiovascular 
 (67). Recent studies showed, however, better 
efficiency HDF (substitution volume > 17 L per session) as 
β2m levels as compared to conventional HD (4
versus general population
(6), adjusted survival probabilities 
ent on age. Renal transplant patients 
versus about 50% after 5 years, respectively). Therefore, the 
(71). 
 
Fig. 5: Expected remaining 
lifespan 
population
prevalent dialysis and 
transplant patients in 2009 and 
2010 (including mortality of the 
first 90 days).
Data of life expectancy were 
collected from 
general population (
ESRD patients on maintenance 
hemodialysis (
transplanted ESRD patients
( ). 
 
ltration 
- and post-
(65). 
he β2m clearance 
(66). 
(62) but long-term 
ion) (68; 69). 
 h session, 
 h 
 
of incident 
or 
CVD (about 40%) 
of the general 
 in 2005 and of 
 
(6) for the 
), the 
), and the 
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3) Albumin binding and impaired drug binding in CKD 
 
Human serum albumin (HSA, MW = 66.5 kDa) is the most abundant plasma protein with a 
concentration of about 570 µM (38 g/L) (37; 72). It is a carrier protein for metallic ions and 
many hydrophobic compounds in plasma like drugs, fatty acids, hormones, and waste 
products (73; 74; 75; 76). Uremic toxins are able to bind specifically to Sudlow’s site I, like 3-
carboxy-4-methyl-5-propyl-2-furanpropionic acid (CMPF) (77), and site II of HSA (78), like IS 
and pCS (77; 79), thereby leading to impaired binding of drugs potentially causing dosage 
problems (1; 46; 80; 81; 82).  
 
 
V. The receptor-ligand binding theory 
 
Proteins like albumin present binding sites on their surface. The binding of ligand L to 
receptor R is based on the law of mass action (83). It assumes that binding is reversible: 
 +  		
  
When equilibrium is reached, new ligand-receptor complexes are formed at the same rate at 
which ligand-receptor complexes dissociate. Thus, the equilibrium dissociation constant (KD), 
inverse of the equilibrium association constant (KA), is given by Eq. 1. 
 []. [][] =  =  = 1 
Eq. 1: Definition of the equilibrium constants (84). 
Where [L] and [RL] are the free and bound ligand concentration, respectively; kon and koff the association and 
dissociation rate constants. 
 
If the receptor has a high affinity for the ligand, then KD will be low and a low concentration 
of ligand will occupy half of the receptors (in that case [L] = KD). This model assumes that all 
receptors are equally accessible to the ligands, the receptors are either free or bound to the 
ligand, the binding does not alter the ligand or receptor, and that the binding is reversible 
(84). 
Ligands may bind to other sites than to the receptors of interest. Binding to the receptor of 
interest is called specific binding, while binding to other sites is called nonspecific binding. 
The latter is usually directly proportional to the ligand concentration. The total binding is the 
sum of specific and nonspecific binding as shown in Fig. 6. It can be assumed that specific 
binding only happens at low ligand concentrations. The specific binding is limited by the 
maximal available binding sites (Bm). 
  
Since uremic toxins, such as IS or 
the law of mass action applies. At high concentrations
toxins will be captured by the protein tertiary structure. Since the IS and the 
concentration is low in uremic patients (about 80 and 100 µM, respectively 
to the albumin concentration (about 570 µM 
Eq. 2 (84): 
 
Eq. 2: One site specific binding equation.
Where [RL] is the bound ligand concentration
concentration [M], and KD the dissociation constant
 
From this equation, it is possible to calculate the protein 
ligand (see the Appendix for the complete demonstration; 
 
 =

Eq. 3: Relationship between PBF, binding constants, and ligand concentration for a one site specific binding 
reaction. 
Where PBF is the protein bound fraction
concentration [M], and KD the dissociation constant
 
This equation, which is adapted from Meyer et al. 
present case a uremic toxin) as a function of the binding constants 
ligand and the receptor at a constant toxin concentration. 
equation by varying the total toxin concentration 
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Fig. 
the total, specific and 
nonspeci
binding to receptors
pCS, bind specifically to albumin on Sudlow’s site II 
, nonspecific binding will occur as if the 
(37)), the bound toxin concentration is given by 
[] =   [] + [] 
 
 [M], [L] the free ligand concentration [M]
 [M]. 
bound fraction 
Eq. 3). 
+ [] + 1   !    1"#  4. 
2. 
 [%], [LT] the total ligand concentration [M]
 [M]. 
(86), describes the PBF
KD and 
Fig. 7 has been obtained from this 
[LT] in the ratio α = [LT]/B
 
6: Representation of 
fic ligand 
. 
(79; 85), 
pCS 
(64)) compared 
, Bm the binding site 
(PBF) of a given 
 
, Bm the binding site 
 of a ligand (in the 
Bm, specific to the 
m. 
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Fig. 7: Dependence of the PBF 
on the ratio KD/Bm for different 
toxin-proteins ratio. 
This figure was obtained by 
varying the ratio [LT]/Bm from 
0.01 to 1 in Eq. 3. 
 
This figure yields important information to understand the protein binding of uremic toxins 
in human plasma and the situation during dialysis. The PBF indeed corresponds to the 
fraction retained in blood during RRT. The PBF decreases by increasing the ratio KD/Bm. This 
happens by increasing KD (i.e. decreasing the binding affinity) and/or decreasing Bm (i.e., 
removing binding sites or diluting blood/plasma). It is important to note that diluting plasma 
will not change the ratio [LT]/Bm since both total binding capacity and total toxin 
concentration are decreased proportionally. During dialysis, the toxin is removed, [LT] and, 
consequently, the ratio [LT]/Bm decreases, which in turn increases the PBF. In other words, 
the toxin removal decelerates during dialysis.  
 
VI. Aim of the study 
 
Based on conventional dialysis strategies, purpose of the present thesis was to develop a 
dialysis method which more effectively removes protein bound uremic toxins. Focus was the 
development of a means to reduce protein binding of such solutes in order to increase their 
dialytic clearances with the potential goal to improve clinical outcomes of hemodialysis 
patients. 
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MATERIALS AND METHODS 
I. Materials 
 
1) Reagents 
 
a. Uremic toxins 
 
IS and PAA were purchased from Sigma-Aldrich (indoxylsulfate potassium salt, ref. I3875; 
phenylacetic acid, 99%, ref. P16621; Steinheim, Germany). 
As a kind gift from Miss N. Meert, pCS was synthesized by the laboratory of Organic & Bio-
organic Synthesis of the University Ghent (Belgium). 
 
b. Chemicals 
 
Ammonium formate (NH4COOH), tetrabutylammonium hydrogensulfate (TBA), heparin, 
lipopolysaccharide (LPS), phosphate buffered saline pH 7.4 (PBS), 4-(2-
Hydroxyethyl)piperazine-1-ethanesulfonic acid N-(2-Hydroxyethyl)piperazine-N′-(2-
ethanesulfonic acid) (HEPES), glucose , N-Formyl-Nle-Leu-Phe-Nle-Tyr-Lys (hexapeptide), 
activated charcoal, and HSA were purchased from Sigma-Aldrich (ammonium formate for 
mass spectrometry, ≥99.0%, ref. 70221, Fluka analytical; tetrabutylammonium 
hydrogensulfate 97%, ref. 155837; heparin sodium salt from porcine intestinal mucosa, ref. 
H3149; Lipopolysaccharides from Salmonella enterica serotype minnesota Re 595, ref. 
L9764; phosphate buffered saline powder, pH 7.4, ref. P3813; HEPES, ≥99.5% by titration, 
ref. H3375; D-(+)-glucose monohydrate for microbiology, ≥99.0%, ref. 49159; N-Formyl-Nle-
Leu-Phe-Nle-Tyr-Lys, ≥97%, ref. F0267; DARCO®, 20-40 mesh particle size, granular, ref. 
242268; albumin from human serum, lyophilized powder, fatty acid free, globulin free, 
≥99.0%, ref. A3782). 
Phenylalanine (Phe), di-potassium hydrogen phosphate (K2HPO4), sodium chloride (NaCl), 
potassium chloride (KCl), magnesium chloride (MgCl2), Titriplex® III (EDTA), PBS pH 7.2 
tablets, sodium acetate (CH3COONa), and ammonium acetate (CH3COONH4) were 
purchased from Merck (DL-phenylalanine for biochemistry, ref. 107257; di-Potassium 
hydrogen phosphate anhydrous for analysis EMSURE®, ref. 105104; sodium chloride for 
analysis EMSURE® ACS, ISO, Reag. Ph Eur, ref. 106404; potassium chloride for analysis 
EMSURE®, ref. 104936; magnesium chloride hexahydrate for analysis EMSURE® ACS, ISO, 
Reag. Ph Eur, ref. 105833; ethylenedinitrilotetraacetic acid, disodium salt dihydrate for 
analysis, ® ACS, ISO, Reag. Ph Eur, ref. 108418; buffer tablets pH 7.2 for preparing buffer 
solution according to WEISE for staining of blood smears, ref. 109468; sodium acetate 
anhydrous for analysis EMSURE® ACS, Reag. Ph Eur, Ref. 106268; ammonium acetate 
Fractopur®, Ref. 116103; Darmstadt, Germany). 
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Sodium citrate (NaCitrate) was purchased from Carl Roth GmbH (tri-sodium citrate 
dehydrate Rotipuran®, ≥99% for analysis ACS, ref. 3580.1; Carl Roth GmbH, Karlsruhe, 
Germany). 
Dihydrorhodamine 123 (D123) was purchased from Invitrogen (molecular probes®, 10 mg, 
ref. D-632). 
 
c. Solutions 
 
Saline was purchased from B.Braun Melsungen (NaCl 0.9% B.Braun, Ecotainer®, ref. 
3570160; or isotonic sodium chloride solution, Perfuflac® N, ref. 6796; Melsungen, 
Germany). 
Deionized ultrapure water was either purchased from B.Braun Melsungen (Aqua B.Braun, 
ref. 0082479E), or prepared with a Barstead Nanopure water preparation system (D11931, 
Thermo Scientific, Langenselbold, Germany). 
HPLC water was purchased from VWR International (water hipersolv chromanorm® for 
HPLC, ref. 23595.328, Darmstadt, Germany). 
Dialysate for in vitro dialysis experiments involving mini-dialyzers was prepared with a 
Nikkiso DBB03 apparatus from bicarbonate concentrate. 
Dialysate acid and alkaline concentrates were purchased from B.Braun Avitum AG (SW 196 
A, ref. 3273; alkaline bicarbonate concentrate 8.4%, ref. 169; Melsungen, Germany). 
Formic acid, acetonitrile,  sodium hydroxide (NaOH), ethanol (EtOH) May-Grünwald’s 
staining solution, Giemsa solution, and acetic acid (CH3COOH) were purchased from Merck 
(EMSURE®, 98-100% purity, ref. 1.00264; LiChrosolv® acetonitrile gradient grade for liquid 
chromatography, ref. 100030; sodium hydroxide solution, for 1000 mL, c(NaOH) = 1 mol/L = 
1 N, Titrisol®, ref. 109956; absolute for analysis EMSURE® ACS, ISO, Reag. Ph Eur, ref. 
100983; May-Grünwald’s eosine-methylene blue solution modified for microscopy, ref. 
101424; Giemsa’s azur eosin methylen blue solution for microscopy, ref. 109204; acetic acid, 
for 500 mL, c(CH3COOH) = 1 mol/L = 1 N, Titrisol®, ref. 109951). 
Dimethyl sulfoxide (DMSO) was purchased from Sigma-Aldrich (Hybri-Max™, sterile-filtered, 
BioReagent, suitable for hybridoma, ≥99.7%, ref. D2650). 
PharmLyse solution was performed by BD Bioscience (ref. 555899, Heidelberg, Germany) 
HSA 20% solution was performed by Biotest (Albiomin® 20%; Dreieich, Germany). 
 
d. Self prepared solutions 
 
Heparin stock solution (350 IU/mL) was prepared by dissolving heparin in saline and was 
readily stored at 4 °C for maximum 4 weeks. 
NaCitrate stock solution (3.8% w/w) was obtained by dissolving NaCitrate in saline and was 
stored at -20 °C. 
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PBS solution (10 mM, pH 7.4) was prepared by dissolving one pack of PBS in 1 L ultrapure 
water; this solution was stored at room temperature for few days. PBS solution (1x PBS, pH 
7.2) was prepared by dissolving one buffer tablet pH 7.2 in 1 L ultrapure water. 
D123 stock solution (200 µM) was prepared by dissolving one vial D123 in 1.45 mL DMSO. 
This solution was then diluted 1:100 in DMSO and 100 µL aliquots were stored at -30 °C 
protected from light.  Before use, one aliquot was mixed with 9.90 mL 30 mM HEPES buffer 
pH 7.4 (final concentration 2 µM D123). 
HEPES buffer (30 mM, calcium free) was prepared by dissolving 14.30 g HEPES, 12.86 g NaCl, 
1.50 g KCl, 0.41 g MgCl2, and 4.00 g glucose in 1.6 L ultrapure water, and adjusted to pH 7.4 
with NaOH. Then, ultrapure water was added to a final volume of 2 L. Finally, it was filtered 
through a 0.20 µm sterile filter. Aliquots (50 mL) were stored at -20 °C. 
HH-Ca
2+
-buffer was prepared by dissolving 7.15 g HEPES, 6.43 g NaCl, 0.75 g KCl, 0.203 g 
MgCl2, and 2 g glucose in 1 L ultrapure water. 
Hexapeptide solution (100 µM) was prepared by dissolving 1 mg hexapeptide in 12.14 mL 
DMSO and 10 µL aliquots were stored at -30 °C. Before use, one aliquot was diluted in 990 
µL 30 mM HEPES buffer pH 7.4 (final concentration 1 µM). 
EDTA solution (100 mM) was prepared by diluting 37.2 g EDTA in 1 L pyrogen free saline, 
aliquoted in 50 mL sterile Falcon tubes and stored at -20 °C. EDTA solution (20 mM) was 
obtained by diluting EDTA 100 mM 1:5 with saline. 
LPS working solution (10 µg/mL) was prepared by dissolving LPS in 5 mL 20 mM EDTA pH 7.4 
which then was completed to 100 mL with HH-Ca2+-buffer (500 mg/L LPS stock solution). 
Before use, LPS working solution was made by diluting the parent solution 1:50 with the HH-
Ca2+-buffer. 
NaCl stock solution (5.00 M) was prepared by dissolving 1,461 g NaCl in 5 L ultrapure water. 
Giemsa working solution was obtained by mixing 4 mL Giemsa solution with 80 mL PBS pH 
7.2. 
PAA stock solution (100 mM) was prepared by diluting 0.136 g PAA in 10 mL 20% EtOH / 
80% H2O (v/v), pH was neutralized with NaOH. 
Phe solution (8 mg/mL) was prepared in saline. 
 
e. Biologic fluids 
 
Frozen human citrate-plasma was obtained from the Bavarian Red Cross blood donor 
service (Munich, Germany). 
Human whole blood was freshly donated by healthy volunteers into transfer bags 
(COMPOFLEX® 600 mL, ref. 501108; Fresenius HemoCare, Bad Homburg, Germany) prefilled 
with 5 IU/mL heparin. 
Normal healthy plasma was separated from human whole blood by centrifugation (2,000 g, 
10 min, 5 °C). 
Uremic plasma was separated by centrifugation (2,000 g, 10 min, 5 °C) from blood drawn 
into EDTA-tubes or heparinized syringes (60 mL, 5 IU/mL) of ESRD patients of a single dialysis 
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center (Dialysis center, Elsenfeld, Germany) after having obtained approval from the 
competent review board (ethics committee of the University Hospital Würzburg, code AZ 
64/12) and written informed consent from the patients. 
 
2) Laboratory equipments 
 
YM30 filter units were purchased from Millipore (Centrifree® ultrafiltration unit with ultracel 
YM-T membrane, red. 4104, Merck; Darmstadt, Germany). 
30 kDa filter units were purchased from VWR international (VWR centrifugal filter, modified 
PES 30k, 500 µL, low protein binding, ref. 516-0231 and ref. 516-0232). 
HPLC glass vials were purchased from Chromacol (ref. 2-CRV, ref. 1.1-CTVG, United 
Kingdom). 
Syringe filters 0.20 µm were purchased from Sartorius (Minisart sterile filter, ref. 17597K; 
Sartorius Stedim Biotech GmbH, Goettingen, Germany). 
Transfusion set was purchased from Codan (Transfusion set for blood or blood components, 
ref. 45.4424; CODAN Medical devices, Lensahn, Germany) 
EDTA S-Monovette® and lithium heparin S-Monovette® were purchased from Sarstedt (S-
Monovette® 2.7 mL K3E and S-Monovette® 7.5 mL K3E, ref. 05.1167 and ref. 01.1605.001; S-
Monovette® 2.7 mL LH, ref. 05.1553.001; Nümbrecht, Germany). 
Tubing systems for dialysis were purchased either by Promedt (Medizintechnik Promedt 
GmbH, Tornesch, Germany) or by Nikkiso (Nikkiso Medical GmbH, Hamburg, Germany). 
Hemodialysis membranes used either in mini- (housing Ø 8mm) or standard-dialyzers are 
presented in Tab. 5. 
Membrane type Purchaser 
Cuprophan®, low-flux cellulosic membrane, 6 kDa cut-off 
Membrana GmbH, 
Wuppertal, Germany 
PUREMA® H dialyzer, high-flux polyethersulfone membrane 
PUREMA® L dialyzer, low-flux polyethersulfone membrane 
DIAPES® HF800, high-flux polyethersulfone membrane 
DIAPES® LF100, low-flux polyethersulfone membrane 
Polyamix™, high-flux polyarylethersulfone, 
polyvinylpyrrolidone, polyamide blend membrane 
Gambro Dialysatoren GmbH, 
Hechingen, Germany 
Helixone®, high-flux polyethersulfone membrane Fresenius Medical Care, 
Bad Homburg, Germany 
Tab. 5: Hemodialysis membranes used during dialysis experiments 
 
3) Analysis tools 
 
Pressures and temperature during in vitro dialysis experiments were recorded with a MSR-
Manager system (LAB-Box1; Hitec Zang GmbH, Herzogenrath, Germany) driven by a 
LabVision software version 2.6 (Hitec Zang GmbH).  
Reversed-phase high pressure liquid chromatography (RP-HPLC) was performed using a 
Gynkotek apparatus (Germering, Germany) with a HPLC pump model M480 and a column 
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thermostat STH 585. A degasser ERC-3315 (ERC GmbH, Riemerling, Germany) was built in 
the system. Detectors were a spectrofluorometric RF-551 detector (Shimadzu, Kyoto, Japan) 
and an UV-VIS detector UVD 340 U (Dionex GmbH, Germering, Germany). A C18 column was 
used (ProntoSIL® Hypersorb, 250 x 4.6 mm, ODS 3.0 µm; Bischoff chromatography, 
Leonberg, Germany) with a guard column (HPLC guard cartridge system, Security Guard™; 
Phenomenex, USA) for all uremic toxins. 
The external pumps were IPC and MCP pumps with CA or Pro-381 heads from ISMATEC 
(IDEX Health & Science, Wertheim-Mondfeld, Germany). 
Centrifuge apparatus: bench top centrifuge Z 513 K (Hermle Labortechnik GmbH, Wehingen, 
Germany) and Eppendorf 5414 centrifuge (Eppendorf Vertrieb Deutschland GmbH, 
Wesseling-Berzdorf, Germany). 
pH meter inoLab pH Level 2 (WTW, Weilheim, Germany). 
A DBB-03 dialysis machine (Nikkiso Medical GmbH) served for the ex vivo experiments with 
human blood or plasma as well as for the animal experiments; a Formula 2000 (Bellco, 
Mirandola, Italy) was used for the pilot experiments in aqueous solution. 
Blood gas analysis (BGA) was performed with an AVL-OMNI 9 and a COBAS b 123 apparatus 
(Roche Roche Diagnostics GmbH, Mannheim, Germany). 
The total protein concentration (TP) was determined with a COBAS C111 apparatus (Roche 
Roche Diagnostics GmbH). 
The albumin concentration was measured using laser nephelometry (BN ProSpec, Siemens, 
Germany). 
Conductivity was measured using a CDM83 apparatus (Radiometer Copenhagen, 
Copenhagen, Denmark). 
Flow cytometry was performed with a FACScan apparatus (BD Bioscience, Heidelberg, 
Germany). 
Microscopic observations were performed using a Laborlux 12 microscope (Leitz) and 
pictures were taken with an AxioCam MRc camera (Zeiss) and an AxioVision software 
(version 4.7.0.0, Carl Zeiss Imaging Solutions). 
Spectrophotometry was performed using a UV-1650PC spectrophotometer (Shimadzu 
Corporation, Kyoto, Japan). 
The cell count in blood was measured with an ABX Pentra 60 cell counter (Agon Lab AG, 
Reichenbach/Stuttgart, Germany) and lactate dehydrogenase (LDH) concentration was 
measured enzimatically (IDEXX Laboratories, Ludwigsburg, Germany). 
 
4) Analytical software 
 
The binding constants KD and Bm were determined with the software GraphPad Prism 
(version 3.00 for Windows; GraphPad Software, San Diego California USA). Linear regression 
applying either a one site specific binding equation or a one site total binding equation was 
performed (see Eq. 2 and Eq. 4, respectively): 
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 =  ×     &'( × ) 
Eq. 4: One site total binding equation. 
Where [RL] is the bound ligand concentration, [L] the free ligand concentration, Bm the binding site 
concentration, KD the dissociation constant, and NS the non specific binding coefficient. 
 
Statistical analyses were performed with either MINITAB® release 14.20 for Windows 
(Minitab Ltd, Coventry, United Kingdom) or with GraphPad Prism. 
The HPLC measurements were analyzed by Chromeleon software (version 6.80; Dionex 
Corporation, Sunnyvale, USA). 
 
II. Methods 
 
1) Standard operating procedures 
 
Measurements of biological parameters have been mostly performed according to the 
laboratory’s standard operating procedures.  
 
a. Free hemoglobin concentration 
 
The free hemoglobin concentration was determined by spectrophotometry. Plasma was 
isolated, diluted 1:5 in saline and transferred in 1 cm PMMA cells. Firstly, the hemoglobin 
(Hb) concentration was determined by measuring the optical density (OD) at a wavelength 
(λ) of 546 nm using a reference in saline. The free hemoglobin concentration was calculated 
according to the Beer-Lambert equation (87): 
 
* = +,-./0 × 1 × , 
Eq. 5: Beer Lambert equation to determine the free hemoglobin concentration (87). 
Where C is the free Hb concentration [g/dL], OD546 the optical density at λ = 546 nm, ε the Hb extinction 
coefficient at λ = 546 nm (ε = 8.37 dL/g/cm), l the cell length equal to 1 cm, and DF the dilution factor of the 
sample. 
 
 
Secondly, the free Hb concentration was measured according to the method of Cripps (88) 
allowing a better estimation at low concentrations. Free Hb concentration was determined 
by measuring the OD at λ = 560 nm, λ = 576 nm, and λ = 592 nm and calculated according 
to: 
 * = &2  +,-2/ − +,-/3 − +,-4#)    , 
Eq. 6: Calculation of the free hemoglobin concentration according to Cripps (88). 
Where C is the free Hb concentration in [mg/dL], OD576, OD560, and OD592 the optical density at λ = 576, 560, 
and 592 nm, respectively, k a constant (k = 99.8 mg/dL), and DF the dilution factor of the sample. 
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b. Hemolysis 
 
Hemolysis referred to the amount of free hemoglobin (plasma Hb) expressed in % of the 
total hemoglobin (blood Hb). 
 
c. Thrombin-antithrombin  III 
 
The thrombin-antithrombin III (TAT) concentration was measured by ELISA assay (Enzygnost 
TAT micro, ref. OWMG 15; Siemens, Marburg Germany). Blood samples (1.8 mL) were 
stopped with 0.2 mL 3.8% NaCitrate in 3.5 mL polystyrene tubes on ice. Then, plasma 
aliquots were stored at -20 °C after isolation. 
 
d. Complement component 5a 
 
The complement component 5a (C5a) concentration was measured by ELISA assay (DRG C5a 
ELISA, ref. EIA-3327; DRG Instruments GmbH, Marburg, Germany). Blood samples (1.8 mL) 
were stopped with 0.2 mL 100 mM EDTA solution in 3.5 mL polystyrene tubes on ice. Then, 
plasma aliquots were stored at -20 °C after isolation. 
 
e. Cell count 
 
Samples were measured in duplicate immediately after sampling. Leucocyte (WBC), 
erythrocyte (RBC), platelet (PLT), and basophilic granulocyte counts were determined by 
impedance. The hematocrit level (Hct) was calculated from these values. Lymphocyte, 
monocyte, neutrophilic, and eosinophilic granulocyte counts were determined by impedance 
and light scattering. The total Hb concentration (tHb) was determined by measuring the 
OD550 after cell lysis. 
 
f. Measurement of the uremic toxin concentration by RP-HPLC 
 
i. Sample preparation 
 
The total toxin concentration was determined in plasma samples diluted 1:5 (final volume 5 
mL) in saline. Then, proteins were heat denatured (30 min at 95 °C) and, subsequently, 
cooled on ice for 10 min. A 1 mL sample was transferred into YM30 filter units and 
centrifuged for 60 min at 2,000 g and 5 °C. This protocol was further refined as follows. 
Plasma samples were diluted 1:5 in PBS pH 7.4 (final volume 0.5 mL), proteins were heat 
denatured and cooled as given above. The sample was transferred into an Eppendorf cup 
and centrifuged at 10,000 g and room temperature for 5 min to pellet precipitated proteins. 
The resulting clear supernatant was filtered through 30 kDa filter units (from VWR) and 
centrifuged for 30 min at 10,000 g and room temperature to remove larger proteins. Finally, 
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filtrate was transferred into HPLC vials and measured by RP-HPLC. Standard curves were 
generated in human plasma using the same preparation method. 
 
The free toxin concentration was determined in plasma samples directly filtered through 
YM30 (1 mL) or 30 kDa units (0.5 mL, VWR) for 30 min at 10,000 g and room temperature. 
The filtrate was transferred into HPLC vials and measured by RP-HPLC. Standard curves were 
produced in saline or PBS pH 7.4 since no difference was seen compared with a standard 
curve in plasma filtrate. 
 
ii. Measurements 
 
RP-HPLC detection parameters were Ex.280 nm / Em.340 nm and Ex.264 nm / Em.290 nm for 
IS and pCS, respectively. Elution gradients started from 15% to 25% eluent B within 10 min at 
1 mL/min and 30 °C; eluent A was 50 mM NH4COOH buffer pH 3.4 adjusted with formic acid, 
eluent B was acetonitrile. Retention times in such conditions were about 5.1 and 6.8 min for 
IS and pCS, respectively. 
PAA was detected with UV-VIS at λ = 259 nm and 30 °C with flow rate of 1 mL/min. 
Retention time was about 14 min. As an internal standard, 1.5 mg/mL Phe was used. 
Gradient: from 5% to 60% eluent B within 20 min. Eluent A: 4 mM TBA + 10 mM K2HPO4 in 
HPLC water at pH 7.0 (with NaOH), Eluent B: 80% acetonitrile + 20% A (v/v). 
 
g. Dialysis experiments 
 
For all dialysis experiments involving standard or mini-dialyzers, the dialyzer and tubing 
system were initially rinsed with 1 L saline in single pass at appropriate flow rate (NB: in the 
case of mini-dialyzer setups, the circuit was rinsed with 100 mL saline only). Then, the circuit 
was closed, the dialysate circuit was connected and the system was recirculated for at least 
20 min. The tubing system was filled with blood or plasma, respectively. In the case of 
standard dialysis with blood, blood was added to reach a pre-determined total blood volume 
within the system. Finally, the venous line was connected to the blood reservoir and the 
dialysis session started. 
 
Note: For the dialysis experiments involving the serial dialyzers setup, the external tubing 
system of the first cartridge was rinsed in single pass with saline and then closed. 
Consecutively, fluid in this closed loop was pumped at the appropriate flow rate until the end 
of the experiment. 
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h. Blood smears 
 
Blood smears were analyzed on microscope slides after May-Grünwald Giemsa staining. 
Staining was performed as follows. After drying, blood smears were immerged for 3 min in 
May-Grünwald staining solution. Then, the May-Grünwald staining solution was diluted 1:1 
in PBS pH 7.4 and microscope slides were further immerged for 1 to 2 min. They were 
immerged 15 to 20 min in the Giemsa working solution, well rinsed with PBS pH 7.2 and 
finally air-dried. 
 
2) Statistical analysis 
 
If normally distributed, comparison of two groups was performed with the Student’s t-test. 
To compare more groups, a one way ANOVA followed by Tukey’s post-hoc test was applied. 
If not normally distributed, the Mann-Whitney-U-test was used. Correlation was assessed 
with the Pearson test. A P-value < 0.05 was considered to be significant (software: Minitab® 
and GraphPad Prism). Results are always given as mean ± SD. 
 
3) Experimental part 
 
Physiological Na+ and Cl- concentrations in human plasma are 140 ± 5 and 100 ± 5 mM 
respectively, corresponding to a physiological NaCl concentration ([NaCl]) of 120 mM 
whereas saline has a concentration of 154 mM for both Na+ and Cl- (308 mOsm/L). Thus, 
isotonic [NaCl] will refer to “0.15 M NaCl”. 
 
a. In vitro uremic toxin binding experiments 
 
i. Effect of storage conditions 
 
Blood from eight ESRD patients was drawn in EDTA-tubes before dialysis and plasma was 
separated. An aliquot (1 mL) was taken to determine total and free IS and pCS 
concentrations while, another aliquot was frozen at -20 °C for 6 months and then thawed to 
repeat the measurements. 
Heparinized plasma (5 IU/mL) was isolated from blood of two healthy volunteers (n = 2) and 
kept either in the fridge or at -20 °C overnight. IS and PBS pH 7.4 were added to the fresh 
and the thawed plasma (650 µL plasma, 900 µL final volume) to reach 22, 44, 111, 222, and 
444 µM IS (corresponding to an albumin/toxin ratio ranging from 0.05 to 1.0). An aliquot of 
each sample was taken to measure total and free IS concentrations as well as the albumin 
concentrations. The binding constants KD and Bm were determined using Eq. 2. 
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ii. Uremic toxin binding affinity in uremic plasma 
 
Blood from 49 ESRD patients was collected in EDTA-tubes pre- and post-dialysis; plasma was 
separated at 2,000 g for 10 min. Four hour dialysis sessions were performed in HD or HDF 
modus. Free and total IS and pCS were determined in these samples. The binding properties 
were assessed by non linear regression using a one site specifying binding equation (Eq. 2) 
by considering each sample as part of a uremic “pool”. 
 
iii. Pilot binding studies of IS, pCS, and PAA in normal human 
plasma 
 
The effect of toxin concentration and increased [NaCl] on different uremic toxins was tested 
in normal human plasma isolated from heparinized blood (5 IU/mL). Toxin concentrations 
were 5, 10, 25, 50, 100, and 200 µM for both IS and pCS, 100, 200, 500, 1000, 2000, and 
4000 µM for PAA. [NaCl] was 0.15, 0.30, 0.50, and 1.00 M. 
Binding studies involving IS and PAA with 0.15, 0.30, and 0.50 M NaCl were performed by 
mixing plasma with a cocktail of IS and PAA; whereas with 1.00 M NaCl, pCS was also added. 
Experiments involving pCS at 0.15, 0.30, and 0.50 M NaCl were performed with pCS only. 
Firstly, toxins were added to 1.5 mL plasma and incubated for 1 h at room temperature. 
Then, 5.00 M NaCl solution and saline were added to reach the target [NaCl] and a final 
volume of 3.0 mL (final plasma dilution 1:2). Again, samples were incubated for 1 h at room 
temperature. Free and total toxin concentrations were measured using RP-HPLC. 
 
iv. Determination of the binding constants of IS in HSA solution 
 
Fatty acid free HSA (8.5 g/L stock solution) was mixed 1:1 with IS, PBS pH 7.4, and 5.00 M 
NaCl (final volume: 1 mL; final concentrations: HSA, 4.25 g/L; IS, 2.5, 5.0, 7.5, 10, 15, and 25 
µM; NaCl, 0.15, 0.30, 0.50, and 0.75 M) and incubated for 30 min at room temperature. The 
toxin-albumin ratio was kept < 0.40 mol/mol. Free and total toxin concentrations were 
measured using RP-HPLC. The binding constants KD and Bm were determined using Eq. 2. Bm 
was set constant and equal to the HSA concentration (65 µM). Two independent 
experiments were performed (n = 2). Scatchard plot analysis was performed on the free and 
bound IS concentrations. 
 
v. Determination of the binding constants of IS, pCS, and PAA in 
normal human plasma 
 
Experiments involving IS were performed with 0.5 mL citrate-plasma after removal of fat 
aggregates with a transfusion set. Plasma was incubated for 30 min at room temperature 
and different [NaCl] in PBS pH 7.4 ([NaCl]: 0.15, 0.30, 0.50, and 0.75 M). IS was added to 
reach a final concentration of 8, 15, 23, 30, 90, and 150 µM. The volume of PBS pH 7.4 was 
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adjusted with respect to the IS and NaCl volumes so that the plasma was always 1:2 diluted. 
The toxin-albumin ratio was kept ≤ 1.0 mol/mol to avoid non-specific binding. Experiments 
involving pCS were performed as already described (refer to “Pilot binding studies of IS, pCS, 
and PAA in normal human plasma”). Both toxins were studied separately in order to avoid 
competition for the binding sites. Three independent experiments were performed using 
plasma of three different donors (n = 3). 
Experiments involving PAA were performed with either 3.48 mL (for 0.15 M NaCl) or 3.08 mL 
citrate-plasma (for 0.40, 0.50, and 0.65 M NaCl). PAA (100 mM stock solution, final 
concentrations: 0.025, 0.1, 0.5, 1.0, 2.0, 4.0, and 8.0 mM) was added with saline, 5.00 M 
NaCl and Phe (0.4 mg/mL final concentration) to reach a final volume of 4 mL. Toxin and 
plasma were incubated for 1 h at room temperature. This experiment was performed in 
triplicate with the plasma of the same donor. 
Free and total toxin concentrations have been measured by RP-HPLC. The binding constants 
KD and Bm were determined using Eq. 2 for IS and pCS and Eq. 4 for PAA. 
For IS, the ratio KD/Bm was calculated from the experimental free and bound IS 
concentrations. The ratio KD/Bm was used as input to calculate the theoretical PBF using Eq. 
3. Theoretical and experimental PBF were compared at low toxin-albumin ratio. The PBF was 
determined as follows: in the theoretical approach, the toxin-albumin ratio was set at 0.1; in 
the experimental approach, the toxin-albumin ratio was obtained from the measured total 
toxin and albumin concentrations. 
 
vi. Binding studies of IS and pCS in uremic plasma 
 
7.5 mL blood from 15 ESRD patients was collected before dialysis in EDTA-tubes, plasma was 
separated and stored at -30 °C. For the binding experiments, 0.5 mL of uremic plasma was 
incubated for 30 min at different [NaCl] (0.15, 0.30, 0.50, and 0.75 M NaCl) in PBS pH 7.4 at 
room temperature. The volume of PBS was adjusted with the NaCl volume so that the 
plasma was always 1:2 diluted. For each sample, free and total IS and pCS concentrations 
were measured by RP-HPLC. KD of uremic plasma proteins for IS and pCS was estimated 
according to Eq. 3 and considering [HSA] = 286 µM after 1:2 dilution (37), thus, 
hypothesizing Bm being constant at 286 µM. 
 
vii. Effect of plasma dilution on the binding properties 
 
These experiments were performed in citrate-plasma with a final dilution of either 1:2 or 
1:10.  Plasma (0.5 or 0.1 mL) was diluted with PBS pH 7.4, NaCl solution, and IS solution to 
reach a final [NaCl] of 0.15 and 0.50 M and a final volume of 1.0 mL. To 1:2-diluted plasma 
samples IS was added to obtain the same concentrations as described above (refer to 
“Determination of the binding constants of IS, pCS, and PAA in normal human plasma”). 
1:10-diluted samples contained only one fifth of IS. The samples were incubated for 30 min 
at room temperature, further analyzed by RP-HPLC, and binding constants KD and Bm were 
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determined as previously described. Scatchard plot analysis was performed on the free and 
bound IS concentrations. 
 
viii. Effect of the temperature on the PBF of IS 
 
Experiments were performed with plasma of two different ionic strengths. Firstly, 17.5 mL 
freshly donated heparinized (5 IU/mL) plasma from a single healthy donor was diluted with 
the same volume of PBS pH 7.4. Secondly, to prepare plasma with higher ionic strength, 17.5 
mL heparinized plasma was mixed with half of the volume (8.75 mL) of PBS pH 7.4 and half 
of the volume (8.75 mL) of a 2.00 M NaCl solution resulting in 1:2 diluted plasma with 0.61 M 
[NaCl]. Both preparations were dialyzed (2.1 mL/min) at 25 and 37 °C against a solution of 
150 µM IS with the corresponding ionic strength (0.15 and 0.61 M NaCl) using a mini-dialyzer 
with a low-flux dialysis membrane (Cuprophan®, 125 cm² membrane surface area; inner and 
outer compartment each 4.6 mL, respectively). Samples for the measurement of the total 
toxin concentration were collected from both compartments when the equilibrium was 
reached (1 h). The equilibrium point previously was determined during a pilot experiment 
with 12 mL plasma and the toxin solution during 150 min. Plasma runs through the dialyzer 
were calculated according to: 
 
5 = 6 × 78 
Eq. 7: Calculation of blood or plasma runs through the dialyzer. 
Where τ is the number of plasma or blood runs, t the dialysis duration [min], Q the flow (plasma or blood) rate 
[mL/min], and V the fluid (plasma or blood) volume [mL]. 
 
ix. Effect of different ion species on the PBF of IS in uremic plasma 
 
Two separate experiments (n = 2) were performed with plasma of the same uremic patient. 
Plasma (1 mL) was mixed with different solutions (final volume 1.75 mL) to compare the 
influence of the ion species and pH value on the PBF of IS. Therefore different stock 
solutions were prepared: 3.00 M NaCl, 3.00 M KCl, 0.15 M CH3COONa pH 4.85 adjusted with 
CH3COOH, and 0.15 M CH3COONH4 pH 4.85 adjusted with CH3COOH. Eight different plasma 
preparations were compared: native plasma diluted with saline, plasma + 0.50 M NaCl, 
plasma + 0.50 M KCl, plasma + 0.25 M NaCl + 0.25 M KCl, plasma with pH decreased to about 
5.4 using either 0.15 M CH3COONa or 0.15 M CH3COONH4 stock solutions and with either 
0.15 or 0.50 M NaCl. Total and free toxin concentrations were measured. 
  
 b. Dialysis experiments in aqueous solution
 
Dialysis experiments in saline were performed using a modified Bellco Formula 2000 dialysis 
apparatus; the setup illustrated in 
blood reservoir (BR), arterial (ART)
monitored at the blood and dialysate inlet and outle
 
 
To determine the ionic strength of the solution contained in the blood line, the conductivity 
was measured. The conductivity 
to Kohlrausch’s law (89): 
 
Eq. 8: Kohlrausch’s law (89). 
Where λi is the ionic molar conductivity [S.m
 
A standard conductivity curve was generated in deionized water at room temperature by 
diluting a 5.00 M NaCl solution to 0.1
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Fig. 8 was initially used. Samples were taken from the 
, and venous (VEN) accesses. System pressures were 
t of the dialyzer. 
 
Fig. 8: Standard pre
setup. 
The fluid is pumped 
through the dialyzer. The substitution fluid is 
driven into the blood stream; the ionic 
strength of the substituate is increased by 
adding (flow rate QNaCl) a 5.00 M NaCl solution. 
The excess volume is removed by adjusting the 
ultrafiltration flow rate 
in the blood reservoir is monitored and kept 
constant by automatically restoring with saline 
the volume lost by QUF. 
σ is directly proportional to the ion concentration according 
9 =:;<. =< 
2
/mol] and [Xi] the concentration of the ion i
0, 0.25, 0.50, 1.00, 2.50, and 5.00 M NaCl.
 
-dilution HDF, initial 
from the blood bag 
QUF. The fluid volume 
 [mol/m
3
]. 
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i. Standard HDF – stability of ionic strength  
 
Initial dialysis experiments were performed in pre-dilution HDF (pre-HDF, Fig. 8) modus using 
a PUREMA® H dialyzer (1.8 m² membrane surface area) and with 525 mL saline in the blood 
circuit. Machine settings were QB = 300 mL/min, QD = 500 mL/min, substituate flow rate Qinf 
= 160 mL/min, and QUF = 40 mL/min. The dialysate temperature was set to 37 °C. In a first 
experiment, the saline was recirculated for 30 min. Then, saline (0.15 M) was injected into 
the substitution fluid at QNaCl = 5, 10, 15, 20, and 25 mL/min, waiting 15 min for equilibration 
after flow rate alteration and before sampling. In a second experiment, a 5.00 M NaCl 
solution was injected during 4 h at QNaCl = 25 mL/min. Samples were drawn after 5, 30, 60, 
120, 180, and 240 min to measure conductivity. 
 
ii. Standard HDF – effect of Qinf 
 
This experiment was performed using the same hemodialyzer and machine settings as 
described above (refer to “Standard HDF – stability of ionic strength”). A 5.00 M NaCl 
solution was infused into the substitution fluid at QNaCl = 5, 10, 15, 20, 25, and 30 mL/min, 
waiting 15 min for equilibration after flow rate alteration and before sampling. Samples 
were drawn at the BR, ART, and VEN accesses to measure conductivity. In a first experiment, 
Qinf and QUF were 160 and 40 mL/min, respectively; whereas in a second experiment, they 
were set to 50 and 30 mL/min, respectively.  
 
iii. Standard HDF – modification of the dialysis setup 
 
In a next step, the dialysis setup was modified (see Fig. 9) so that the external pump, which 
infused the 5.00 M NaCl solution, simultaneously removed substitution fluid at the same 
flow rate QNaCl to keep Qinf constant. Dialysis experiment was performed in pre-HDF modus 
as described above (see “Standard HDF – stability of ionic strength”).  Samples were taken 
with the BR, ART, and VEN accesses to measure conductivity. 
 
  
iv. Standard HDF 
 
This pre-HDF experiment (Fig. 
membrane surface area) and with 525 mL saline in the blood circuit.
QB = 200, 300, 400, and 500 mL/min, Q
40 mL/min. Dialysate temperature was set to 37 °C. After 30 min recirculation, the 5.00 M 
NaCl solution was infused into the substitution fluid at Q
waiting 15 min for equilibration
were drawn with the BR, ART, and VEN accesses to measure conductivity.
  
v. Serial dialyzers 
 
Three pre-HDF sessions lasting 2 h were performed with 1 L saline using two 
as presented in Fig. 10: the first cartridge contained DIAPES® HF800
the second cartridge contained PUREMA® H membranes (
in Tab. 6. Samples (2 mL) were drawn at the first dialyzer blood outlet (BM, also second 
dialyzer blood inlet), second dialyzer blood outle
outlet (OUT) after 0, 15, 30, 60, 90, and 120 min to monitor the [NaCl].
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Fig. 9: Standard pre-dilution 
setup. 
The initial standard pre
(Fig. 8) was modified by simultaneously 
infusing 5.00 M NaCl solution and removing
substitution fluid at the same flow rate 
via the external pump (as indicated by the grey 
arrow). 
– effect of QB and QD 
8) was performed using a PUREMA® H dialyzer (1.8 m² 
 Machine settings were 
D = 500 and 800 mL/min, Qinf = 160 mL/min, and
NaCl = 5, 10, 15, 20, and 25 mL/min, 
 after flow rate alteration and before sampling.
 
– stability of ionic strength  
 membranes (1.4 m²
1.7 m²). Flow rates used are given 
t (VEN), first dialyzer dialysate inlet (IN) and 
 
 
HDF, second 
-dilution HDF setup 
 
QNaCl 
 QUF = 
 Samples 
serial dialyzers 
); 
 Session QB 
1 150 
2 150 
3 150 
Tab. 6: Flow rate used to determine the stability of the ionic strength
dialyzers setup. 
Flow rates are given in [mL/min]. The dialysis sessions correspond to: 1) Q
3) Qex > (QB + Qinf). Abbreviations: Q
ultrafiltration flow rate (weight-loss); Q
rate; Qex, dialysate flow rate (closed loop) of the first cartridge.
 
 
 
vi. Serial dialyzers 
 
The impact of the dialysate flow rate in the first cartridge 
525 mL human whole blood using different flow rates (
and QUF) and hemodialyzers were the same as
ionic strength”). The dialysate temperature was set to 39 °C. 
was measured in the first dialyzer blood outlet (BM) and first dialyzer dialysate outlet (IN).
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QD QUF Qinf Q
500 0 75 200
500 0 75 225
500 0 75 250
 during pre-dilution HDF with the 
ex < (QB + Qinf), 2) Q
B, blood flow rate; QD, dialysate flow rate (second cartridge); Q
inf, substitution fluid flow rate; QNaCl, 5.00 M NaCl solution infusion flow 
 
 
Fig. 10: Serial dialyzer
dilution HDF. 
The standard pre
was improved by adding a second 
cartridge in which t
circuit is connected in a closed loop 
(here “dialyzer 1”) and filled with 
saline; the solution is pumped 
counter-current the 
with a flow 
strength is increased 
loop by substituting
M NaCl solution. 
strength in the 
increased by 
semi-permeable membrane
experiments involving the serial 
dialyzers setup were performed on 
a Nikkiso DBB03 dialysis apparatus.
– influence of Qex 
Qex on the [NaCl] was studied in 
Tab. 7). Machine settings (Q
 above (refer to “Serial dialyzers 
As exposed in 
 
ex QNaCl 
 14.4 
 16.2 
 18.0 
serial 
ex = (QB + Qinf), and 
UF, 
s setup in pre-
-HDF setup (Fig. 9) 
he dialysate 
blood stream 
rate Qex. The ionic 
in the closed 
 saline with 5.00 
Thus, the ionic 
blood stream is 
diffusion through the 
. All 
 
B, QD, Qinf, 
– stability of 
Fig. 10, [NaCl] 
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 Qex [ mL/min ] 
 100 200 300 400 500 
QNaCl 
[mL/min ] 
3.1 6.2 9.3 12.4 15.5 
7.2 14.4 21.6 28.9 36.1 
12.4 24.7 37.1 49.5 61.9 
Tab. 7: Flow rates used to determine the influence of Qex on the ionic strength in blood. 
Abbreviations: QNaCl, 5.00 M NaCl solution infusion flow rate; Qex, dialysate flow rate (closed loop) of the first 
cartridge. 
 
vii. Serial dialyzers with transmembrane pre-dilution 
 
In a first experiment, the serial dialyzers setup with transmembrane pre-dilution HDF (SDial-
TM pre-HDF, Fig. 11) was tested with saline at QB = Qex = 150 mL/min, QD = 500 mL/min, Qinf 
= 75 mL/min, and QUF = 0 mL/min. The dialysate temperature was set to 39 °C. Filters were 
the same as already described (see “Serial dialyzers – stability of ionic strength”). After 10, 
20, and 30 min of dialysis with QNaCl = 6.5 mL/min, 3 mL samples for [NaCl] measurement 
were drawn BM, IN, and OUT. The same was repeated with QNaCl = 10.8 mL/min. 
In a second experiment, the [NaCl] was measured during different sessions (see flow rates in 
Tab. 8). Samples were drawn over 3 min (interval of 1 min), waiting 15 min for equilibration 
after flow rate alteration and before sampling. Note: [NaCl]OUT for the third setting was not 
measured. 
 
Session QB QD QUF Qinf Qex QNaCl 
1 150 500 0 75 25 13.5 
2 150 500 0 75 200 17.0 
3 300 500 0 75 200 27.0 
Tab. 8: Flow rates used to determine the stability of the ionic strength with SDial-TM pre-HDF. 
Flow rates are given in [mL/min]. Abbreviations: QB, blood flow rate; QD, dialysate flow rate (second cartridge); 
QUF, ultrafiltration flow rate (weight-loss); Qinf, substitution fluid flow rate; QNaCl, 5.00 M NaCl solution infusion 
flow rate; Qex, dialysate flow rate (closed loop) of the first cartridge. 
 
  
c. Ex vivo hemocompatibility of increased ionic strength
 
i. Cell damage in single pass dialysis
 
Human heparinized blood (5 I
in single pass against different 
NaCl) using a mini-module 
effective surface area) in order 
increased ionic strength was collected in Petri dishes and
°C under agitation (70 rpm). Samples (1 mL) were taken after 0, 15, 30, 60, 90, 120, and 240 
min to measure cell count and hemolysis
blood in the last sample (240 min).
Hemolysis levels resulting from this experiment were compared to a reference: 3 mL human 
heparinized blood (5 IU/mL) from 21 volunteers (n = 21) was diluted
saline and 2.00 M NaCl in order to increase [NaCl]
incubated at room temperature for 1 h. Finally, free Hb, tHb and cell counts were 
determined. 
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Fig. 11: Serial dialyzer
transmembrane 
This setup differs from 
dialyzers in pre
substituate line which is connected 
to the closed loop of the first 
hemodialyzer (indicated by the grey 
arrow). 
 
U/mL; pool from 3 donors) was dialyzed (QB 
dialysate solutions (0.15, 0.40, 0.50, 0.60, 0.75, and 1.00 M
setup (Fig. 12; containing Polyamix™ membranes, 258 cm² 
to test increasing [NaCl]blood. Blood (8 mL)
 then incubated 
. Na+ and Cl- concentrations were measured in 
 
 with 1.44 mL of a mix of 
blood. Blood of the references was 
 
s with 
pre-dilution HDF. 
Fig. 10 (serial 
-dilution HDF) by the 
 
= QD = 4.3 mL/min) 
 
 subjected to 
for 240 min at 37 
  
Blood smears at different [NaCl] were performed in human blood, after setting Hct and 
heparin concentration to 32% and 10 IU/mL, respectively, as follows: blood was diluted 1:10 
in plastic tubes with different NaCl solutions to reach a final concentration 
0.50, and 0.75 M NaCl.  
 
In order to study the blood cell morphology before and after contact with high ionic 
strength, human heparinized 
a setup with serial mini-dialyzers (
effective surface area). In the first cartridge, the same dialysate solutions as above were 
used to increase [NaCl]blood;
dialysate to bring back to physiological ionic strength. 
second dialyzer inlet and outlet to measure cell count; 15 min have been waited for 
equilibration after [NaCl] alteration and before sampling. Blood smears were also 
performed. 
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Fig. 12: Setup for single pass
with NaCl solution. 
Blood is pumped from a plastic tube through a 
mini-dialyzer in which a NaCl solution flows 
counter-currently. [NaCl] increases in blood within 
the dialyzer. 
blood was dialyzed (QB = QD = 4.1 mL/min) in single pass using 
Fig. 13; containing Helixone® membranes
 in the second cartridge blood was dialyzed against fresh 
Blood samples w
 
 experiment of blood 
of 0.15, 0.25, 
, 239 cm² 
ere drawn in the 
  
ii. Effect
 
Dialysis experiments were performed 
area) in heparinized human blood (5 IU/mL) with Q
10 mL/min, and Qinf = QNaCl 
substitution fluid ([NaCl]SUB) was increased to 1.00 M. Blo
single donor) or 1500 mL (pool from 3 donors). ART and VEN samples were taken after 0
30, 60, 90, 120, and 180 min. Cell count and hemolysis were measured only in venous 
samples, whereas BGA and ion concentrations were me
samples. Pressures were recorded online. Two separate experiments were performed (n = 
2). Blood runs were calculated according to 
calculated according to Eq. 9 (90)
 
>? =
Eq. 9: Calculation of the transmembrane pressure.
 
iii. Maximizing 
 
Standard pre-dilution HDF pilot experiments 
(1.7 m² membrane surface area
150 mL/min, QD = 500 mL/min, and 
rates were tested (Tab. 9). Samples were drawn after 0, 15, 30, 60, 90, 120, 
min to perform BGAs (samples ART and VEN), cell counts and hemolysis measurements 
(samples VEN only). 
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Fig. 13: Serial dialyzers setup
experiment of blood with NaCl solution.
Blood is pumped from a plastic
mini-dialyzer in which a NaCl solution flows 
counter-currently to increase [NaCl] in blood. 
Then, blood passes a second dialyzer in which 
counter-currently flowing dialysate to restitute 
physiological ionic strength in blood.
 of blood volume on hemolysis and cell count
using PUREMA® H dialyzer (1.7 m² 
B = 150 mL/min, QD = 500 mL/min, Q
(150 mL/min) using standard pre-HDF (Fig. 
od volume was either 500 (one 
asured in both arterial and venous 
Eq. 7. The transmembrane pressure (TMP) was 
 : 
@AB<ACD  @ABEDACD2  B<FAGHFDC
<ACD  B<FAGHFDCEDACD2  
 
the NaCl concentration in blood 
were performed using a PUREMA® H dialyzer 
) in human heparinized blood (500 mL; 5 IU/mL) with
QUF = 0 mL/min. Different settings and infusion flow 
 
 for single pass 
 
 tube through a first 
 
 
membrane surface 
UF = 
9). [NaCl] in the 
, 15, 
 QB = 
150, and 180 
 Setting NaCl solution infused
Single infusion (Fig. 9) 
Single infusion (Fig. 9) 
Spread infusion (Fig. 14) 
Single infusion (Fig. 9) 
Tab. 9: Settings and flow rates tested to determine the maximal [NaCl] in blood
Flow rates are given in [mL/min]. Abbreviations: Q
flow rate; [NaCl]blood, NaCl concentration
 
 
 
iv. Role of the 
 
A HD pilot experiment (n = 1) 
h with QB = 150 mL/min, QD
heparinized blood (10 IU/mL; pool of 2 donors
saline. Dialysate temperature was set to 39
membranes (1.4 m²) and the second cartridge contained PUREMA® H membranes (1.7 m²).
The first part of the experiment was performed with Q
[NaCl]IN 1 ≈ 0.55 M, whereas the second 
leading to [NaCl]IN 1 ≈ 1.17 M. 
were replaced with new ones, and blood from the same pool was used. 
5.00 M NaCl was infused during the first 2
were performed in isotonic conditions (Q
52 
 QNaCl Qinf 
0.15 M 14.5 50 
1.00 M 150 150 
1.00 M 150 150 
1.55 M 14.5 50 
. 
inf, substitution fluid flow rate; QNaCl, NaCl solution infusion 
 in blood after increased ionic strength. 
 
Fig. 14: Standard pre-dilution HDF with spread 
infusion of the substitution fluid.
To perform the spread infusion (see grey arrows), 
the substituate line was connected 
line at 4 different accesses. 
first-cartridge membrane in the osmotic 
using the serial dialyzers setup (Fig. 10) was
 = 500 mL/min, and QUF = Qinf (0 mL/min)
) after adjustment of the 
 °C. The first cartridge contained DIAPES® LF100 
ex = 300 mL/min (> 
part was performed with Qex = 
Between both parts, the tubing systems and both cartridges 
In each experiment 
 h (QNaCl = 11 mL/min) while the remaining 2 h 
NaCl = 0 mL/min). Samples were taken 
 
Target [NaCl]blood 
0.15 M 
0.50 M 
0.50 M 
0.50 M 
 
to the blood 
shock 
 performed over 4 
 and with 525 mL 
Hct to 32% with 
 
QB) leading to 
50 mL/min (< QB) 
after 0, 15, 
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30, 45, 60, 90, 120, 135, 150, 180, 210, and 240 min. The [NaCl] was measured in both 
arterial and venous samples; cell count and hemolysis were determined only in venous 
samples. Pressures and the temperature were monitored online. The TMP of each 
hemodialyzer was calculated according to Eq. 9.  
 
v. Comparison between standard and serial dialyzers pre-dilution 
HDF 
 
Dialysis treatments were performed during 2 h in pre-HDF modus with human whole blood 
(525 mL) after adjustment of Hct, heparin, and TP to 32%, 10 IU/mL, and 65 g/L with saline, 
heparin, and 20% HSA solution, respectively. Flow rates were:  QB = 150 mL/min, QD = 500 
mL/min, Qinf = 75 mL/min, Qex = 225 mL/min, and QUF = 0 mL/min. The same hemodialyzers 
as already described (refer to “Serial dialyzers – stability of ionic strength”) were used. 
During standard pre-HDF (Fig. 9), different [NaCl]SUB were tested: 0.15, 0.75, 1.00 (Qinf = 50 
mL/min), and 1.20 M NaCl, which corresponds to [NaCl]blood = 0.15, 0.36, 0.36, and 0.50 M 
NaCl, respectively. For this purpose, the external pump provided 5.00 M NaCl solution flow 
rates QNaCl of 0, 10, 9.5, and 16 mL/min, respectively. During serial dialyzers pre-dilution HDF 
(SDial pre-HDF, Fig. 10), QNaCl was set to 0, 16, 20, and 30 mL/min to provide [NaCl]blood of 
0.15, 0.36, 0.50, and 0.75 M, respectively. The dialysate temperature was set to 39 °C. Blood 
was recirculated for 5 min before starting the experiment (NaCl pump start). ART (standard 
pre-HDF) and BM (SDial pre-HDF) samples (1 mL) were drawn after 0, 15, 30, 45, 60, 90, and 
120 min to measure [NaCl]. VEN samples (7.5 mL) for cell count, free Hb, [NaCl], C5a 
concentration, and TAT concentration were drawn simultaneously. Pressures were 
monitored online: blood ART and VEN, dialysate inlet and outlet (second cartridge only); 
TMP was calculated with Eq. 9. 
 
vi. Serial dialyzers transmembrane pre-dilution HDF 
 
The serial dialyzers setup as described above (Fig. 10) was compared to the SDial-TM pre-
HDF (see Fig. 11) using 0.50 M [NaCl]blood. Dialysis parameters, blood preparation and 
sampling were the same as above mentioned (see “Comparison between standard and serial 
dialyzers pre-dilution HDF”). Several pressure transducers were added to separately detect 
the TMP of both filters. Three separate experiments (n = 3) were performed. 
 
 Fig. 15: Experimental setting of serial dialyzer
 
d. Removal of uremic toxins by dialysis
 
i. Clearance
 
Single pass dialysis experiments were performed with mini
membranes (258 cm² effective surface area
corresponded to QB eq = 300
membrane surface area of 1.8 m² according to 
 
Eq. 10: Flow rate extrapolation from minituarized to standard setup
 
The mini-dialyzer and tubing system were initially rinsed with saline for 20 min. Then, a 20 
µM aqueous IS solution was dialyzed (Q
dialysate in counter-current flow. 
min to measure the IS concentration. The same was repeated with Q
8.33 and 10.9 mL/min for QB 
was rinsed with saline and heparinized plasma (5 IU/mL) from healthy donors spiked with 20 
54 
s transmembrane pre-dilution HDF. 
 
 measurement in a miniaturized setup
-dialyzers containing Polyamix™ 
) at QB = 4.3 and 5.7 mL/min. This setup 
 and 400 mL/min, respectively, when extrapolated to 
Eq. 10: 
7I = JI × 7#J#  
. 
B = 4.3 mL/min) at room temperature against 
Arterial and venous samples were taken after 5, 6, and 7 
B = 5.7 mL/min (Q
= 4.3 and 5.7 mL/min, respectively). In a next step, the system 
 
 
 
a 
D = 
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µM IS was used applying the same method. Finally, the system was rinsed with saline and 
the first trial in aqueous solution was repeated. The free IS fraction was also determined in 
arterial samples. The instantaneous clearance of IS was calculated according to Eq. 11: 
 
 = 7K. *L − *MNO*L  
Eq. 11: Instantaneous clearance (91). 
Where K is the clearance [mL/min], QB the blood flow rate [mL/min], CART and CVEN the arterial and venous 
concentrations, respectively. 
 
The calculated clearance from the free toxin fraction was determined according to Eq. 12: 
 CHD = FPECEH   
Eq. 12: Estimated clearance of the free toxin fraction. 
Where Kest is the blood or plasma estimated clearance [mL/min], Kaqueous the aqueous clearance of the 
compound [mL/min], and FF the free toxin fraction. 
 
ii. Comparison of HD, HDF, and increased ionic strength HDF in 
healthy plasma 
 
IS (final concentration: 90 µM) and heparin (5 IU/mL) were added to freshly frozen human 
citrate plasma. After one hour incubation at room temperature, in vitro dialysis using the 
conditioned plasma (about 115 mL) and mini-dialyzers (31 mL; housing containing 
Polyamix™ membranes, 258 cm² effective surface area;  two blood flow rates QB = 4.3 and 
5.7 mL/min corresponding to QB eq = 300 and  400 mL/min, respectively, when extrapolated 
(Eq. 10) to a membrane surface area of a 1.8 m² dialyzer) was performed at room 
temperature in three different modes (Fig. 16): i) HD, ii) pre-HDF with infusion of saline, and 
iii) pre-HDF with infusion of 1.00 M NaCl (final concentration in plasma: 0.36 and 0.32 M for 
QB eq = 300 and  400 mL/min, respectively). During HDF Qinf was 1.4 mL/min (corresponding 
to Qinf eq = 100 mL/min when extrapolated (Eq. 10) to the membrane surface area of a 1.8 m² 
dialyzer). Dialysate was prepared by a Nikkiso DBB 03 dialysis machine from bicarbonate and 
electrolyte concentrate. The counter-current dialysate flow rates were QD = 8.3 and 11.0 
mL/min (corresponding to QD eq = 580 and 770 mL/min, respectively) at QB eq = 300 and 400 
mL/min, respectively. After equilibration of the toxins in the plasma during recirculation for 
10 min, a baseline sample was drawn and the treatment simulation was started. Further 
samples were drawn at 20, 50, 85, and 180 min when using QB eq = 300 mL/min and at 15, 40, 
65, and 140 min when using QB eq = 400 mL/min. The total IS concentration and the albumin 
concentration were measured.  
 
  
Kinetics of the IS removal from plasma 
exponential decay curve (Eq. 
Appendix (see “Interest of calculat
 
Eq. 13: Interpolation of toxin removal during dialysis
Where C is the remaining toxin concentration
experiment set equal to 100%, τ the number of blood runs
and γ the removal rate [%/run]. 
 
Since the volume is constant in the plasma reservoir (including tubing), dialysate is able to 
flow into the plasma when samples are drawn. The toxin concentration 
calculated with correction because of dilution due to sampling. Three independe
experiments (n = 3) were performed. The removal rates (
14) were determined from each replicate. 
 
Eq. 14: Removal ratio (64). 
Where RR is the removal ratio [%], 
experiment [µM], respectively. 
 
iii. Removal rates in uremic and normal plasma 
 
Plasma from three healthy 
hemodialysis (n = 3) was freshly prepared from heparinized blood (5 I
overnight in the fridge. IS and 
µM, respectively, taking the native total toxin concentration into account
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Fig. 16: Mini-module dialysis 
compare HD, HDF, and increased ionic strength
HDF. 
During HD, Qinf was set to 0 mL/min whereas 
during HDF, either saline or 1.00 M NaCl solution 
was infused at a flow rate Qinf eq
was interpolated using non linear regression of an 
13). The interest of such a calculation is presented in the 
ing the blood runs through the dialyzer”)
* = *3. QRS.T 
 (84). 
 [% of C0], C0 the toxin concentration at the beginning of the 
 through the dialyzer calculated according to 
γ; Eq. 13) and removal ratio (RR;
 
 = *3  **3 × 100 
C0 and Cf the toxin concentrations at the beginning
using the mini setup
volunteers (n = 3) and three patients on maintenance 
pCS were added to reach a final concentration 
.
 
setup used to 
 
 = 100 mL/min. 
. 
Eq. 7, 
was therefore 
nt 
 Eq. 
 and at the end of the 
 
U/mL) and stored 
of 100 and 130 
 In vitro pre-HDF at 
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QB eq = 300 mL/min and the determination of total toxin concentrations were performed as 
described above (refer to “Comparison of HD, HDF, and increased ionic strength HDF in 
healthy plasma”). The experiment was done in two parts: during the first 90 min, saline was 
infused into the plasma. After 90 min, the infusion solution was switched to 1.00 M NaCl 
(0.36 M final concentration in plasma). The albumin concentration was measured before and 
after the experiment to quantify the albumin loss. The toxin removal rate was determined 
according to Eq. 13. 
 
iv. Complete removal of IS and pCS with HDF 
 
Pre-dialysis uremic plasma (40 mL) from one patient (n = 1) on  maintenance hemodialysis 
was separated from heparinized blood (5 IU/mL) and dialyzed against fresh dialysate with a 
mini-dialyzer (31 mL; housing containing Helixone® membranes, 250 cm² effective surface 
area) in pre-HDF modus with a 1.00 M NaCl infusion. Flow rates were QB = 5.7 mL/min, QD = 
10.5 mL/min, and Qinf = 1.4 mL/min (resulting in 0.32 M NaCl in plasma). Samples were taken 
at the dialyzer blood outlet after 0, 2, 10, 25, 40, 60, 80, and 100 plasma runs (corresponding 
to 0, 11, 53, 134, 214, 320, 427, and 534 min, respectively; Eq. 7) to measure total IS and pCS 
concentrations. The results were calculated with correction because for dilution due to 
sampling (see above). 
 
v. Standard versus serial HD 
 
Heparinized plasma (5 IU/mL) from different donors was pooled and IS was added to reach 
about 100 µM. The added volume was only about 5% of the final volume. Then, the plasma 
was incubated for at least 15 min at room temperature to allow equilibration. The same 
mini-dialyzers as above (refer to “Complete removal of IS and pCS with HDF”) were used to 
compare standard and serial HD (Fig. 17) at room temperature with the same conditioned 
plasma. Flow rates were set at QB = 5.7 mL/min and QD = 10.5 mL/min. After rinsing both 
setups in single-pass with saline, they were filled with conditioned plasma (standard HD: 31 
mL, serial HD: 35 mL) which recirculated for 10 min without dialysate flow. Subsequently, 
the experiment was started and venous samples were drawn after 0, 30, 60, 120, 180, 240, 
and 300 min to measure the total IS concentration. Two independent experiments were 
performed with different plasma pools (n = 2). The concentration was calculated with 
correction because for dilution due to sampling (see above), and the number of blood runs 
was calculated (Eq. 7) from the respective plasma volumes. 
 
 Fig. 17: Mini-dialyzers setup to compare 
Serial HD consists of two hemodialyzers in series with independent dialysate circuits.
 
vi. Toxin removal using a standard dialysis machine
 
Before each experiment, 850 mL human citrated plasma was filtered through a transfusion 
set to remove fat aggregates and heparin was added (final concentration: 10 IU/mL). From 
this preparation, 50 mL plasma
prepare 4 syringes each containing 15 mL conditioned plasma (2 mM IS). The remaining 
plasma (800 mL) was mixed with 2 mM IS solution to reach a 100 µM IS final concentration.
One single setup was assembled to allow switching between three different HDF modi (see 
Fig. 18): standard pre-HDF (refer to 
without charcoal adsorber. To increase [NaCl]
used to replace part of the substitution fluid in case of standard pre
in case of SDial pre-HDF. Flow rates were:  Q
mL/min, Qinf = 75 mL/min, net ultrafiltration flow rate 
hemodialyzers had a high-flux polyethersulfone dialysis membrane (PUREMA® H, 1.7
The dialysate temperature was set 
The blood circuit was filled with conditioned plasma which was recirculated for 5 min. 
Subsequently, pre-HDF was performed for each setup during 30 min. After testing one 
setting, it was switched randomly t
Samples were taken after 5, 10, 15, 20, 
dialyzer blood outlet (BM; corresponding also to the second dialyzer blood inlet), and second 
dialyzer blood outlet (VEN) to measure [NaCl] and total IS concentration
pressures were monitored online. Three experiments (n = 3) were performed with each 
setting. 
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standard HD (A) and serial HD (B). 
 
 was drawn and mixed with 12.5 mL of 10 mM IS solution to 
Fig. 9) and SDial pre-HDF (refer to 
blood to 0.50 M, a 5.00 M NaCl solution was 
-HDF or part of the sal
B = 150 mL/min, QD = 500 mL/min, Q
QUF = 0 mL/min. Both serial 
at 39 °C. 
o the next and plasma again was recirculated for 5 min. 
and 30 min at the first dialyzer blood inlet (ART), first 
 
 
 
 
Fig. 10) with or 
ine 
ex = 300 
 m²). 
. Temperature and 
 Fig. 18: Dialysis setup used to switch
pre-dilution HDF with or without charcoal adsorber.
NaCl was infused either within the substitution line or within the external loop.
experimental setting. 
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 from standard pre-dilution HDF (dialyzer 1 in bypass) to serial 
 
 Top, schema; bottom, 
 
 
dialyzers 
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e. Experimental transfer into the animal model 
 
Animal experiments were performed adhering to the German Protection of Animals Act. 
After having received approval from the district government of Lower Franconia (registration 
no. 55.2-2531.01-17/09), four female Merino sheep (mean weight 42.8 ± 3.0 kg) were 
enrolled for the trials. 
 
i. RBC resistance to increased ionic strength under static 
conditions 
 
Blood from four sheep was drawn (30 mL) via the dialysis catheter before the dialysis 
experiments and anticoagulated with heparin (5 IU/mL). As already described in “Cell 
damage in single pass dialysis”, 3 mL blood was mixed with 1.44 mL of saline and 2.00 M 
NaCl in order to increase [NaCl]blood to 0.15, 0.20, 0.25, 0.35, 0.50, 0.60, and 0.75 M. Samples 
were incubated at room temperature for 1 h and hemolysis was determined. 
 
ii. RBC resistance to increased ionic strength under dynamic 
conditions 
 
Heparinized blood (100 mL, 5 IU/mL) from two human healthy donors (n = 2) and from 2 
sheep (70 mL) was drawn in order to perform standard pre-HDF with infusion of saline or 
1.20 M NaCl solution in a mini-dialyzers setting (see Fig. 16 and Fig. 19; housing containing 
PUREMA® H membranes, 250 cm² effective surface area). Hct in human blood was adjusted 
to 30% with saline. Dialysis parameters were: QB = 5.6 mL/min, Qinf = 2.8 mL/min, and QD = 
10 mL/min corresponding to QB eq = 400 mL/min, Qinf eq = 200 mL/min, and QD eq = 800 
mL/min, respectively (Eq. 10). The tubing systems were filled with blood (31 mL) and venous 
samples were taken after 30, 60, 90, 120, and 180 min to determine hemolysis. Arterial and 
venous samples were taken post-dialysis to measure the respective [NaCl]. 
 
 Fig. 19: Experimental in vitro HDF setup filled with blood (
 
iii. In vivo 
 
Pre-dilution HDF was performed 
animals were instrumented and anticoagulated as already described
Briefly, vascular access was achieved with a 20 cm double lumen dialysis cathete
into one jugular vein by Seldinger technique after local anesthesia. To avoid hypotension the 
priming fluid within the extracorporeal circuit (400 mL) was administered to the sheep at the 
start of dialysis. For anticoagulation, an initial bolus 
heparin and a continuous injection of 0.015 M NaCitrate were used. 
the sheep were observed for
monitored via tail cuff (neonatal cuff no. 4)
Tampa, USA) device.  
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A). Detail of the mini-dialyzers (
pre-dilution HDF experiments 
in a randomized crossover fashion in the
 by Krieter et al. 
dose of 10,000 units of 
During 
 symptoms of adverse reactions and blood pressure
 by using the DINAMAP® PRO 100 (Critikon, 
 
 
B). 
 four sheep. The 
(92). 
r inserted 
unfractionated 
the experiments, 
 was 
 Two hours pre-dilution HDF were performed using the two setups as already illustrated: 
standard pre-HDF (Fig. 9; PUREMA® H membranes, 1.9 m²) and SDial
first cartridge, PUREMA® L membranes, 1.
1.9 m²). Flow rates were: QB 
QD = 500 mL/min, Qinf = 75 mL/min, Q
200 mL/min, and QUF = 0 mL/min. The 
dialysate temperature was set at 37 °C. 
[NaCl]blood was increased after an initial 30 
min baseline period of standard pre
using online prepared substitution fluid in 
order to reach the following [NaCl]
standard pre-HDF 0.36 M and 0.45 M 
(corresponding to about 0.75 M and 1.10 M 
[NaCl]SUB, respectively) and SDial
HDF 0.36 M and 0.60 M. Blood samples 
were drawn from the extracorporeal circuit 
before the substitution line (ART), before 
the second dialyzer blood inlet (BM), and 
after the second dialyzer outlet (VEN) to 
measure whole blood cell count, free 
LDH concentration, BGA, and electrolyte 
concentration (Na+, Cl-, K+, Ca2+
 
 
Fig. 20: Animal model of pre-dilution HDF
A, Hemodiafiltration apparatus; B, standard pre
62 
-TM pre
8 m²; second cartridge, PUREMA® H membranes, 
= 150 mL/min, 
ex = 
-HDF 
blood: 
-TM pre-
Hb, 
, HCO3
-). 
                
. 
-HDF; C, SDial-TM pre-HDF. 
 
-HDF (Fig. 11; 
 
 I. Binding of uremic toxins in human biological fluids
 
1) Effect of storage conditions
 
In order to assess the influence of sample freezing on the binding properties of IS and 
human plasma, two experiments have been performed. In the first one, total and free toxin 
concentrations were measured in the same uremic plasma samples before and after storage 
for 6 months at -20 °C. In the second one, the binding constants 
calculated in normal plasma before and after freezing.
 
Fig. 21: Effect of freezing on total and free toxin concentrations.
IS ( , ) and pCS ( , ) concentrations were measured in plasma from 8 ESRD patients before (full bars) 
and after (hatched bars) freezing at 
 
In uremic plasma (see Fig. 21), the PBF of IS was higher (
versus 94.5 ± 1.5% before and after freezing, respectively) resulting from a decrease of the 
total (95 ± 62 versus 91 ± 60 µM
concentrations (6.7 ± 4.7 versu
0.01). In the case of pCS, the PBF (95.8 
respectively; P = 0.06), total toxin concentration (172 
after freezing, respectively; P 
µM before and after freezing, respectively; 
patients of total and free toxin concentrations was high for both IS (range 27.8 to 191.9 µM 
and 1.3 to 14.5 µM for total and free toxin concentration, respectively) and 
to 257.8 µM and 4.1 to 17.6 µM for total and free toxin co
In normal plasma, the freezing of plasma did not change 
before and after freezing, respectively) but decreased 
before and after freezing, respectively). The HSA concentration was however constant after 
freezing (32.3 ± 1.5 versus 32.6 
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RESULTS 
 
KD and 
 
 
-20 °C for 6 months. A, total concentration; B, free concentration.
P < 0.001) after freezing (93.3 
 before and after freezing, respectively;
s 5.3 ± 4.3 µM before and after freezing, respectively;
± 1.6% versus 97.0 ± 0.9% before and after freezing, 
± 51 versus 176 ± 
= 0.21), and free toxin concentration (7.4 ± 4.6 
P = 0.06) were constant. The variabili
ncentration). 
KD (14.3 ± 5.3 versus
Bm (614 ± 47 versus
± 1.9 g/L). 
 
 
pCS in 
Bm for IS were 
 
 
± 1.6% 
 P < 0.01) and free 
 P < 
49 µM before and 
versus 5.5 ± 2.7 
ty between 
pCS (range 101.1 
 14.7 ± 7.5 µM 
 565 ± 33 µM 
 2) Determination of the 
plasma 
 
Fig. 22: Binding study of native uremic plasma pre
Binding curves of IS ( ) and pCS (
and free toxin concentrations pre (A) and post (B) dialysis session. 
 
Mean IS and pCS concentrations were 82.0 
84.9 µM (range of 1.8 to 372.3 µM), respectively. Binding constants in uremic plasma were 
pre-dialysis KD = 5.3 ± 1.7 and 8.0
and 384 ± 64 µM for IS and pCS, respectively. Post
IS and pCS, respectively, and B
 
Fig. 23: Comparison between pre- and post
IS ( ) and pCS ( ) total concentrations were measured in plasma of 
 
As shown in Fig. 23, pre- and post
for both IS (r² = 0.89, P < 0.001) and 
removal rates were 37 ± 2% and 31 
correlation was found between IS and 
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uremic toxin binding affinity in uremic 
 
- and post-dialysis. 
) in plasma of ESRD patients (n = 49) were obtained by measuring bound 
 
± 46.3 (range of 2.9 to 187.4 µM) and 139.3 
 ± 2.4 µM for IS and pCS, respectively, and B
-dialysis KD = 3.5 ± 1.5 and 1.8
m = 151 ± 37 and 160 ± 29 µM for IS and pCS, respectively.
-dialysis total toxin concentrations in uremic plasma.
49 ESRD patients. 
-dialysis total toxin concentrations were highly correlated 
pCS (r² = 0.91, P < 0.001). In this cohort of patients, the 
± 2% for IS and pCS, respectively. However, no 
pCS concentrations neither pre- nor post
 
 
± 
m = 217 ± 36 
 ± 1.0 µM for 
 
 
 
-dialysis. 
 3) Pilot binding studies of different uremic toxins in normal 
plasma 
 
The influence of the [NaCl] on the binding of the uremic toxins IS, 
in a pilot experiment in normal human plasma. As shown in 
concentration, the PBF of all three toxins decreased (
 
 
Since the HSA concentration was constant in all samples, the results were compared to the 
model presented in Fig. 7 hypothesizing a B
denaturation despite increasing [NaCl]. The binding affinity for the most relevant uremic 
toxins, here IS and pCS, was estimated:
 
 IS (α 
[NaCl] PBF KD
0.15 M 82% 0.16
0.30 M 78% 0.21
0.50 M 73% 0.28
Tab. 10: Estimated binding affinity of 
strength. 
The binding affinity KD of IS and pCS for plasma proteins was calculated according to
PBF at a toxin-albumin ratio of 0.33. Abbreviations: 
sodium chloride concentration. 
 
As shown in Fig. 25, the PBF of the three uremic toxins is strongly dependa
concentration itself. 
 
65 
pCS, and PAA was studied 
Fig. 24
P < 0.05) with increasing ionic strength. 
 
Fig. 24: PBF
versus the 
plasma. 
Uremic toxins were added to 
normal human
µM for both IS (
and pCS (
200 µM for PAA (
The PBF of all three toxins was 
negatively correlated with the 
ionic strength (r² = 0.99, 
0.01): IS, PBF = 
84.9; pCS, PBF = 
97.8; PAA, 
with PBF 
[M]. Results are mean ± SD; 
< 0.05 versus
 
m = 300 µM = HSA concentration and no protein 
 
= 0.33) pCS (α =
/Bm KD PBF KD/B
 48 µM 92% 0.06
 63 µM 88% 0.10
 84 µM 84% 0.14
the uremic toxins IS and pCS in normal plasma at different ionic 
 Eq. 
α, toxin-albumin ratio; PBF, protein bound fraction; 
 
 at a given toxin 
 
 of uremic toxins 
[NaCl] in human 
 plasma to 100 
, n = 4) 
, n = 3), and to 
, n = 3). 
P < 
-22.2 × [NaCl] + 
-23.9 × [NaCl] + 
-37.2 × [NaCl] + 67.6; 
in [%] and [NaCl] in 
*, P 
 0.15 M NaCl. 
 0.33) 
m KD 
 18 µM 
 30 µM 
 42 µM 
3 from the measured 
[NaCl], 
nt on the toxin 
  
4) Effect of sodium chloride
 
a. Effect of NaCl
 
In fatty acid free HSA solution at pH 7.4 and room temperature IS was bound to one high 
affinity binding site as demonstrated by Scatchard plot (
denaturation of the binding sites was noted while increasing the [NaCl]. Measured HSA 
concentration in the stock solution was 8.5 ± 0.1 g/L (128 ± 2 µM).  As determined f
binding curves (Fig. 26, A), KD
strength: KD = 8.7 ± 0.6, 17.4 ± 3.4, 27.2 ± 3.8, and 40.8 ± 10
0.75 M NaCl, respectively; KD
[M]. 
 
Fig. 26: Binding of IS on HSA at different ionic strengths.
Binding experiments (n = 2) were performed in 
temperature, pH 7.4, and with 0.15 (
Scatchard plot. 
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Fig. 25: PBF
toxins 
concentration in 
plasma. 
The PBF is shown for IS (
n = 4), pCS (
PAA (
are given. 
 
 on plasma proteins 
 on the IS binding ability of HSA 
Fig. 26, B). Furthermore, no 
 was positively correlated (r² = 1.00, P < 0.001) with the ionic 
.8 µM at 0.15, 0.30, 0.50, and 
 = 53.0 × [NaCl] + 1.0 (r² = 0.89) with KD in [µM] and 
 
4.25 g/L HSA solution (8.5 g/L stock solution) 
), 0.30 ( ), 0.50 ( ), and 0.75 M ( ) NaCl
 
 of three uremic 
versus their 
normal human 
, 
, n = 3) and 
, n = 3). Means ± SD 
rom the 
[NaCl] in 
 
at room 
. A, binding curves; B, 
 b. Effect of NaCl
and PAA 
 
The binding affinity and capacity of normal human plasma for IS, 
determined at room temperature and pH 7.4 by ultrafiltration.
 
Fig. 27: Binding of IS and pCS in normal human plasma at different ionic strengths.
Binding experiments were performed in half
(A) and pCS (B) at room temperature, pH 7.4, and with 0.15 (
 
As shown in Fig. 27, binding properties of human plasma were altered for both IS and 
similar effect was seen for PAA (
strength was positively correlated with 
0.78, P = 0.11) as shown in Fig. 
data were collected. Furthermore, 
was greater than 0.30 M. 
Fig. 28: Effect of [NaCl] on the binding constants of uremic toxins in normal human plasma.
The effect of increased ionic strength on
binding constants were determined using a one site specific binding equation 
pCS ( ). For PAA ( ), a one site total binding 
were interpolated with linear regression
pCS, KD = 82.4 × [NaCl] + 1.9 (r² = 0.58) and K
+ 55.3 (r² = 0.41) and KD/Bm = 3.19 × [NaCl] 
versus 0.15 M NaCl. 
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 on the binding ability of normal plasma fo
p
 
 
-diluted human plasma from three different donors (n = 3) with IS 
), 0.30 ( ), 0.50 ( ), and 0.75 M
see binding curves in Appendix, Fig. 81). Increasing
KD for IS (r² = 0.98, P < 0.05) but not for PAA (r² = 
28. Correlation was not assessed for pCS because too few 
KD for IS and pCS was increased (P <
 KD (A) and on the ratio KD/Bm (B) at 25 °C and pH 7.
(Eq. 2) for 
equation (Eq. 4) was applied. Plo
: IS, KD = 71.2 × [NaCl] + 5.1 (r² = 0.82) and KD/Bm
D/Bm = 0.18 × [NaCl] + 0.02 (r² = 0.68); and PAA, K
- 0.03 (r² = 0.81); with KD in [µM] and [NaCl]
 
r IS, pCS, 
CS, and PAA was 
 
 ( ) NaCl. 
pCS. A 
 the ionic 
 0.05) when [NaCl] 
 
 
4 is shown. The 
both IS ( ) and 
ts (mean ± SD, n = 3) 
 = 0.20 × [NaCl] + 0.03; 
D = 1007 × [NaCl] 
 in [M]. *, P < 0.05 
 For both IS and pCS, Bm was not different with increasing ionic strength: IS,  
290 ± 57, 317 ± 62, and 326 ± 69 µM at 0.15, 0.30, 0.50
Bm = 324 ± 34, 296 ± 49, and 401 ± 120 µM at 0.15, 0.30
experiments with PAA were performed with different plasma
impossible to assess. Thus, increasing the ionic strength was positively correlated with the 
ratio KD/Bm for both IS (r² = 0.98, 
a 2.2 fold increase of the ratio for IS, 2.3 fold for 
increased from 0.15 to 0.50 M. The ratio 
M for both IS and pCS, and [NaCl] > 0.50 M for PAA.
 
Fig. 29: Scatchard plot deriving from the binding studies 
The Scatchard plot is shown for IS (A) and 
0.75 M ( ) NaCl.  Regression coefficients 
NaCl, respectively; B, 0.49, 0.50, and 0.36 at 0.15, 0.30, and 0.50 M NaCl, respectively.
 
Scatchard plot analysis (Fig. 29
normal human plasma in the range of 0.15 to 0.75 M [NaCl]
demonstrated that two different classes 
Appendix, Fig. 82) with different binding affinities: a high affinity binding site and a low
affinity binding site corresponding to the unspecific binding.
 
[NaCl] 
[M] 
KD 
[µM] [µM]
0.15 13.2 ± 3.7 250
0.30 28.1 ± 18.4 290
0.50 43.9 ± 13.2 (a) 317
0.75 56.2 ± 2.0 (a,b) 326
Tab. 11: Binding constants KD and B
human plasma. 
Abbreviations: [NaCl], sodium chloride concentration; 
Values are mean ± SD (n = 3). Higher [NaCl] significantly increased 
concentration, both experimental and theoretical PBF, as predicted by 
of an increased [NaCl] and plasma dilution on the 
versus 0.15 M NaCl; 
(b)
, P < 0.05 versus
68 
, and 0.75 M NaCl
, and 0.50 M NaCl,
 volumes, change of 
P < 0.01) and PAA (r² = 0.95, P < 0.05). This corresponded to 
pCS, and 3.5 fold for PAA when [NaCl] was 
KD/Bm was significantly increased with [NaCl] 
 
on uremic toxins in normal human plasma.
pCS (B) as mean ± SD (n = 3) with 0.15 ( ), 0.30 (
r² are: A, 0.55, 0.41, 0.33, and 0.36 at 0.15, 0.30, 0.50, and 0.75 M 
 
) confirmed that IS and pCS were bound to one binding site 
. Scatchard plot 
of binding sites were involved in the binding (see 
 
Bm 
 
KD/Bm 
Theoretical 
PBF at α = 0.1
 ± 48 0.05 ± 0.02 94 ± 2% 
 ± 57 0.10 ± 0.03 (a) 90 ± 2% (a) 
 ± 62 0.14 ± 0.04 (a,b) 87 ± 3% (a,b) 
 ± 69 0.18 ± 0.03 (a,b,c) 84 ± 3% (a,b,c) 
m and the PBF of IS incubated at room temperature in 1:2
α, toxin-albumin ratio; PBF, protein bound fraction. 
KD resulting in a decreased PBF. At low toxin 
Eq. 3, were similar (
PBF of IS, as assessed by Eq. 3, are also shown
 0.30 M NaCl; 
(c)
, P < 0.05 versus 0.50 M NaCl. 
 
Bm = 250 ± 48,  
, respectively; pCS, 
 respectively. Since 
Bm was 
≥ 0.30 
 
 
), 0.50 ( ), and 
in 
analysis of PAA 
 
 
Experimental 
PBF at α = 0.1 
95 ± 1% 
91 ± 2% (a) 
87 ± 3% (a,b) 
84 ± 2% (a,b) 
-diluted normal 
P > 0.05). The effects 
. 
(a)
, P < 0.05 
 As presented in Tab. 11, the PBF of IS in normal plasma could be accurately predicted by 
3. Experimental and theoretical v
 
c. Effect of NaCl
 
Normal plasma was incubated 
56.7 ± 54.5 µM) and pCS concentrations ranging
µM), whereas native toxin concentrations in 
(mean = 69.5 ± 35.5 µM) and from 30.6
respectively. Thus, the toxin concentrations were not different between uremic and normal 
plasma. 
 
Fig. 30: Effect of increased ionic strength on the PBF
The PBF was determined in uremic (A and C, n = 15, native toxin concentration
different donors with 6 different toxin concentrations, i.e.
and B) and pCS (C and D). Increased ionic strength decreased the PBF of IS and 
plasma. *, P < 0.05; **, P < 0.01; and ***, 
has not been studied. 
 
The PBF of both IS and pCS decreased (
with increasing ionic strength (
NaCl was about 4% higher than in uremic plasma (
3% higher in normal plasma than uremic one 
69 
alues did not differ. 
 on the PBF in uremic plasma 
at IS concentrations ranging from 9.5 to 161.2 µM
 from 6.9 to 186.1 µM (mean = 
uremic plasma ranged from 2
 to 135.4 µM (mean = 90.2 ± 27.9 µM)
 of IS and pCS in both uremic and normal
) and normal
, n = 18) at room temperature and at pH 7.4 for IS (
pCS in both uremic and normal 
P < 0.001. Part D: the effect of 0.75 M NaCl in 
P < 0.05) in plasma of uremic and healthy individuals 
Fig. 30). In normal plasma, the PBF of IS at 0.15 and 0.30 M 
P < 0.01); the PBF of pCS was always about 
(P < 0.05).  
 
Eq. 
 (mean = 
61.6 ± 63.4 
3.5 to 136.6 µM 
 for IS and pCS, 
 
 
 plasma. 
 plasma (B and D, 3 
A 
normal plasma on pCS 
 Because of the high patient intervariability and the small population (n = 15; see Appendix
Fig. 83), the KD of uremic plasma proteins fo
3 with an experimental albumin concentration of 286 µM after 1:2 dilution, hypothesizing 
being constant at 286 µM, increasing the [NaCl] in uremic plasma correlated with increased 
KD: IS, KD = 27.3 ± 8.6, 37.1 ± 10.6, 46.5 ± 16.9, and 55.9 ± 15.3 µM at 0.15, 0.30, 0.50, and 
0.75 M NaCl, respectively (r² = 0.40, 
and 39.7 ± 9.4 µM at 0.15, 0.30, 0.50, and 0.75 M NaCl, respectively (r² = 0.51, 
Linear regression of the results on uremic plasma led to K
and KD = 32.6 × [NaCl] + 16.0 (r² = 0.99)
[NaCl] in [M]. 
 
5) Influence of other parameters on plasma binding ability for IS
 
a. Plasma dilution
 
Binding constants KD and Bm
plasma dilutions: 1:2- and 1:
presented in Fig. 31. 
 
Fig. 31: Binding constants of IS determined at different plasma dilutions and ion
The binding constants KD (A) and Bm
1:10-diluted ( ) at room temperature and pH 7.4
 
For a given [NaCl], dilution did not affect the binding affinity 
1:10 dilutions. In contrast, the number of binding sites 
dilution without a difference between 0.15 and 0.50 M NaCl. 
was in the range of the albumin concentration: 238 ± 90 µM for a dilution factor of 2 
(corresponding to 48 ± 18 µM for a dilution factor of 10). Thus, both
ionic strength decreased the PBF of IS in normal human plasma (
theoretical PBFs were highly correlated (r² = 0.98, 
these data confirmed a stoichiometry of 1 for IS in human plasma (
70 
r both IS and pCS was assessed according to 
P < 0.001); pCS, KD = 20.1 ± 5.3, 26.5 ± 4.9, 33.5 ± 8.7, 
D = 47.0 × [NaCl] + 21.7 (r² = 0.99) 
 for IS and pCS, respectively, with 
 
 were determined in normal human plasma at two different 
10-diluted plasma (see Fig. 84 in Appendix
ic strengths.
 (B) were calculated at 0.15 and 0.50 M NaCl in plasma 
. Results are mean ± SD (n = 3). 
KD with respect to the 1:2 and 
Bm was decreased (
Bm decreased with dilution and 
 dilution and increased 
Tab. 12). Experimental and 
P < 0.0001). Scatchard plot analysis of 
Fig. 32) at both 
 
, 
Eq. 
Bm 
P < 0.001). 
KD in [µM] and 
 
). Results are 
 
 
1:2-diluted ( ) or 
P < 0.05) by 
[NaCl]. 
 Fig. 32: Scatchard plot deriving from
and ionic strengths. 
The Scatchard plots are shown for IS incubated in plasma 
with 0.15 ( ) and 0.50 M ( ) NaCl.
respectively; B, 0.40 and 0.11 at 0.15 and 0.50 M NaCl, respectively.
 
 
[NaCl] 
[M] 
DF 
KD 
[µM] 
0.15 1:2 13.4 ± 3.6 
0.50 1:2 40.1 ± 18.4 
0.15 1:10 8.9 ± 2.7 
0.50 1:10 44.7 ± 18.3 
Tab. 12: Binding constants KD and 
normal human plasma.  
Abbreviations: [NaCl], sodium chloride concentration; DF, dilution factor; 
bound fraction. Values are mean ± SD (n = 3). Plasma dilution only influenced 
effects of increased [NaCl] and plasma dilution on the 
versus dilution factor 1:2; 
(b)
 P < 0.05 
fraction. 
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 the binding studies on IS in normal human plasma
with 1:2 (A) or 1:10 dilution (B) as mean 
 Regression coefficients r² are: A, 0.34 and 0.21 at 0.15 and 0.50 M NaCl, 
 
Bm 
[µM] 
KD/Bm 
Theoretical
PBF α = 0.1
[%] 
261 ± 64 0.05 ± 0.02 94 ± 2 
297 ± 64 0.13 ± 0.05 (b) 87 ± 4 (b) 
59 ± 24 (a) 0.16 ± 0.02 (a) 85 ± 1 (a) 
109 ± 27 (a) 0.41 ± 0.11 (a, b) 70 ± 5 (a, b)
Bm and PBF of IS incubated at room temperature in 1:2
α, toxin-albumin ratio; PBF, protein 
Bm and, thus
PBF of IS, as assessed by Eq. 3, are also shown
versus 0.15 M NaCl; 
(c)
 P < 0.05 theoretical versus
 
 
 at different dilutions 
± SD (n = 3) 
 
 
Experimental 
PBF α = 0.1 
[%] 
95 ± 2 (c) 
88 ± 4 (b) 
86 ± 3 (a) 
 73 ± 6 (a, b) 
- and 1:10-diluted 
, the ratio KD/Bm. The 
. 
(a)
 P < 0.05 
 experimental bound 
 b. Temperature
 
In a pilot experiment, the equilibrium point of equilibrium dialysis using a mini
apparatus was assessed by measuring the IS concentration within the aqueous compartment 
(thus corresponding to the free toxin concentration). Using 12 mL plasma, 50 µM IS solution 
and QB = 2.2 mL/min, the free IS concentration decreased within the first 10 runs through 
the dialyzer and reached equilibrium (
equilibrium was largely reached after 1 h, corresponding to 28 runs.
 
Fig. 33: Decrease of the IS concentration in the aqueous compartment during equilibrium dialysis.
Regression coefficient is r² = 1.00. 
 
This setup was used to assess the PBF of IS in normal plasma at 25 and 37 °C and at 0.15 and 
0.61 M NaCl. In plasma from a single donor, an increase in the temperature from 25
significantly decreased the PBF of IS in 0.15 M NaCl as well as in 0.61 M NaCl solution (91 ± 
2% to 85 ± 2%, P < 0.01; and 85 ± 2% to 79 ± 2%, 
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Fig. 33). Using a smaller volume (4.6 mL), the 
 
P < 0.001; respectively). 
 
-dialyzer 
 
 
 to 37 °C 
 c. Influence of other ion species
 
 
The influence of different ion species on the PBF of IS was studied 
The PBF was decreased (about 8%) with addition of either NaCl or KCl as compared to native
plasma (Fig. 34). At similar ionic strength, mixing NaCl and KCl did not further decrease the 
binding (the high variability was due to a manipulation error). 
an acetate buffer also reduced the protein binding (PBF about 5% lower compared to native 
plasma) and adding NaCl at lower pH further decreased the PBF of IS. The latter effect is of 
the same magnitude as simply increasing ion
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Fig. 34: Influence of different 
ion species on the 
uremic plasma.
The PBF is represented for 
different treatments of the 
plasma as mean ± SD (n = 2). 
Increasing the ionic strength and 
decreasing the pH both 
decreased the PBF of IS in 
uremic plasma; 
effects did not cumulate.
in vitro
Decreasing the pH to 5.4 with 
ic strength with NaCl only. 
 
PBF of IS in 
 
however, both 
 
 in uremic plasma. 
 
 II. Modification of the ionic strength in aqueous solution
a dialysis machine
 
A standard curve of the conductivity 
Fig. 35. 
 
Fig. 35: Standard curve of the conductivity 
The conductivity was measured in deionized
linearization in the range of 0.10 to 
 
The relationship between the [NaCl] expressed in [mM] and the conductivity 
[mS/cm] in the range of 0.10 to 5.00 M NaCl was:
 
'V*1
 
When 10 ≤ σ ≤ 35 mS/cm, it was possible to use linear regression. The following relationship 
was found: 
'V*1 = 90
 
Thus, the [NaCl] can be rapidly assessed by measuring the conductivity when 10 
mS/cm corresponding to the range of 0.10 to 0.50 M NaCl, by:
 
Eq. 15: Estimation of the NaCl concentration from the conductivity 
Where [NaCl] is the NaCl concentration in [mM] and 
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versus the [NaCl] in deionized water is presented in 
versus the [NaCl]. 
 water (A) in the range of 0.10 to 5.00 M NaCl
0.50 M NaCl was calculated (B). 
 
 = 3878 × 9307.4  9⇔ 9 = 307.4 × 'V*13878  'V*1  
 1.218.06842 ⇔ 9 = 0.06842 × 'V*1  1.218
 
'V*1 \ 13.6 × 9 
in aqueous solution.
σ the conductivity of the solution in [mS/cm].
 
 applied on 
 
 
. The corresponding 
σ expressed in 
 
≤ σ ≤ 35 
 
 
 1) Standard pre
 
a. Ionic strength stability
 
 
During infusion of saline into the substitution fluid (
at all sampling sites independently of the infusion flow rate of saline (
conductivity was measured in the blood reservoir and the highest
difference was minimal (0.5 mS/cm).
 
 
When infusing 5.00 M NaCl at a constant flow rate 
the 4 h dialysis session at 13.1 
arterial, and venous line, respectively (
177 ± 3 mM NaCl, respectively (
 
75 
-dilution HDF 
 
 
Fig. 36: 
conductivity in aqueous 
solution during
The conductivity was measured 
in the blood 
the arterial line (
the venous line (
standard pre
dialysis machine
saline did 
conductivity over time.
Fig. 36), the conductivity stayed constant 
 in the venous line but this 
 
 
Fig. 37: 
conductivity 
solution during
M NaCl over
Standard pre
performed 
with QNaCl
conductivity was measured in 
the blood 
the arterial line (
the venous line (
time. The conductivity was 
higher in the arterial line as 
compared to the blood reservoir 
and the v
exactly similar).
QNaCl, the conductivity was steady over 
± 0.2, 29.3 ± 0.3, and 13.0 ± 0.2 mS/cm in the blood reservoir
Fig. 37) (corresponding to about 178 
Eq. 15)).  
 
Course of the 
 infusion of NaCl. 
reservoir ( ), in 
), and in 
) during 
-dilution HDF on a 
. Infusion of 
not change 
 
QNaCl). The lowest 
Course of the 
in aqueous 
 infusion of 5.00 
 4 h. 
-dilution HDF was 
on a dialysis machine 
 = 25 mL/min. The 
reservoir ( ), in 
), and in 
) over 
enous line (both were 
 
, 
± 3, 398 ± 4, and 
 b. Influence of 
 
 
Increasing QNaCl (see Fig. 38) positively correlated with the conductivity within the blood 
reservoir (Qinf = 50 mL/min, r² = 0.99, 
arterial line (both Qinf, r² = 0.99, 
< 0.001 ; Qinf = 160 mL/min, r² = 0.81, 
conductivity (P = 0.22), whereas the conductivity in the blood reservoir and in the venous 
line was higher (P < 0.05) with Q
 
 
After modification of the setup, higher 
blood reservoir, the arterial and venous line was positivel
with the infusion flow rate of the 5.00 M NaCl solution. In this experiment the maximal 
conductivity reached was 87.0 and 22.5 mS/cm in the arterial and venous line, respectively, 
corresponding to approximately 1183 and
76 
Qinf on the ionic strength 
 
Fig. 38: 
conductivity 
The conductivity was measured 
during standard pre
on dialysis machine
mL/min (s
mL/min (dot
blood reservoir
in the arterial line (
and in the venous line (
). The infusion flow rate of 
the 5.00 M NaCl soluti
was adjusted between 5 and 30 
mL/min. Increasing 
positively correlated (
with the conductivity.
P < 0.001; Qinf = 160 mL/min, r² = 0.95, 
P < 0.001), and the venous line (Qinf = 50 mL/min, r² = 0.99, 
P < 0.05 ). Increasing Qinf did not influence the arterial 
inf = 50 mL/min. 
 
Fig. 39: 
conductivity with 
modification of the 
The conductivity was measured 
in the blood 
the arterial line (
the venous line (
standard HDF 
NaCl solution 
same flow rate 
substitution fluid wa
Increasing 
correlated (r² = 0.99, 
with the conductivity.
QNaCl could be studied. The conductivity within the 
y correlated (r² = 0.99, 
 306 mM NaCl, respectively (Eq. 
 
Course of the 
with Qinf and QNaCl. 
-dilution HDF 
 at Qinf = 160 
olid lines) and Qinf = 50 
ted lines) in the 
 ( , ), 
, ), 
, 
on QNaCl 
QNaCl 
P < 0.05) 
 
P < 0.01), the 
P 
Course of the 
QNaCl after 
setup. 
reservoir ( ), in 
), and in 
). In this 
set-up, a 5.00 M 
was infused at the 
QNaCl while 
s removed. 
QNaCl positively 
P < 0.0001) 
 
P < 0.0001) 
15). 
 c. Effect of Q
 
Fig. 40: Influence of QB and QD on the conductivity in aqueous solution.
The conductivity was measured during 
800 mL/min (B, D, and F) in the blood 
(E-F, dark grey) at different blood rates: Q
 
For all QB and both QD, conductivity positively correlated (r² > 0.92, 
except at QB = 200 mL/min in the blood reservoir (only for Q
0.06) and in the venous line (Q
0.45, P = 0.21) for which no correlation was found. Furthermore, increasing 
correlated with the conductivity in the blood reservoir (Q
77 
B and QD 
 
standard pre-dilution HDF with QD = 500 mL/min (A, C
reservoir (A-B, hell grey), the arterial line (C-D, black
B = 200 ( ), 300 ( ), 400 ( ), and 500 mL/min (
P 
D = 800 mL/min, r² = 0.75, 
D = 500 mL/min, r² = 0.70, P = 0.08; QD = 800 mL/min, r² = 
D = 500 mL/min, r² = 0.99, 
 
 
, and E) and QD = 
) and the venous line 
). 
< 0.01) with QNaCl, 
P = 
QB positively 
P < 0.01; 
 QD = 800 mL/min, r² = 0.99, P
0.01; QD = 800 mL/min, r² = 0.99, 
not correlated with QB (r² = 0
correlated with QB (r² = 0.94, P
 
2) Serial dialyzer
 
a. Ionic strength stability in pre
 
In order to determine the stability of 
setup in pre-dilution HDF, the ionic strength was
dialysate flow rates in the first cartridge 
 
 
The [NaCl] was constant over time in all compartments
Venous ionic strength was isotonic. The [NaCl] measured in the first dialyzer dialysate inlet 
(IN) was higher than the arterial one indicating an incomplete diffusion of the Na
ions through the dialysis membrane; increasing 
and [NaCl]BM: [NaCl]IN / [NaCl]
225, and 250 mL/min, respectively.
 
b. Influence of 
 
The impact of Qex on the difference between first dialyzer blood outlet (BM) and dialysate 
inlet (IN) ionic strengths was determined in blood. Increasing 
with the difference between both concentrations: [NaCl]
0.02, 1.27 ± 0.03, 1.22 ± 0.07, and 1.16 ± 0.14 for Q
(r² = 0.88, P < 0.05). 
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 < 0.0001) and the venous line (QD = 500 mL/min, r² = 0.98, 
P < 0.01). In the arterial line, however, the conductivity was 
.78, P = 0.12) at QD = 500 mL/min, although, it negatively 
 < 0.05) at QD = 800 mL/min. 
s setup 
-dilution HDF 
the [NaCl] over time with the serial dialyzer
 monitored in all compartments at different 
(Qex). 
 
Fig. 41: Ionic strength 
during HDF
setup. 
The [NaCl] was measured in 
different locations of the setup: 
BM (
( ), and OUT (
dialysis sessions (2 h) have been 
performed: 0 
+ Qinf; 120 
Qinf; and 240 
+ Qinf. 
 independently of the flow rates. 
Qex reduced the difference between [NaCl]
BM = 1.45 ± 0.05, 1.38 ± 0.10, and 1.36 ± 0.05 for 
 
Qex 
Qex was negatively correlated 
IN / [NaCl]BM = 1.74 ± 0.70, 1.44 ± 
ex = 100, 200, 300, 400, and 500 mL/min 
 
P < 
s (SDial) 
stability 
 using the SDial 
), VEN ( ), IN        
). Three 
– 120 min, Qex < QB 
– 240 min, Qex = QB + 
– 360 min, Qex > QB 
+ and Cl- 
IN 
Qex = 200, 
 3) Simulation of the NaC
 
a. Standard pre
 
i. Comparison to experimental data
 
A simulation of the [NaCl] during standard pre
(see corresponding algorithm in Appendix
Formula 2000 dialysis machine, was performed and compared to the results presented in
Fig. 40. The mean mass transfer area coefficient of a Nipro Pureflux® 170 H filter (PUREMA® 
H membrane, 1.7 m² membrane surface area) was determined from the specification data 
sheet (93) and calculated from the instantaneous clearances according to 
mean K0A for this hemofilter was 1152 mL
 

Eq. 16: Calculation of the mass transfer area coefficient from measured clearances
Where K0A is the mass transfer area coefficient [mL/min]; 
[mL/min], respectively, and K the clearance [mL/min].
 
 
Fig. 42: Relative error between experimental and simulated 
Relative errors were calculated as error
and B, QD = 800 mL/min; arterial (
mL/min ( ). Simulations fitted well with experimental data.
 
As shown in Fig. 42, the simulation fitted well the 
10%) at QD = 800 mL/min for both arterial and venous [NaCl] ([NaCl]
respectively), and at QD = 500 
mL/min, [NaCl]VEN was, however, overestimated by the simulation (relative error > 10%). 
Simulations highly correlated with the experiment (Q
and r² = 0.93, P < 0.0001 for [NaCl]
P < 0.0001 and r² = 0.82, P < 0.0001 for [NaCl]
79 
l concentration 
-dilution HDF 
 
-dilution HDF, based on an iterative procedure 
, Fig. 85) using the parameters of the Bellco
/min. 
3J = 7K. 77K  7 . ln _7 . &7K  )7K. &7  )` 
 (11)
QB and QD are the blood and dialysate flow rates 
 
[NaCl] during standard pre
 = ([NaCl]experiment – [NaCl]simulation) / [NaCl]experiment
) and venous [NaCl] ( ); QB = 200 ( ), 300 (
 
experimental results (relative error of ± 
mL/min for the [NaCl]ART. For QNaCl > 15 mL/min and Q
D = 500 mL/min, r² = 0.98, 
ART and [NaCl]VEN, respectively; QD = 800 mL/min, r² = 0.99, 
ART and [NaCl]VEN, respectively) and confirmed 
 
 
 
Eq. 16 (11). The 
. 
 
-dilution HDF. 
: A, QD = 500 mL/min; 
), 400 ( ), and 500 
ART and [NaCl]VEN, 
D = 500 
P < 0.0001 
 that increasing QB reduces the clearance of the semi
accumulation of NaCl in the blood reservoir.
 
ii. Influence of 
 
 
 
As shown in Fig. 43, increasing 
low QB. Whereas at high QB and in the range 500 < 
than 140 mM. Increasing the dialysate flow rate decreased the [NaCl].
 
b. Serial dialyzer
 
i. With pre
 
A simulation of the [NaCl] during pre
algorithm in Appendix, Fig. 87
been performed and compared to the results presented in 
DIAPES® BLS 714 G and Xenium® 170 H filters was determined based on clearance 
measurements presented on the respective data sheets and
and K0AXenium 170 H = 1483 mL/min. Mean [NaCl]
cartridges) and [NaCl]VEN acceptably matched the simulation ([
mM, 491 ± 55 versus 472 mM, and 508 ± 13 
mM, 137 ± 2 versus 136 mM, and 139 ± 0 
mL/min, respectively; experiment 
in the first cartridge dialysate inlet and outlet, respectively) were und
simulation ([NaCl]IN, 643 ± 20 
80 
-permeable membrane leading to
 
K0A on the removal of NaCl excess 
 
Fig. 43: Influence of 
venous [NaCl] during standard 
pre-dilution HDF.
The [NaCl]
using the simulations of 
standard pre
varying blood and dialysate flow 
rates: QB 
and 500 mL/min (
QD = 500 (solid line) and 800 
mL/min (dotted line). The [NaCl] 
in the dialysate was set to 120 
mM. The h
corresponds to physiologic 
[NaCl] in blood, being in the 
range of 115 to 125 mM. Q
QNaCl = 10 mL/min, Q
mL/min. NaCl accumulates in 
blood when decreasing 
 
K0A reduced [NaCl]VEN reaching physiologic concentrations at 
K0A < 1500 mL/min, [Na
 
s setup 
-dilution HDF 
-dilution HDF with the SDial setup (see corresponding 
) using the parameters of the Nikkiso DBB
Fig. 41. The 
 Eq. 16: K0ABLS 714 G
BM ([NaCl] in the blood line between both 
NaCl]BM, 443 ± 2 
versus 509 mM; [NaCl]VEN, 137 ± 1 
versus 137 mM; for Qex = 200, 225, and 250 
versus simulation) whereas [NaCl]IN and [NaCl]
erestimated by the 
versus 558 mM, 674 ± 28 versus 593 mM, and 688 ± 7 
 
 an 
K0A on the 
 
VEN was assessed by 
-dilution HDF with 
= 200 ( , ) 
, ), 
atched area 
inf = 
UF = 0 
K0A. 
Cl]VEN was higher 
-03 apparatus has 
K0A of urea for 
 = 635 mL/min 
versus 431 
versus 134 
OUT ([NaCl] 
versus 
 624 mM; accordingly, [NaCl]OUT
14 versus 285 mM). 
 
The simulation was also compared to 
generally underestimated the experimental results of about 15 ± 21 mM (BM) and 65 ± 12 
mM (IN) but similar ratios [NaCl]
1.68 ± 0.21, 1.28 ± 0.06, 1.18 ± 0.03, 1.14 ± 0.02, and 1.12 ± 0.02 for Q
and 500 mL/min, respectively.
 
ii. With transmembrane pre
 
The simulation of the SDial setup with transmembrane pre
algorithm in Appendix, Fig. 88
mL/min, QD = 500 mL/min, Qinf
acceptably matched the simulation: 250 ± 19 
for QNaCl = 6.5 and 10.8 mL/min, respectively, experiment 
simulation underestimated [NaCl]
± 12 versus 393 mM for QNaCl 
158 mM and 233 ± 12 versus 182 mM
 
 
In this second experimental part (
[NaCl]IN, and [NaCl]OUT at various 
 
iii. Serial dialyzer
pre-HDF
 
Simulation of the [NaCl]BM and the [NaCl]
influence of the transmembrane pre
dialysate in the first cartridge. Therefore, the 
81 
, 314 ± 1 versus 218 mM, 357 ± 33 versus 252 mM, and 356 ± 
the results presented above (“Influence of 
IN / [NaCl]BM were obtained: simulation [NaCl]
ex = 100, 200, 300, 400, 
 
-dilution HDF 
-dilution (see corresponding 
) was compared to experimental results for Q
 = 75 mL/min, QNaCl = 6.5 and 10.8 mL/min. Again, the [NaCl]
versus 264 mM and 351 ± 23 
versus simulation; whereas the 
IN and [NaCl]OUT: [NaCl]IN, 333 ± 45 versu
= 6.5 and 10.8 mL/min, respectively; [NaCl]OUT
 for QNaCl = 6.5 and 10.8 mL/min, respectively.
 
Fig. 44: Comparison between 
simulation and experimental 
[NaCl] for the 
The [NaCl] was measured in 
aqueous solution (full bars) and 
compared to the simulation 
(hatched bars) for Q
mL/min and Q
( ), QB = 150 mL/min and Q
200 mL/min (
mL/min and Q
( ). 
Fig. 44), the simulations approximated well [NaCl]
Qex and QB with the SDial-TM pre-HDF. 
s pre-HDF versus serial dialyzer
 
IN  (see Fig. 11) was performed to assess the 
-dilution on the [NaCl] gradient between blood and 
K0A of urea for DIAPES® BLS 
 
Qex”). It 
IN / [NaCl]BM = 
B = Qex = 150 
BM 
versus 358 mM 
s 285 mM and 433 
, 184 ± 38 versus 
 
SDial setup. 
B = 150 
ex = 25 mL/min       
ex = 
), and QB = 300 
ex = 200 mL/min    
BM, 
s transmembrane 
714 G (first 
 dialyzer) and the one for Xenium® 170 H (second dialyzer) were considered; Q
mL/min, QD = 500 mL/min, Qinf
NaCl solution). 
The results (see Fig. 45) indicated that the [NaCl] gradient decreased when increasing 
and that the gradient largely decreased when using transmembrane pre
compared to normal pre-dilution.
 
Fig. 45: Simulation of the influence of the mode of pre
The simulation of the [NaCl] was performed for: SDial pre
TM pre-HDF, [NaCl]BM ( ) and [NaC
mL/min, Qinf = 75 mL/min, QUF = 0 mL/min, and Q
635 mL/min, K0A second dialyzer = 1483 mL/min. Transmembrane pre
concentration gradient in the first dialyzer.
 
 
III. Ex vivo hemocompatibility of increased ionic strength
 
1) Cell damage after contact with NaCl
 
a. Effect on red blood cells
 
In a first experiment, blood was dialyzed against different NaCl solutions so 
was increased to 0.15, 0.26, 0.39, 0.48, 0.58, and 0.75 M. During 240 min incubation at 37 °C 
with increased ionic strength, hemolysis was steady. Hemolysis was plotted against 
[NaCl]blood. In a second experimental setup, blood was incubat
after dilution with different NaCl solutions to increase ionic strength. Results are presented 
in Fig. 46.  
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 = 75 mL/min, QUF = 0 mL/min, and QNaCl = 20 mL/min (5.00 M 
 
-dilution with the SDial setup on the 
-HDF, [NaCl]BM ( ) and [NaCl]
l]IN ( ). Dialysis parameters were: QB = 150 mL/min, Q
NaCl = 20 mL/min (5.00 M NaCl solution); K
-dilution reduced gre
 
 
 
ed 1 h at room temperature 
 
B = 150 
Qex 
-dilution as 
 
[NaCl]. 
IN ( ); and SDial-
D = 500 
0A first dialyzer = 
atly the 
 
that [NaCl]blood 
  
In both experimental settings, no hemolysis was seen after exposure to [NaCl] ranging from 
0.15 to 0.50 M. When [NaCl]
with the [NaCl]. This increase was faster during the single pass dialysis experiment compared 
to the static experiment in test tubes.
 
Fig. 47: Hemolysis in human blood after contact with 0.75 M NaCl.
Blood from single donors (n = 21) was diluted with different NaCl solution to reach a final concentration of 0.75 
M NaCl and incubated 1 h at room temperature. Hemolysis is presented 
count (B). Solid line: linear regression; dotted 
with tHb and RBC count. 
 
As presented in Fig. 47, hemolysis in blood with 0.75 M NaCl slightly negatively correlated 
with the RBC count (r² = 0.20, 
found neither between hemo
or tHb level and hemolysis at lower [NaCl]
= 0.83, P < 0.0001). 
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Fig. 46: Hemolysis in human 
blood after contact with NaCl.
Hemolysis
single pass dialysis (
blood dilution (
are presented as 
7 and n = 21, respectively). *, 
0.05 versus
Hemolysis non linearly increased 
with higher [NaCl]
blood was further increased, hemolysis enhanced 
 
 
versus either tHb level (A) or the RBC 
lines: 95% confidence interval. Hemolysis negatively correlated 
P < 0.05) and tHb level (r² = 0.26, P < 0.05). No correlation was 
lysis and mean cell volume (P = 0.63) nor between RBC count 
blood. RBC count and tHb levels highly correlated (r² 
 
 
 was studied during 
) and 
); results 
mean ± SD (n = 
P < 
 0.15 M NaCl. 
blood. 
exponentially 
 
 Fig. 48: May-Grünwald staining of blood smear
Optical microscopy (×100) of RBC after staining. Blood was diluted 1:10 with different NaCl solutions.
 
Blood samples at different [NaCl]
Fig. 48. Normal morphology of RBC was visible at physiologic [NaCl]
strength was increased to 0.25 M NaCl, exclusively 
intact. At [NaCl]blood ≥ 0.50 M, both 
visible. 
 
Fig. 49: May-Grünwald staining of blood smear
The arterial (ART) [NaCl] was about 0.50 M, 
 
During dialysis, echinocytes were prevalent in arterial samples when [NaCl]
0.50 M, whereas a normal morphology was seen in venous samples where [NaCl]
physiologic (0.15 M). 
  
84 
s at different [NaCl]. 
blood were stained with May-Grünwald solution as shown in 
blood
echinocytes were seen but cells were still 
echinocytes and blasted cells (hemoglobin release) were 
s of arterial and venous samples during dialysis
venous (VEN) [NaCl] was physiologic. Optical microscopy (
 
 
 
. When the ionic 
 
. 
×100). 
blood was about 
blood was 
 b. Effect on white blood cells
 
Fig. 50: Dot plots of WBC subpopulation
Dot plots of WBC subpopulations
(physiologic ionic strength) blood samples after contact with different [NaCl] during single pass dialysis. 
areas are highlighted: dead cells (DC
and monocytes (MON, bottom right).
 
With [NaCl]blood ≤ 0.26 M, no change in the WBC subpopulations was observed (
neither in arterial nor in venous samples. With [NaCl]
changed significantly: the monocyte, granulocyte neutrophiles and basophiles 
subpopulations seem to vanish since granularity and cell size decreased; the proportion of 
lymphocyte- and dead cells increased. This abnormality was more pronounced with higher 
[NaCl]blood. These changes were, however, not visible in corresponding venous samples in 
which normal dot plots were obtained similar to those found in arterial blood with [NaCl]
= 0.15 M. 
 
2) Effect of the blood volume on the 
 
Hemolysis rates and cell counts were studied during 
using two different blood volumes: 500 and 1500 mL.
 
[NaCl]ART was higher (P < 0.05, 
the one with 1500 mL blood (489 
was similar (P = 0.06; 135 ± 6 
the experiments with 500 mL blood but these differences depended only on the donor 
variability. Arterial Ca2+ and K
0.05) between both experiments but ve
mL blood. 
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s subjected to NaCl. 
 were obtained from arterial (increased ionic strength) and venous 
, bottom left), lymphocytes (LYM, bottom middle), granulocytes (
 
blood ≥ 0.39 M, the arterial dot plots
ex vivo results 
ex vivo standard pre
 
Tab. 13) in the experiment using 500 mL blood compared to 
± 35 versus 464 ± 19 mM, respectively) whereas [NaCl]
versus 140 ± 5 mM, respectively). Hct and tHb were higher in 
+ as well as venous Ca2+ concentrations were not different (
nous K+ concentration was lower (
 
 
Four 
NEU, top) 
Fig. 50) 
 
blood 
-HDF experiments 
VEN 
P > 
P < 0.01) in 1500 
  pH pO2 
[mmHg] 
pCO
[mmHg]
5
0
0
m
L ART 
7.22 
± 0.06 
112.1 
± 27.8 
25.8
± 8.3
VEN 
7.17 
± 0.07 
101.8 
± 18.8 
77.5
± 13.5
1
5
0
0
m
L ART 
7.18 
± 0.05 
97.2 
± 33.5 
27.5
± 2.8
VEN 
7.12 
± 0.04 
88.6 
± 24.6 
89.3
± 6.8
Tab. 13: Arterial and venous ion concentrations, pH, gas satura
vivo standard pre-dilution HDF. 
Results are presented as mean ± SD (2 independent experiments, 6 measurements, i.e. n = 12) of dialysis 
experiments performed with 500 mL and 1500 mL blood.
 
 
Fig. 51: Effect of the blood volume on the hemolysis during 
Hemolysis rates versus time (A) and 
sessions with either 500 mL ( ) or 1500 mL (
 
When ploting the hemolysis versus
blood compared with 1500 mL blood. Post
0.6% and 1.6 ± 1.3%, respectively. When ploting the same experimental values 
runs through the dialyzer according to 
between both blood volumes.
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2 
 
HCO3
-
 
[mM] 
Na
+
 
[mM] 
K
+
 
[mM] 
Ca
2+
 
[mM] 
Cl
-
 
[mM]
 
 
10.1 
± 1.9 
513 
± 36 
0.62 
± 0.19 
0.47 
± 0.06 
465 
± 34
 
 
27.5 
± 0.9 
158 
± 6 
2.65 
± 0.40 
1.13 
± 0.06 
112 
± 5 
 
 
10.1 
± 1.0 
491 
± 19 
0.56 
± 0.16 
0.48 
± 0.03 
437 
± 19
 
 
28.2 
± 1.0 
163 
± 6 
2.26 
± 0.11 
1.17 
± 0.02 
116 
± 5 
tion, hemoglobin and hematocrit during 
 
ex vivo standard pre-dilution HDF.
versus blood runs through the dialyzer (B) are presented for dialysis 
) blood. Means ± SD (n = 2) are given.
 time (Fig. 51, A), the rate was higher when using 500 mL 
-dialysis (180 min) hemolysis levels were 21.2 
Eq. 7 (Fig. 51, B), the hemolysis rate was similar 
 
 
 
tHb 
[g/dL] 
Hct 
[%] 
 
- - 
18.1 
± 1.1 
52.9 
± 3.7 
 
- - 
15.8 
± 0.4 
47.4 
± 0.9 
ex 
 
 
 
± 
versus blood 
 Fig. 52: Effect of the blood volume on the cell count during 
Mean (n = 2) cell counts versus time (A) and 
[× 10
3
/mm
3
] ( , ), RBC [× 10
were performed with 500 mL (solid lines) or 1500 mL blood (do
 
When using 500 mL blood, the mean WBC and PLT counts were decreased after 180 min 
treatment, whereas only a slight decrease was observed when using a larger blood volume 
(Fig. 52, A). However, when comparing the results for the same mechanical stress, i.e., 
number of passages through the blood pump (
observation was confirmed by similar findings for the WBC subpopulations in the dot plots 
(Fig. 53). 
 
Fig. 53: Dot plots of the WBC subpopulation
Four areas are highlighted: dead cells (
top), and monocytes (MON, bottom right).
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ex vivo standard pre-dilution HDF.
versus blood runs through the dialyzer (B) are presented for WBC 
6
/mm
3
] ( , ), and PLT [× 10
3
/mm
3
 ] (
tted lines). 
Fig. 52, B), the results were similar. This 
s during standard pre-dilution HDF with different blood volumes.
DC, bottom left), lymphocytes (LYM, bottom middle), 
 
 
 
 
, ). Experiments 
 
 
granulocytes (NEU, 
 Fig. 54: Effect of the blood volume on the pressures during 
Mean (n = 2) pressures recorded were: arterial (
( ), and TMP ( ). A, 500 mL blood; B, 1500 mL blood.
 
Arterial, venous, dialysate inlet, and outlet pressures were higher for the experiment 
performed with low blood volume, maybe due to the higher 
0.9%). The TMP was constant when using 1500 mL blood volume, whereas with 500 mL 
blood it increased after 90 min of dialysis because 
 
3) Maximal NaCl concentration in blood
 
Standard pre-HDF pilot experiments (n = 1) were perfo
different [NaCl] in the substitution fluid in order to determine the maximal admissible ionic 
strength under dynamic conditions.
 
Setting Hct 
[ % ] 
Single 0.15 M 43.3 ± 2.1 
Single 1.00 M 50.4 ± 2.7 
Spread 1.00 M 54.0 ± 4.5 
Single 1.55 M 38.2 ± 2.5 
Tab. 14: Hematocrit, hemoglobin and sodium chloride concentrations with 
dilution HDF. 
Spread infusion was performed with four different accesses. Results are mean ± SD 
measurements, i.e. n = 7). 
 
 
 
88 
standard pre-dilution HDF. 
), venous ( ), dialysate inlet (
 
Hct (52.9 ± 
PIN decreased and PART increased. 
 
rmed in human blood while using 
 
tHb 
[ g/dL ] 
[Na
+
]ART 
[ mM ] 
[Na
+
]VEN 
[ mM ] 
[Cl
-
]
[ mM ]
14.8 ± 0.6 141 ± 1 141 ± 1 103 
17.2 ± 0.5 534 ± 9 155 ± 6 485 
18.5 ± 1.5 486 ± 37 161 ± 5 439 ± 36
13.5 ± 0.6 444 ± 49 149 ± 8 390 ± 44
a different 
 
 
), dialysate outlet 
3.7% versus 47.4 ± 
 
ART 
 
[Cl
-
]VEN 
[ mM ] 
± 1 99 ± 2 
± 7 110 ± 5 
 115 ± 4 
 107 ± 7 
setup of standard pre-
(single experiment, 7 
 Fig. 55: Hemolysis in blood using different 
Final [NaCl]blood was 0.50 M using three different 
NaCl, and single infusion of 1.55 M NaCl (
versus blood runs through the dialyzer; B,
 
As shown in Tab. 14, [NaCl]ART
1.00 M NaCl solution, a spread 1.00 M NaCl solution, and a single 1.55 M NaCl solution in 
blood, respectively. When comparing the different settings, the higher the [NaCl]
higher the hemolysis rate. There was no difference between single and spread infusion of 
the 1.00 M NaCl in blood.  
 
4) Role of the semi
 
In order to assess the impact of the semi
setup on the protection against osmotic choc, hemodialysis treatments were performed
the same pool of human whole blood using this setup in HD
[NaCl]blood = 0.50 M.  For that purpose, only the dialysate flow rate of the first dialyzer 
was varied leading to two different [NaCl] at the first dialyzer dialysate inlet: 0.55 
M NaCl. After 120 min dialysis with increased ionic strength, blood was further dialyzed (120 
min) under physiologic conditions (0.15 M NaCl).
 
89 
[NaCl] in the substitution fluid during standard pre
[NaCl]SUB: single ( ) and spread (
). Reference: infusion of saline ( ). A, h
 detail of A. Results derived from a single pilot experiment (n = 1).
 reached about 0.51, 0.46, and 0.42 M when infusing a single 
-permeable membrane in the osmotic 
-permeable membrane (first dialyzer) in the SDial 
-modus (Qinf
 
 
 
-dilution HDF. 
) infusion of 1.00 M 
emolysis in blood 
 
SUB, the 
shock 
 in 
 = 0 mL/min) and 
Qex 
versus 1.10 
  
[NaCl] were measured as: BM, 498 ± 2 and 129 ± 0 mM between 0 
min, respectively, for Qex = 300 mL/min,  and 526 ± 5 and 123 ± 1 mM between 0 
and 120 – 240 min, respectively, for Q
300 and 50 mL/min, respectively. Even though the [NaCl]
the hemolysis was largely higher with the lowest 
min treatment, as shown in 
permeable membrane, the hemolysis augme
stopped (after 120 min treatment), hemolysis stayed constant.
 
 
The WBC count decreased in both experiments 
faster for Qex = 50 mL/min (Fig. 
after stopping of the 5.00 M Na
dot plot (Fig. 58). The RBC count slightly decreased over the whole experiment. 
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Fig. 56: Hemolysis rate during 
HD experiments with the 
setup at 0.50 M NaCl.
Results are presented 
pilot experiment (n = 1) for
300 mL/min ([NaCl]
) and
([NaCl]IN 1 
120 min, [NaCl]
to 240 min, [NaCl]
Time points correspond to 0.0, 
4.3, 8.7, 13.2, 26.8, 36.0, 40.7, 
45.5, 55.1, 64.7, and 74.5 blood 
runs through the dialyzer 
according to 
– 120 min and 120 
ex = 50 mL/min; VEN, 126 ± 1 and 124 ± 0 mM for Q
BM was similar with both settings, 
Qex reaching 4.0% (versus
Fig. 56. Thus, with increasing [NaCl] gradient on the semi
nted. When infusion of 5.00 M NaCl w
 
 
Fig. 57: Cell count during HD 
experiments with the 
setup at 0.50 M NaCl.
WBC (
counts (
presented 
(solid line) 
(dotted line
expressed in % of the cell count 
of t = 0 min (n = 1).
correspond to 0.0, 4.3, 8.7, 13.2, 
26.8, 36.0
and 74.5 blood runs through the 
dialyzer according to 
within the first half but the reduction was 
57). Similarly to hemolysis, the WBC count stayed constant 
Cl infusion. This finding was confirmed by the results of the 
 
SDial 
 
from a 
 Qex = 
IN 1 ≈ 0.55 M, 
 Qex = 50 mL/min 
≈ 1.10 M, ). 0 to 
BM = 0.50 M;  120 
BM = 0.15 M. 
Eq. 7. 
– 240 
– 120 min 
ex = 
 0.2%) after 120 
-
as 
SDial 
 
, ) and RBC 
, ) are 
for Qex = 300 mL/min 
and Qex = 50 mL/min 
). Values are 
 Time points 
, 40.7, 45.5, 55.1, 64.7, 
Eq. 7. 
 
 Fig. 58: Dot plots of the WBC subpopulation
Four areas are highlighted: dead cells (
top), and monocytes (MON, bottom right).
 
  T PART 1 P
Q
e
x=
3
0
0
 
m
L/
m
in
 0 – 120 
min 
35.4 
± 0.3 
128 
± 2 
120 – 
240 min 
35.3 
± 0.1 
123 
± 2 
Q
e
x=
5
0
 
m
L/
m
in
 0 – 120 
min 
34.8 
± 0.2 
134 
± 2 
127
120 – 
240 min 
35.3 
± 0.1 
131 
± 1 
120
Tab. 15: Temperatures and pressure
Abbreviations and units: T, temperature 
outlet pressure [mmHg]; PIN, dialyzer dialysate inlet pressure [mmHg]; 
[mmHg]; and TMP, transmembrane pressure [mmHg]
 
Overall, the temperature was similar in both experiments (
dialyzer were higher at low Q
pressures at the second filter were similar in both experimen
dialysate side of the first dialyzer decreased when the infusion of 5.00 M NaCl solution was 
stopped resulting in a higher TMP: during the first 120 min, the TMP of the first dialyzer was 
negative in both experiments, wher
59). The TMP of the second dialyzer did not depend on the infusion of 5.00 M NaCl solution 
but was greater for Qex = 50 mL/min compared to Q
91 
s during HD experiments with the SDial setup
DC, bottom left), lymphocytes (LYM, bottom middle), 
 
VEN 1 PIN 1 POUT 1 TMP1 PART 2 PVEN 2 P
94 
± 1 
129 
± 3 
123 
± 1 
-15 
± 1 
94 
± 1 
57 
± 1 
69
±
93 
± 1 
91 
± 5 
92 
± 5 
17 
± 4 
93 
± 1 
57 
± 1 
71
±
 
± 2 
155 
± 4 
148 
± 4 
-21 
± 2 
127 
± 2 
58 
± 0 
64
±
 
± 2 
114 
± 6 
119 
± 6 
9 
± 4 
120 
± 2 
57 
± 1 
64
±
s during HD experiments with the SDial setup at 0.50 M NaCl
[°C]; PART, dialyzer blood inlet pressure [mmHg]; 
POUT, dialyzer dialysate outlet pressure 
. 
Tab. 15). Pressures at the first 
ex (corresponding to high [NaCl] on the dialysate side) whereas 
t. Interestingly, pressure at the 
eas during the next 120 min, it was positive (see also 
ex = 300 mL/min. 
 
 
 at 0.50 M NaCl. 
granulocytes (NEU, 
IN 2 POUT 2 TMP2 
 
 1 
59 
± 2 
11 
± 1 
 
 2 
56 
± 3 
12 
± 1 
 
 0 
54 
± 3 
34 
± 1 
 
 0 
43 
± 2 
35 
± 1 
. 
PVEN, dialyzer blood 
Fig. 
  
5) Comparative 
 
The ex vivo hemocompatibility of increased ionic strength was assessed for two dialysis 
setups using the flow rates of the animal model:
• Standard pre-dilution HDF 
• Serial dialyzers pre-dilution HDF.
 
a. Standard 
 
It is important to note that the 
[NaCl]blood (also [NaCl]BM) whereas
[NaCl]SUB. The following concentrations were tested: standard pre
1.20 M NaCl; SDial pre-HDF, 0.15, 0.36, 0.50, and 0.75 M NaCl.
 
Serial dialyzers pre-dilution 
[NaCl]SUB [NaCl]blood 
 Target Real
120 120 125 ± 
120 360 377 ± 
120 500 474 ± 
120 750 731 (*)
Tab. 16: [NaCl] during both dialysis treatments.
Concentrations are given in [mM] as mean ± SD 
substitution fluid; [NaCl]blood,  NaCl 
downstream the pre-dilution; SDial pre
venous line (blood downstream the second dialyzer).
 
Blood temperature was between 33.8 ± 0.4 and 35.2 ± 0.7 °C and was not different between 
the settings. The NaCl concentrations at the different samples sites of both setups are 
presented above (Tab. 16). Real [NaCl]
settings, [NaCl]blood was increased (
92 
 
Fig. 59: 
experiments 
setup at 0.50 M NaCl
TMP of dialyzer 1 
and 2 (
300 mL/min (
50 mL/min (
ex vivo hemocompatibility 
 
(single dialyzer), 
 
versus serial dialyzers pre-dilution HDF
serial dialyzers system is described according to the 
 the standard HDF is described according to the 
-HDF, 0.15, 0.75, 1.00, and 
 
HDF Standard pre-dilution HDF
[NaCl]VEN [NaCl]SUB [NaCl]blood
   Target Real
3 127 ± 3 120 120 126 ± 3
40 127 ± 4 750 360 336 ± 
7 122 ± 4 1000 360 344 ± 
 145 (*) 1200 500 463
 
(n = 3). Abbreviations: [NaCl]SUB, NaCl concentration in the 
concentration in blood with increased ionic strength (standard pre
-HDF: second dialyzer blood inlet); [NaCl]VEN, NaCl concentration in the 
 
(*)
, n = 1. 
blood largely matched the target [NaCl]
P < 0.0001) compared to physiologic controls. 
 
TMP during HD 
with the SDial 
. 
( , ) 
, ) for Qex = 
solid line) and Qex = 
dotted line). 
 
 
 [NaCl]VEN 
  
 128 ± 2 
8 122 ± 2 
18 122 ± 1 
 ± 39 126 ± 5 
-HDF: 
blood. For all 
 Furthermore, settings with comparative ionic strength (SDial pre
standard pre-HDF 0.75 and 1.00 M NaCl; SDial pre
1.20 M NaCl) also were similar. [NaCl]
controls. 
 
Fig. 60: Ex vivo hemolysis in human hepar
A, standard pre-HDF with substitution fluid 
corresponding to [NaCl]blood of 0.15, 0.36, 0.36, and 0.50 M, res
0.36 ( ), 0.50 ( ), and 0.75 M 
sections: -1% to 5% and 5% to 75%. 
 
As demonstrated in Fig. 60, a second serial hemodialyzer did not induce hemolysis itself. In 
the standard pre-HDF group (
ionic strength in the substitution fluid to 0.75 M NaCl. A further increase of the [NaCl] led to 
significant hemolysis after 120 min (corresponding to 36.7 blood runs) reaching 3.1 ± 1.5% 
and 17.6 ± 7.2% for 1.00 and 1.20 M [NaCl]
correlated with both [NaCl]blood
respectively). In the SDial pre-
0.36 M NaCl did not induce hemolysis. Hemolysis occurred when using 0.50 M or greater 
[NaCl]blood. No correlation was found between post
0.18, P = 0.16). Hemolysis after 60 min and 120 min dialysis was significantly higher (
0.05) for standard pre-HDF 1.20 M NaCl as compared to all other treatments.
experiment was performed with the SDial pre
became unacceptably high not justifying further
 
At the beginning of the dialysis experiments, WBC, RBC, and PLT counts were in the range of 
4.3 ± 0.2 to 6.0 ± 2.7 ×103 cells /mm
to 163 ± 34 ×103 cells /mm3, respectively; Hct and tHb were in the range of 31 ± 2
6% and 10.4 ± 1.2 to 12.8 ± 1.7 g/dL, respectively.
time in the standard pre-HDF group with 0.15, 0.75, and 1.00 M [NaCl]
pre-HDF group with 0.15 and 0.36 M [NaCl]
SDial pre-HDF 0.50 M [NaCl]
93 
-HDF 0.36 M NaC
-HDF 0.50 M NaCl versus
VEN was not different compared to the isotonic 
inized blood during pre-dilution HDF at different 
of 0.15 ( ), 0.75 ( ), 1.00 ( ), and 1.20 M NaCl (
pectively; B, SDial pre-HDF with 
 [NaCl]blood ( ). *, P < 0.05 versus t0. The Y
Mean ± SD (n = 3). 
Fig. 60, A), no hemolysis was observed when increasing the 
SUB, respectively. Post-
 and [NaCl]SUB (r² = 0.47, P < 0.05; and r² = 0.43, 
HDF group (Fig. 60, B) increasing the ionic strength in blood to 
-dialysis hemolysis and [Na
-HDF and 0.75 M [NaCl]blood
 testing. 
3, 3.45 ± 0.51 to 4.19 ± 0.65 ×106 cells /mm
 The WBC count (Fig. 61) was constant over 
SUB
blood. In standard pre-HDF 1.20 M [NaCl]
blood, the WBC count decreased (P < 0.05) at the end of the 
 
l versus 
 standard pre-HDF 
 
[NaCl] and setups. 
) 
0.15 ( ), 
-axis is divided in two 
dialysis hemolysis 
P < 0.05, 
Cl]blood (r² = 
P < 
 Only a single 
 since hemolysis 
3, and 87 ± 10 
% to 37 ± 
, and in the SDial 
SUB and in 
 dialysis session. When comparing all treatments, the post
significantly lower for standard pre
were similar between each other. The WBC count was lower for standard pre
NaCl as compared to the physiologic ionic strength already after 60 min treatment.  Both 
RBC and PLT counts so that Hct and tHb were constant over time for all treatments. After 15 
minutes, the C5a concentrations were below the detection limit for all treatments. The TAT 
concentrations were constant during all dialysis treatments (range 6 to 32 µg/L).
 
Fig. 61: Ex vivo WBC count in human hepar
setups. 
For both standard and SDial pre-HDF, the WBC count was decreased at the highest ionic strengths. 
pre-HDF with substitution fluid of 
corresponding to [NaCl]blood of 0.15, 0.36, 0.36, and 0.50 M, respectively; 
0.36 ( ), 0.50 ( ), and 0.75 M 
HDF 0.75 M NaCl (n = 1)); *, P < 0.05 
 
The dot plots of the WBC (Fig. 
0.15 and 0.75 M [NaCl]SUB and during SDial pre
higher [NaCl]SUB, the monocyte and granulocyte counts decreased and dead cells increased. 
This phenomenon also occurred during SDial pre
and monocyte subpopulations completely disappeared during SDial pre
[NaCl]blood whereas few cells still were present in standard pre
 
As presented in Fig. 63, there was no
and 90 min of standard pre-HDF at 0.15, 0.75, and 1.00 M [NaCl]
larger than 15 fL (corresponding to cell fragments or dead cells) increased after 45 min of 
standard pre-HDF at 1.20 M [NaCl]
were detected in the 120 min sample at 0.50 M [NaCl]
min SDial pre-HDF at 0.75 M [NaCl]
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-dialysis (120 min) WBC count was 
-HDF 1.20 M NaCl and SDial pre-HDF 0.50 M NaCl; both 
inized blood during pre-dilution HDF at different 
0.15 ( ), 0.75 ( ), 1.00 ( ), and 1.20 M NaCl (
B, SDial pre-HDF with 
 [NaCl]blood ( ). Results are mean ± SD (n = 3, except for SDial pre
versus t0. 
62) did not reveal any change during standard pre
-HDF with 0.15 and 0.36 M [NaCl]
-HDF at higher [NaCl]blood
-HDF at 1.20 M [NaCl]
 visible change of the PLT volume histograms between 0 
SUB. The number of particles 
SUB. In the SDial pre-HDF group, few of these particles 
blood. Their number increased after 45 
blood. 
 
-HDF 1.20 M 
 
 
[NaCl] and 
A, standard 
) 
0.15 ( ), 
-
-HDF with 
blood. At 
. The granulocyte 
-HDF with 0.50 M 
SUB. 
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Fig. 62: Dot plots of the WBC 
subpopulations during pre-dilution 
HDF at different [NaCl] and setups. 
Typical dot plots of 45 and 90 min 
samples compared to baseline for 
both dialysis setups: standard (left) 
and SDial pre-HDF (right). The X-axis 
represents the [NaCl] (standard pre-
HDF, concentration in the 
substitution fluid; SDial pre-HDF, 
concentration in the blood). Four 
areas are highlighted: dead cells (DC, 
bottom left), lymphocytes (LYM, 
bottom middle), granulocytes (NEU, 
top), and monocytes (MON, bottom 
right). 
Fig. 63: Platelet volume histograms 
during pre-dilution HDF at different 
[NaCl] and setups. 
Obtained during standard (left) and 
SDial pre-HDF (right) from samples 
drawn at 0, 45, and 90 min (0, 13.3, 
and 27.2 runs, respectively). The X-
axis represents the [NaCl] (standard 
pre-HDF, concentration in the 
substitution fluid; SDial pre-HDF, 
concentration in the blood). 
 Fig. 64: Course of the online pressures 
Results are mean (n = 3): standard pre
HDF with 0.15 (E), 0.36 (F), 0.50 (
upstream the pre-dilution port (
and outlet ( ). 
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during pre-dilution HDF at different [NaCl] and setup
-HDF with 0.15 (A), 0.75 (B), 1.00 (C), and 1.20 M (
G), and 0.75 M (H, n = 1) [NaCl]blood. Pressures were measured on
), in the venous line ( ), at the second dialyzer 
 
 
s. 
D) [NaCl]SUB; SDial pre-
-line 
dialysate inlet ( ) 
 All pressures were constant during the experiments except f
M [NaCl]blood (Fig. 64, H) and the standard pre
which the arterial (upstream the pre
decreased.  
 
Fig. 65: Comparison of the TMP during
Course of mean TMP (n = 3): A, standard pre
( ) [NaCl]SUB; B, SDial pre-HDF with 
[NaCl]blood. The TMP was lower (P < 0.05) in the standard pre
group. 
 
Since the arterial pressure (upstream the pre
dialyzer in the SDial pre-HDF group, the pressure was higher (
standard pre-HDF group due to the pressure drop along the serial setup (first dialyzer: 50 
mmHg, second dialyzer: 52 mmHg). During the dialysis session with the SDial setup, the 
pressure in between both dialyzers was not transduced. Therefore, as s
TMP was higher (P < 0.05) in the SDial pre
second hemodialyzer of the SDial setup, the TMP was in the range 30 to 35 mmHg with both 
setups. [NaCl] did not have any effect on the TMP.
 
b. Serial dialyzer
transmembrane pre
 
In order to decrease the [NaCl] gradient between the buffered solution and blood using the 
serial dialyzers system (see also 
dialysate loop of the first dialyzer
for 0.50 M [NaCl]blood. 
 
Temperature and pressures remained unchanged for both settings. [NaCl]
were higher with the SDial-TM pre
versus 474 ± 7 mM, P < 0.01; [NaCl]
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or the SDial pre
-HDF with 1.20 M [NaCl]
-dilution) pressure increased and dialysate pressure 
 pre-dilution HDF at different [NaCl] and setups. 
-HDF with 0.15 ( ), 0.75 ( ), 1.00 (
0.15 ( ), 0.36 ( ), 0.50 ( ), and 0.75 M (
-HDF group as compared to the serial dialyzer
-dilution port) was measured before the first 
P < 0.05) as compared
hown in 
-HDF group. However, when considering only the 
 
s pre-dilution HDF  versus 
-dilution HDF  
Fig. 45), the substituate line was connected to the external 
. The SDial-TM pre-HDF was compared to the SDial pre
-HDF as compared to SDial pre-HDF: [NaCl]
VEN,  135 ± 4 versus 122 ± 4 mM, P < 0.0
 
-HDF with 0.75 
SUB (Fig. 64, D), in 
 
), and 1.20 M        
, n = 1) 
s 
 to the 
Fig. 65, the 
serial dialyzers 
-HDF 
blood and [NaCl]VEN 
blood, 535 ± 19 
5.  
 Fig. 66: Comparison of the pre-dilution 
the SDial setup. 
A, hemolysis; B, WBC count. Results were obtained with the SDial pre
( ) both at 0.50 M [NaCl]blood. Mean ± SD (n = 3); *, 
the experiment for both settings, whereas the WBC count decreased only with the SDial pre
 
At baseline, WBC, RBC, and PLT counts were similar (
hemolysis increased (P < 0.05) at the end of the treatment for both settings; the difference 
in hemolysis between both settings was not significant (
experiment. Different to the SDial pre
during SDial-TM pre-HDF, although, the difference between both settings was not 
significant. RBC and PLT counts were steady during dialysis with both SDial pre
SDial-TM pre-HDF at 0.50 M [NaCl]
 
Fig. 67: Dot plots of the WBC subpopulation
setup. 
Typical dot plots obtained at baseline,
normal (top) and transmembrane (bottom) pre
left), lymphocytes (LYM, bottom middle), 
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mode on ex vivo hemocompatibility of increased ionic strength with 
-HDF ( ) and the SDial
P < 0.05 versus t0. Hemolysis increased at the end of 
P > 0.05). As shown in 
P = 0.34) at the end of the 
-HDF, the WBC count (Fig. 66, B) did not decrease 
blood. 
s during different modes of pre-dilution HDF 
 45, and 90 min for both serial dialyzers setups
-dilution HDF. Four areas are highlighted: dead cells (
granulocytes (NEU, top), and monocytes (MON
 
 
-TM pre-HDF    
-HDF. 
Fig. 66, the 
-HDF and 
 
with the SDial 
 at 0.50 M [NaCl]blood:  
DC, bottom 
, bottom right). 
 Fig. 68: Platelet volume histograms 
Baseline, 45, and 90 min (0, 13.3, and 27.2 
transmembrane (bottom) pre-dilution HDF with the serial dialyzer
 
The dot plots of the WBC (Fig. 
after 45 and 90 min treatment when using the SDial
of dead cells was still important, particles bigger than 15 fL were not observed (see 
 
 
IV. In vitro toxin removal with NaCl dialysis
 
1) Mini-dialyzer model
 
a. Effect of plasma proteins on the instantaneous clearance
 
The instantaneous clearance of IS was determined using the 
similar flow rates as for the experiments described below. Aqueous clearance was compared 
before and after coating of the membrane with plasma proteins; plasma clearance was 
compared to the aqueous clearance after membrane c
fraction (Eq. 12). 
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during different modes of pre-dilution HDF with the 
blood runs, respectively) samples are depicted.
s setup at 0.50 M [NaCl]
67) demonstrated less loss of monocytes and granulocytes 
-TM pre-HDF. Even though the number 
 
 
same type of mini
oating calculated from the free toxin 
 
 
SDial setup. 
 Normal (top) and 
blood. 
Fig. 68). 
 
-dialyzers and 
 The instantaneous clearance (
with QB eq = 300 mL/min. Coating of the membrane with plasma proteins decreased the 
aqueous IS clearance (P < 0.05). The plasma (
calculated from the free toxin fraction in plasma (
the aqueous clearance.  
 
b. Comparison
 
In this experiment, the mean 
mean IS concentrations at the start of the dialysis were 
= 300 mL/min and QB eq = 400 mL/min, respectively.
 
Fig. 70: In vitro removal of IS from
strategies. 
Dialysis experiments were performed at Q
dilution HDF with saline ( ) and pre
NaCl solution). Results are presented as mean ± SD 
100 
 
Fig. 69
equivalent clearance of 
mini-dialyzer 
The IS clearance
for QB eq = 300 m
QB eq = 400 m
aqueous solution before and 
after coating of the membrane 
with plasma proteins, in plasma 
and calculated from the toxin 
free fraction.
presented as mean ± SD 
Equivalence calculations 
referred to a membrane of 1.8 
m² surface area. *, 
Abbreviations: FF, free fraction; 
Keq, equivalent instantaneous 
clearance.
Fig. 69) was higher (P < 0.05) for QB eq = 400 mL/min compared 
P < 0.001) and the aqueous clearances 
P < 0.01) were largely lower compared to 
 of HD, HDF, and HDF with NaCl using normal plasma
albumin concentration in plasma was 28.3 
95.0 ± 8.7 and 88.4 
 
 normal human plasma using mini-dialyzers and different dialysis 
B eq = 300 mL/min (A) and QB eq = 400 mL/min (B) in HD (
-dilution HDF with increased ionic strength (
(n = 3). 
 
: Instantaneous 
IS in the 
setup. 
 was determined 
L/min ( ) and 
L/min ( ) in 
 Results are 
(n = 3). 
P < 0.05. 
 
 
± 3.7 g/L and the 
± 9.6 µM for QB eq 
 
), pre-
, infusion of 1.00 M 
 As presented in Fig. 70, the removal 
different between standard pre
2.1 %/run and γ = 2.9 ± 0.4 %
respectively) and HD (γ = 3.1 ± 
QB eq = 400 mL/min, respectively
higher using 1.00 M NaCl as substitution fluid particularly at lower Q
and γ = 4.3 ± 1.3 %/run for QB eq
and P = 0.22, respectively)
concentration. For both QB, it was lower when using 1.00 M NaCl as substitution fluid 
compared to the other treatments (
400 mL/min, respectively). 
 
c. Removal rates in uremic and normal plasma
 
The efficacy of dialysis with increased ionic strength was tested in uremic plasma. At the 
beginning of the experiments, the IS concentrations of 
similar being 98.3 ± 5.4 and 105.8
plasma was lower (P < 0.05) compared to uremic plasma (
respectively). No difference was seen
concentrations: 38.9 ± 0.5 versus
± 4.8 g/L in uremic plasma. 
 
Fig. 71: In vitro removal of uremic toxins in normal an
The experiment was performed at Q
( , ) and uremic plasma ( , ) at 0.15 (
means (n = 3). 
 
When switching the substitution fluid from saline to 1.00 M NaCl solution (plasma [NaCl] = 
0.36 M), the IS removal rate 
neither in plasma of healthy individuals (3.8 
plasma of ESRD patients (4.5 
[NaCl]SUB, the removal rate of IS was not different (
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rate γ of IS from plasma of healthy 
-HDF (i.e., physiological saline as substitution 
/run for QB eq = 300 mL/min and QB eq
1.5 %/run and γ = 2.5 ± 0.4 %/run for QB eq
). Compared to standard pre-HDF, the 
B (γ
 = 300 mL/min and QB eq = 400 mL/min, respectively; 
. This finding was also confirmed by the post dialysis IS 
P < 0.05 and P < 0.01 for QB eq = 300 mL/min and Q
 
normal and uremic plasma
 ± 13.6 µM, respectively. The pCS concentratio
119.0 ± 5.4 versus
 between the pre- and post
 34.2 ± 3.3 g/L in normal plasma and 35.
d uremic human plasma using mini
B eq = 300 mL/min; removal of IS (A) and pCS (B) was determined 
solid lines) and 0.36 M NaCl (dotted lines). Results are presented as 
during HDF using mini-dialyzers did not significantly increase 
± 1.9 versus 5.0 ± 0.4 %/run; 
± 3.1 versus 6.6 ± 1.3 %/run; P = 0.20). Additionally,
P > 0.05) between plasma from healthy 
 
donors was not 
fluid; γ = 3.7 ± 
 = 400 mL/min, 
 = 300 mL/min and 
removal rate was 
 = 6.1 ± 2.9 %/run 
P < 0.05 
B eq = 
 were 
n in normal 
 139.0 ± 6.4 µM, 
-dialysis albumin 
1 ± 4.0 versus 35.3 
 
-dialyzers. 
in normal  
P = 0.36) nor in 
 at similar 
 and uremic individuals. No difference between physiological and increased ionic strength 
was found in the post-dialysis IS concentration in both normal a
results were obtained for pCS
%/run with infusion of saline and 1.00
%/run and γ = 6.20 ± 1.19 %/run
 
 
In this experiment comparing the removal of IS and 
the toxin removal rate (Fig. 72
= 0.07, and r² = 0.55, P = 0.09, for [NaCl] = 0.15 and 0.36 M, respectively)
 
d. Complete removal of IS and 
 
It can argued that protein bound molecules cannot be fully removed during dialysis
of the protein binding even after a very long treatment. In order to 
of IS and pCS from native uremic plasma, an experiment was performed using a mini
in HDF modus with infusion of 1.00 M NaCl.
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nd uremic plasma. 
: in normal plasma, γ = 3.37 ± 1.56 %/run and 
 M NaCl, respectively; in uremic plasma, 
 with infusion of saline and 1.00 M NaCl, respectively
 
Fig. 72: Comparison of the 
removal rate of uremic toxins 
versus 
concentration.
The mean removal rate of IS and 
pCS is plotted 
albumin 
pre-post 
[NaCl] of 0.15 (
( ). Regression coefficients are: 
0.15 M NaCl, r
NaCl, r² = 0.52
pCS between normal and uremic plasma, 
) did not correlate with the albumin concentrati
. 
pCS with HDF 
assess complete removal 
 
 
Similar 
γ = 4.85 ± 0.79 
γ = 4.33 ± 3.04 
. 
the albumin 
 
versus the 
concentration (mean 
dialysis) for plasma 
) and 0.36 M     
² = 0.61; 0.36 M 
. 
on (r² = 0.61, P 
 because 
-dialyzer 
  
Both IS and pCS were removed completely from uremic plasma 
dialysis (about 9 h, i.e., 100 blood runs through the dialyzer). The corresponding removal 
rates were 4.66 %/run for both toxins. 
 
e. Single- versus
 
In order to quantify the removal rate of IS when using two serial dialyzers, an experiment 
was performed comparing single and serial HD in plasma of healthy individuals.
 
  
In normal plasma, the removal rate of IS with serial HD (
twice the one of single HD (γ = 2.81 
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Fig. 73: In
and pCS from uremic 
IS (
concentration
pre-dilution HDF 
1) with infusion of 1.00 M NaCl 
are shown.
decreased exponentially over 
time and reached 0 after 100 
blood runs.
in vitro
 
 serial-hemodialysis 
Fig. 74: In
normal human
single or serial hemodialysis
Comparison between single HD
( ) and serial HD (
mean ± SD (n = 2)
γ = 5.72 ± 0.21 %/run) was about 
± 1.09 %/run). 
 
 vitro removal of IS 
plasma. 
) and pCS ( ) 
s during a pilot 
experiment (n = 
 Toxin concentrations 
 
 during extended 
 
 vitro removal of IS in 
 plasma using 
. 
  
), 
. 
 2) Comparative toxin removal with the dialysis machine
 
The in vitro removal of IS from normal human plasma during pre
machine preparing online substitution fluid was studied using different setups and 
[NaCl]blood: standard pre-HDF with 0.15 and 0.50 M [NaCl]
0.50 M [NaCl]blood or SDial pre
The temperature during dialysis was similar for all treatments and in the range of 36.0 ± 0.7 
to 36.5 ± 0.1 °C. Blood and venous [NaCl] were higher (
strength HDF as compared to isotonic HDF (
 
Setting 
Standard pre-HDF 0.15 M 
Standard pre-HDF 0.50 M 
SDial pre-HDF 0.15 M 
SDial pre-HDF 0.15 M + charcoal
SDial pre-HDF 0.50 M 
Tab. 17: [NaCl] during different dialysis treatments.
Concentrations are given in [mM] as mean ± SD 
with increased ionic strength (standard pre
inlet); [NaCl]VEN, NaCl concentration in the venous
versus standard pre-HDF 0.15 M, SDial pre
 
The IS concentration at the beginning of the dialysis experiments were similar for each 
setting being in the range of 65 to 74 µM. As presented in 
normalized to the blood runs through the dialyzer was increased in both standard and SDial 
pre-HDF with increased [NaCl]
yielded similar results. The presence of a charcoal adsorber within the closed dia
of the first hemodialyzer did not increase the removal rate of IS.
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-dilution HDF with a dialysis 
blood, SDial pre-
-HDF with a charcoal adsorber and 0.15 M [NaCl]
P < 0.001) when using increased ionic 
Tab. 17). 
[NaCl]blood 
[ mM ] 
126 ± 1 
477 ± 23 (*) 
126 ± 0 
 125 ± 1 
485 ± 8 (*) 
 
(n = 3). Abbreviations: [NaCl]blood, NaCl concentration in blood 
-HDF: downstream the pre-dilution; SDial: second dialyzer blood 
 line (blood downstream the second dialyzer). 
-HDF 0.15 M, and SDial pre-HDF 0.15 M + charcoal.
Fig. 75, the removal rate of IS 
blood (P < 0.001). Both standard and serial 
 
 
Fig. 75: In vitro removal rate of IS in normal
human plasma on a dialysis machine
Increasing the ionic strength significantly 
the IS removal rate. Different settings of pre
dilution HDF and [NaCl]blood: standard pre
0.15 or 0.50 M NaCl, SDial pre
0.50 M NaCl, and SDial pre
adsorber and 0.15 M NaCl. Mean ± SD (n = 9); *, 
< 0.001 versus standard 0.15 M NaCl, SDial 0.15 M, 
and SDial 0.15 M + charcoal. The removal rate is 
expressed in %/run. 
 
 
different 
HDF with 0.15 and 
blood. 
[NaCl]VEN 
[ mM ] 
126 ± 1 
132 ± 2 (*) 
126 ± 0 
126 ± 0 
131 ± 1 (*) 
(*)
, P < 0.001 
 
dialyzers setups 
lysate loop 
 
. 
increased 
-
-HDF with 
-HDF with 0.15 and 
-HDF with charcoal 
P 
 V. Animal model 
 
1) Ovine RBC resistance to increased ionic strength
 
a. Resistance under static conditions
 
Blood from 4 sheep was incubated at different ionic strengths as performed with human 
blood (see Fig. 46). As shown in 
static conditions in both human and ovine blood. Furthermore, hemolysis at 0.35, 0.60, and 
0.75 M NaCl was higher (P < 0.05) in human blood as compared to ovine blood.
 
 
b. Resistance under dynamic conditions
 
Human and ovine RBC resistance to osmotic changes was also studied under dynamic 
conditions using a mini-dialyzer system with infusion of either 0.15 or 1.20 M NaCl solution. 
[NaCl]VEN resulting from infusion of saline was 
blood, respectively, whereas infusion of 1.20 M NaCl led to 354 ± 10 and 503 ± 24 mM, 
respectively. Infusion of saline yielded [NaCl]
human blood, respectively, whereas inf
22 mM, respectively. 
 
As presented in Fig. 77, hemolysis did not increase during dialysis with infusion of saline i
both human and ovine blood. On the opposite, hemolysis occurred when infusing 1.20 M 
NaCl solution with a trend to being higher in ovine blood as compared to human blood (at 
180 min 13.7 ± 2.0% and 10.7 ± 3.6%, respectively). However, the difference was 
significant (P = 0.41, n = 2). 
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Fig. 76, hemolysis increased with [NaCl]blood
 
Fig. 76: Static 
of human and ovine 
erythrocytes to increased 
[NaCl]. 
Results are mean ± SD from 
experiments in human (
= 21; same data as presented in 
Fig. 46) and sheep (
blood. *, P
NaCl; #, P 
 
134 ± 1 and 130 ± 5 mM in ovine and human 
ART of 141 ± 1 and 140 ± 0 mM in ovine and 
usion of 1.20 M NaCl resulted in 618 ± 12 and 687 ± 
 
 > 0.50 M under 
 
in vitro resistance 
, n 
, n = 4) 
 < 0.001 versus 0.15 M 
< 0.05 versus sheep. 
n 
not 
  
2) In vivo dialysis experim
 
The biocompatibility of increased ionic strength during modified HDF was studied during 2 
hours on four female Merino sheep (mean weight 42.8 ± 3.0 kg, n = 4) using standard pre
HDF with 0.36 and 0.45 M [NaCl]
respectively) and SDial-TM pre
 
Fig. 78: Visual effects of increased ionic strength HDF 
experiments. 
Left: standard pre-HDF; arterial mixing chamber (pre
blood flew direction from left to right. Right: 
venous line). Change of blood coloration from dark to light red after infusion of NaCl.
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Fig. 77: Ex vivo
human and ovine blood under 
dynamic conditions
The hemolysis rate was studied 
during pre
either infusion of saline (
) or 1.20 M NaCl solution
( , 
(dotted line) and ovine (solid 
line) blood. Mean ± SD (n = 2); *, 
P < 0.05 versus
ovine blood was significantly 
increased after 5 blood runs.
ents 
blood (corresponding to [NaCl]SUB of 0.75 and 1.10 M, 
-HDF with 0.36 and 0.60 M [NaCl]blood. 
     
in the extracorporeal circuit during 
-dilution position) of blood and modified substitution fluid; 
SDial setup (bottom, arterial line; middle, between dialyzer
 
 
 hemolysis rate in 
. 
-dilution HDF with 
, 
   
) in human 
 t0. Hemolysis in 
 
-
 
the animal 
s; top, 
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As presented in Tab. 18, arterial and venous pH, partial pressure of arterial pO2 and pCO2, 
venous K+ concentration, and arterial and venous HCO3
- concentration were constant during 
all dialysis treatments while increasing the ionic strength in blood. In all settings, arterial K+ 
concentration decreased (P < 0.01) compared to baseline. Arterial Ca2+ concentration was 
constant over time. Venous Ca2+ concentration decreased (P < 0.05) and [NaCl]blood 
increased. [NaCl] was constant in arterial blood over the treatment for all settings (see Tab. 
19). The [NaCl]blood downstream of the substitution fluid was in the expected range. For all 
settings, [NaCl]VEN increased (P < 0.05) together with the ionic strength of the substitution 
fluid. Increased ionic strength led to a change of the blood coloration into light red (arterial 
and venous line: dark red) (Fig. 78). Interestingly, downstream the pre-dilution (BM) the 
proportion of oxy- and deoxyhemoglobin (O2Hb and HHb, respectively) significantly changed 
when increasing the ionic strength with the standard pre-HDF at 0.36 M [NaCl]blood (Tab. 20). 
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Setting 
Standard pre-HDF 
0.36 M [NaCl]blood 
(0.75 M [NaCl]SUB) 
Standard pre-HDF 
0.45 M [NaCl]blood 
(1.10 M [NaCl]SUB) 
SDial-TM pre-HDF 
0.36 M [NaCl]blood 
SDial-TM pre-HDF 
0.60 M [NaCl]blood 
Time [min]  0 30 60 120 0 30 60 120 0 30 60 120 0 30 60 120 
pH 
ART 
7.46 
± 0.02 
7.48 
± 0.02 
7.48 
± 0.02 
7.49 
± 0.02 
7.47 
± 0.01 
7.46 
± 0.05 
7.49 
± 0.01 
7.48 
± 0.01 
7.45 
± 0.03 
7.45 
± 0.02 
7.46 
± 0.03 
7.47 
± 0.03 
7.46 
± 0.02 
7.48 
± 0.02 
7.49 
± 0.01 
7.47 
± 0.02 
VEN - 
7.36 
± 0.03 
7.34
 (b)
 
± 0.03 
7.35 
± 0.02 
- 
7.35 
± 0.03 
7.35 
± 0.02 
7.35 
± 0.02 
- 
7.35 
± 0.02 
7.33
 (b)
 
± 0.03 
7.34 
± 0.02 
- 
7.37 
± 0.02 
7.32
 (b)
 
± 0.02 
7.33
 (b)
 
± 0.00 
pO2 [mmHg] ART 
54.0 
± 7.0 
44.0 
± 2.5 
44.1 
± 4.9 
43.5 
± 4.6 
47.9 
± 5.3 
43.8 
± 13.0 
42.7 
± 2.3 
40.5 
± 7.5 
65.2 
± 11.5 
43.2
 (a)
 
± 1.8 
46.7
 (a)
 
± 0.8 
43.5
 (a)
 
± 1.3 
51.0 
± 8.2 
43.2 
± 2.6 
43.5 
± 8.5 
43.2 
± 3.0 
pCO2 [mmHg] ART 
38.5 
± 3.5 
39.1 
± 3.6 
38.7 
± 3.3 
38.6 
± 2.6 
41.8 
± 0.9 
45.4 
± 5.3 
41.9 
± 1.8 
42.5 
± 2.3 
41.3 
± 4.4 
41.5 
± 4.0 
40.6 
± 3.9 
41.9 
± 4.3 
41.4 
± 2.2 
41.5 
± 1.5 
42.5 
± 2.6 
42.7 
± 1.6 
HCO3
- [mM] 
ART 
26.6 
± 2.6 
28.5 
± 1.6 
28.2 
± 1.5 
28.7
 (a)
 
± 1.3 
29.5 
± 0.9 
31.1
 (a)
 
± 0.2 
30.6 
± 0.7 
30.4 
± 0.8 
27.7 
± 2.3 
28.1 
± 2.3 
27.9 
± 1.9
 (§)
 
29.3
 (a)
 
± 1.8 
28.8 
± 0.8 
30.6
 (a)
 
± 1.4 
31.2
 (a)
 
± 1.5 
30.5
 (a)
 
± 0.7 
VEN - 
30.4 
± 0.8 
31.0 
± 0.8 
30.7 
± 0.6 
- 
31.0 
± 0.7 
31.4 
± 0.3 
31.3 
± 0.6 
- 
29.9 
± 0.9 
30.5 
± 0.6 
30.5 
± 0.6 
- 
31.2 
± 0.6 
31.6 
± 0.3 
31.6 
± 0.2 
K+ [mM] 
ART 
4.26 
± 0.41 
3.62
 (a)
 
± 0.32 
3.58
 (a)
 
± 0.26 
3.64
 (a)
 
± 0.22 
4.24 
± 0.60 
3.40
 (a)
 
± 0.48 
3.49
 (a)
 
± 0.35 
3.48
 (a)
 
± 0.38 
4.11 
± .033 
3.45
 (a)
 
± 0.10 
3.53
 (a)
 
± 0.21 
3.40
 (a)
 
± 0.10 
4.20 
± 0.25 
3.43
 (a)
 
± 0.26 
3.38
 (a)
 
± 0.28 
3.40
 (a)
 
± 0.22 
VEN - 
2.01 
± 0.10 
2.03 
± 0.08 
2.3 
± 0.08 
- 
2.02 
± 0.03 
2.02 
± 0.03 
2.01 
± 0.03 
- 
2.06 
± 0.09 
2.03 
± 0.07 
2.02 
± 0.09 
- 
2.01 
± 0.04 
2.00 
± 0.05 
1.95 
± 0.12 
Ca2+ [mM] 
ART 
1.21 
± 0.10 
1.19 
± 0.09 
1.19 
± 0.06 
1.16 
± 0.06 
1.13 
± 0.09 
1.10 
± 0.04 
1.09 
± 0.04 
1.08 
± 0.04 
1.20 
± 0.06 
1.20 
± 0.06 
1.20 
± 0.07 
1.17 
± 0.08 
1.14 
± 0.06 
1.13 
± 0.07 
1.11 
± 0.07 
1.08 
± 0.08 
VEN - 
1.13 
± 0.05 
1.09
 (b)
 
± 0.04 
1.07
 (b)
 
± 0.03 
- 
1.11 
± 0.01 
1.06
 (b)
 
± 0.01 
1.06
 (b)
 
± 0.01 
- 
1.13 
± 0.06 
1.09
 (b)
 
± 0.04 
1.08
 (b)
 
± 0.04 
- 
1.13 
± 0.05 
1.07 
± 0.02 
1.04
 (b)
 
± 0.01 
Tab. 18: Blood gas analyses and electrolyte concentrations during modified HDF in the animal model. 
The [NaCl] was increased after a 30 min baseline period. The presented parameters were constant when [NaCl] was increased. Abbreviations: pO2, dioxygen partial 
pressure; pCO2, carbon dioxide partial pressure. Results are mean ± SD (n = 4); 
(a)
, P < 0.05 versus 0 min; 
(b)
, P < 0.05 versus 30 min; 
(§)
, P < 0.05 versus SDial-TM pre-HDF 0.60 
M NaCl. 
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Setting 
Standard pre-HDF 
0.36 M [NaCl]blood  
(0.75 M [NaCl]SUB) 
Standard pre-HDF 
0.45 M [NaCl]blood 
(1.10 M [NaCl]SUB) 
SDial-TM pre-HDF 
0.36 M [NaCl]blood 
SDial-TM pre-HDF 
0.60 M [NaCl]blood 
Time [min] 0 30 60 120 0 30 60 120 0 30 60 120 0 30 60 120 
Na+ 
[mM] 
ART 
143.6 
± 4.4 
143.0 
± 3.8 
143.2 
± 3.7 
141.9 
± 4.4 
143.5 
± 1.7 
141.6 
± 1.8 
142.6 
± 1.5 
142.3 
± 1.6 
144.0 
± 3.9 
142.8 
± 3.7
 (a)
 
142.4 
± 3.9
 (a)
 
142.0 
± 4.1
 (a)
 
145.3 
± 2.7 
143.9 
± 3.0 
145.9 
± 4.6 
145.3 
± 4.9 
BM - 
138.8 
± 4.6 
392.4 
± 15.1
 (b)
 
383.4 
± 14.8
 (b)
 
- 
139.0 
± 1.3 
501.8
 (#)
 
± 6.0
 (b)
 
498.7
 (#)
 
± 17.6
 (b)
 
- 
138.6 
± 3.9 
385.2 
± 14.0
 (b)
 
387.9 
± 4.0
 (b)
 
- 
141.7 
± 3.1 
647.1
 ($)
 
± 15.8
 (b)
 
649.9
 ($)
 
± 11.8
 (b)
 
VEN - 
137.3 
± 3.4 
141.1 
± 3.3
 (b)
 
140.5 
± 3.1
 (b)
 
- 
138.5 
± 1.2 
143.3 
± 1.2
 (b)
 
143.1 
± 1.1
 (b)
 
- 
137.3 
± 3.2 
140.9 
± 3.0
 (b)
 
140.3 
± 3.3
 (b)
 
- 
139.3 
± 2.3 
148.9 
± 6.3
 (b)
 
146.7 
± 4.0
 (b)
 
Cl- 
[mM] 
ART 
110.3 
± 3.1 
109.6 
± 2.9 
110.3 
± 2.6 
110.0 
± 2.4 
107.3 
± 1.1 
106.7 
± 1.6 
108.0 
± 0.6 
108.6 
± 0.6 
110.3 
± 1.4 
110.2 
± 0.8 
110.1 
± 0.7 
109.2 
± 1.2 
108.5 
± 1.3 
109.3 
± 1.3 
109.9 
± 1.6 
110.1 
± 1.1 
BM - 
109.8 
± 2.5 
348.1 
± 12.8
 (b)
 
340.6 
± 13.3
 (b)
 
- 
107.7 
± 1.0 
454.4
 (#)
 
± 5.6
 (b)
 
450.7
 (#)
 
± 17.6
 (b)
 
- 
110.2 
± 1.0 
342.4 
± 9.8
 (b)
 
344.8 
± 3.9
 (b)
 
- 
109.4 
± 0.8 
586.3
 ($)
 
± 14.5
 (b)
 
588.5
 ($)
 
± 14.5
 (b)
 
VEN - 
104.5 
± 2.2 
107.3 
± 2.2
 (b)
 
107.5 
± 1.8
 (b)
 
- 
103.1 
± 0.6 
107.7 
± 0.5
 (b)
 
107.6 
± 0.6
 (b)
 
- 
104.7 
± 1.9 
(b)
 
107.3 
± 2.0
 (b)
 
107.1 
± 2.2
 (b)
 
- 
104.6 
± 1.7 
111.9 
± 5.0
 (b)
 
110.5 
± 2.5
 (b)
 
Tab. 19: Sodium and chloride concentration during modified HDF in the animal model. 
The [NaCl] was increased after a 30 min baseline period. Both Na
+
 and Cl
-
 concentrations were constant in arterial blood whereas they increased (P < 0.05) in venous blood 
when the ionic strength was increased in the blood stream; the venous Na
+
 and Cl
-
 concentrations did not differ significantly between the different treatments at 60 and 
120 min dialysis. Abbreviations: ART, arterial line ; BM, between hemodialyzers (downstream the pre-dilution) ; VEN, venous line. Results are mean ± SD (n = 4); 
(a)
, P < 0.05 
versus 0 min; 
(b)
, P < 0.05 versus 30 min; 
($)
, P < 0.001 versus all other treatments; 
(#)
, P < 0.001 versus standard pre-HDF 0.36 M [NaCl]blood and SDial-TM pre-HDF 0.36 M 
[NaCl]blood. 
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Setting 
Standard pre-HDF 
0.36 M [NaCl]blood  
(0.75 M [NaCl]SUB) 
Standard pre-HDF 
0.45 M [NaCl]blood 
(1.10 M [NaCl]SUB) 
SDial-TM pre-HDF 
0.36 M [NaCl]blood 
SDial-TM pre-HDF 
0.60 M [NaCl]blood 
Time [min] 0 30 60 120 0 30 60 120 0 30 60 120 0 30 60 120 
O2Hb 
[%] 
ART 
73.4 
± 8.6 
58.7 
± 8.1 
61.1 
± 10.2 
63.8 
± 13.0 
71.2 
± 1.8 
63.3 
± 16.0 
64.8 
± 6.1 
59.7 
± 9.2 
82.1 
± 10.3 
57.0 
± 6.1
 (a)
 
64.2 
± 6.4
 (a)
 
60.4 
± 8.8
 (a)
 
77.4 
± 8.4 
63.4 
± 5.4 
58.7 
± 4.8 
65.6 
± 8.9 
BM - 
89.4 
± 4.2 
63.5 
± 3.4
 (b)
 
68.4 
± 9.5
 (b)
 
- 
83.2 
± 10.1 
82.7 
± 3.8 
72.0 
± 9.6 
- 
77.3 
± 10.2 
81.7 
± 6.3 
71.0 
± 6.9
 (c)
 
- 
83.5 
± 11.5 
70.7 
± 6.6 
78.4 
± 12.2 
VEN - 
73.9 
± 7.7 
70.1 
± 10.6 
71.2 
± 12.2 
- 
76.3 
± 12.7 
78.9 
± 3.1 
74.2 
± 5.9 
- 
78.5 
± 5.8 
73.5 
± 4.6 
71.6 
± 5.3 
- 
77.9 
± 6.6 
71.6 
± 1.6 
71.2 
± 3.1 
COHb 
[%] 
ART 
1.8 
± 0.2 
1.8 
± 0.1 
1.7 
± 0.2 
1.7 
± 0.2 
1.7 
± 0.1 
1.6 
± 0.2 
1.7 
± 0.1 
1.6 
± 0.2 
1.3 
± 1.2 
1.5 
± 0.1 
1.8 
± 0.3 
1.7 
± 0.3 
1.7 
± 0.2 
1.7 
± 0.1 
1.6 
± 0.2 
1.7 
± 0.2 
BM - 
2.1 
± 0.0 
1.6 
± 0.0 
1.7 
± 0.3 
- 
1.9 
± 0.1 
1.7 
± 0.3 
1.8 
± 0.1 
- 
2.0 
± 0.5 
1.8 
± 0.3 
1.8 
± 0.5 
- 
1.9 
± 0.1 
1.6 
± 0.1
 (b)
 
1.6 
± 0.1
 (b)
 
VEN - 
1.9 
± 0.1 
1.8 
± 0.2 
2.0 
± 0.1 
- 
1.9 
± 0.2 
1.9 
± 0.1 
1.8 
± 0.2 
- 
1.9 
± 0.3 
1.9 
± 0.2 
1.9 
± 0.3 
- 
1.8 
± 0.1 
1.8 
± 0.1 
1.7 
± 0.2 
MetHb 
[%] 
ART 
0.9 
± 0.2 
1.0 
± 0.0 
1.0 
± 0.1 
0.9 
± 0.2 
0.8 
± 0.1 
0.9 
± 0.1 
0.9 
± 0.1 
0.9 
± 0.2 
0.7 
± 0.2 
1.0 
± 0.1 
0.9 
± 0.1 
0.9 
± 0.1 
0.8 
± 0.1 
1.0 
± 0.0 
1.0 
± 0.1 
0.8 
± 0.2 
BM - 
0.4 
± 0.0 
1.1 
± 0.0
 (b)
 
1.0 
± 0.2
 (b)
 
- 
0.6 
± 0.1 
0.8 
± 0.1
 (b)
 
0.9 
± 0.1
 (b)
 
- 
0.7 
± 0.1 
0.8 
± 0.1 
0.9 
± 0.2 
- 
0.6 
± 0.2 
1.0 
± 0.3 
1.0 
± 0.1 
VEN - 
0.8 
± 0.1 
0.9 
± 0.2 
0.8 
± 0.1 
- 
0.8 
± 0.2 
0.7 
± 0.1 
0.8 
± 0.1 
- 
0.7 
± 0.2 
0.8 
± 0.1 
0.9 
± 0.1 
- 
0.8 
± 0.2 
0.9 
± 0.1 
0.8 
± 0.1 
 ART 
24.0 
± 8.6 
41.9 
± 13.8 
36.2 
± 10.3 
33.6 
± 13.1 
26.4 
± 1.8 
34.3 
± 16.1 
32.7 
± 6.1 
37.8 
± 9.3 
15.3 
± 10.3 
40.4 
± 6.5
 (a)
 
33.0 
± 6.6
 (a)
 
37.0 
± 9.0
 (a)
 
20.2 
± 8.3 
34.0 
± 5.5 
38.7 
± 5.0 
31.9 
± 8.9 
HHb 
[%] 
BM - 
8.1 
± 4.2 
33.8 
± 3.5
 (b)
 
28.9 
± 9.5
 (b)
 
- 
14.4 
± 10.1 
14.9 
± 3.8 
25.3 
± 9.5 
- 
20.0 
± 10.5 
15.7 
± 6.4 
26.3 
± 7.1
 (c)
 
- 
14.0 
± 11.4 
26.6 
± 6.5 
19.1 
± 12.0 
 VEN - 
23.3 
± 7.7 
27.2 
± 10.6 
26.0 
± 12.2 
- 
21.1 
± 12.7 
18.6 
± 3.0 
23.3 
± 5.8 
- 
18.9 
± 6.0 
23.9 
± 4.7 
25.6 
± 5.3 
- 
19.5 
± 6.5 
25.6 
± 1.5 
26.2 
± 3.2 
Tab. 20: Hemoglobin states during modified HDF in the animal model. 
The [NaCl] was increased after a 30 min baseline period. Infusion of NaCl during standard pre-HDF with 0.36 M [NaCl]blood decreased the amount of O2Hb and increased the 
one of HHb downstream the pre-dilution (BM). Abbreviations: O2Hb, oxyhemoglobin; COHb, carboxyhemoglobin; MetHb, methemoglobin; HHb, deoxyhemoglobin; ART, 
arterial line ; BM, between hemodialyzers (downstream the pre-dilution) ; VEN, venous line. Results are mean ± SD (n = 4); 
(a)
, P < 0.05 versus 0 min; 
(b)
, P < 0.05 versus 30 
min; 
(c)
, P < 0.05 versus 60 min. 
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As shown in Tab. 21, the WBC count was constant over the dialysis time in all treatments 
except for SDial-TM pre-HDF at 0.36 M [NaCl]blood. There it increased after 60 min of dialysis 
(P < 0.05). The differential cell counts did not reveal any change in the WBC subpopulations. 
For all settings, RBC and PLT counts, Hct, and tHb were decreased after 30 min as compared 
to the beginning of the dialysis session. 
 
Setting Time 
[min] 
WBC 
[103/mm3] 
RBC 
[106/mm3] 
PLT 
[103/mm3] 
Hct 
[%] 
tHb 
[g/dL] 
S
ta
n
d
a
rd
 p
re
-H
D
F 
0
.3
6
 M
 [
N
a
C
l]
b
lo
o
d
 
(0
.7
5
 M
 [
N
a
C
l]
S
U
B
) 0 
6.2 
± 0.6 
9.4 
± 1.2 
446 
± 28 
27 
± 4 
9.9 
± 1.4 
30 
6.4 
± 0.7 
8.6 (a) 
± 0.7 
358 (a) 
± 44 
25 (a) 
± 3 
9.0 (a) 
± 0.7 
60 
7.9 
± 2.0 
8.4 (a) 
± 0.7 
334 (a) 
± 52 
24 (a) 
± 2 
8.9 (a) 
± 0.8 
120 
8.1 
± 1.8 
8.4 (a) 
± 0.7 
338 (a) 
± 50 
25 (a) 
± 3 
8.8 (a) 
± 0.7 
S
ta
n
d
a
rd
 p
re
-H
D
F 
0
.4
5
 M
 [
N
a
C
l]
b
lo
o
d
 
(1
.1
0
 M
 [
N
a
C
l]
S
U
B
) 0 
7.1 
± 1.7 
9.8 
± 0.6 
460 
± 82 
27 
± 2 
10.0 
± 1.0 
30 
7.4 
± 1.3 
8.9 (a) 
± 0.4 
407 
± 74 
24 (a) 
± 2 
9.1 
± 0.4 
60 
8.1 
± 2.4 
8.7 (a) 
± 0.5 
386 (a,b) 
± 69 
25 (a) 
± 2 
8.9 (a) 
± 0.8 
120 
8.4 
± 2.3 
8.7 (a) 
± 0.7 
336 (b) 
± 43 
24 (a) 
± 2 
9.0 
± 0.9 
S
D
ia
l-
T
M
 p
re
-H
D
F 
0
.3
6
 M
 [
N
a
C
l]
b
lo
o
d
 0 
6.0 
± 0.9 
9.4 
± 0.3 
493 
± 72 
26 
± 3 
9.4 
± 0.5 
30 
6.6 
± 0.9 
8.8 
± 0.7 
406 (a) 
± 91 
25 
± 2 
8.8 
± 0.7 
60 
7.7 (a) 
± 1.4 
8.8 
± 0.6 
397 (a) 
± 88 
24 
± 3 
8.9 
± 0.6 
120 
8.0 (a,b) 
± 1.7 
8.6 (a) 
± 0.6 
361 (a) 
± 76 
24 
± 3 
8.7 
± 0.6 
S
D
ia
l-
T
M
 p
re
-H
D
F 
0
.6
0
 M
 [
N
a
C
l]
b
lo
o
d
 0 
7.3 
± 2.3 
10.0 
± 1.1 
481 
± 162 
27 
± 4 
10.1 
± 1.4 
30 
6.8 
± 1.5 
8.5 (a) 
± 0.6 
348 
± 115 
23 (a) 
± 2 
8.6 (a) 
± 1.0 
60 
7.3 
± 1.9 
8.5 (a) 
± 0.8 
342 (a,b) 
± 136 
24 (a) 
± 3 
8.6 (a) 
± 1.4 
120 
6.8 
± 2.5 
8.7 (a) 
± 1.0 
311 (a,b) 
± 113 
24 (a) 
± 3 
8.7 (a) 
± 1.3 
Tab. 21: Cell count, hematocrit, and total hemoglobin during modified HDF in an animal model. 
The [NaCl] was increased after a 30 min baseline period. No change of the leucocyte subpopulations was 
observed. Abbreviations: WBC, leucocytes; RBC, erythrocytes; PLT, platelets; Hct, hematocrit; tHb, total 
hemoglobin concentration. Results are mean ± SD (n = 4); 
(a)
, P < 0.05 versus 0 min; 
(b)
, P < 0.05 versus 30 min. 
 
 
 
 
112 
 
The heart rate decreased (P < 0.01) within the first 30 min of treatment in all settings (range: 
t = 0 min, 100 to 125 beats/min; t = 30 min, 70 to 90 beats/min) except for the SDial-TM pre-
HDF with 0.60 M [NaCl]blood. There, it was steady at about 100 beats/min. After the 90 min of 
increased ionic strength, the heart rate was constant for standard pre-HDF at 0.45 M 
[NaCl]blood and SDial-TM pre-HDF at 0.36 M [NaCl]blood. It slightly decreased (P < 0.05, range 
80 to 90 beats/min) during standard pre-HDF at 0.36 M [NaCl]blood and SDial-TM pre-HDF at 
0.60 M [NaCl]blood. On the opposite, the mean arterial pressure was constant at about 60 
mmHg (P > 0.05) during the whole dialysis session at the different settings. 
 
As presented in Fig. 79, hemolysis slightly increased (P < 0.05) during dialysis independently 
of the setup and the [NaCl]blood. After 120 min of treatment, the hemolysis level was not 
different (P > 0.05) between each setting. Furthermore, the LDH concentration was constant 
during dialysis with increased ionic strength. 
  
 Fig. 79: Hemolysis and LDH concentration during modified HDF
Hemolysis (A-D) increased during standard pre
[NaCl]blood. LDH concentration (E-H) was constant. During the first 30 min of treatment, physiologic saline was 
infused; the [NaCl]blood was increased during the followi
standard pre-HDF at 0.36 M [NaCl]
[NaCl]blood; C and G, standard pre-HDF at 0.45 M [NaCl]
TM pre-HDF at 0.60 M [NaCl]blood. Mean ± SD (n
0 min; *, P < 0.05 versus 30 min. 
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 in an animal model. 
-HDF at 0.36 M [NaCl]blood and SDial-TM pre
ng 90 min. Treatment modalities were: A and E, 
blood (substitution fluid 0.75 M NaCl); B and F, SDial-
blood (substitution fluid 1.10 M NaCl); and D
 = 4); arterial ( ) and venous samples (
 
 
-HDF at 0.60 M 
TM pre-HDF at 0.36 M 
 and H, SDial-
); #, P < 0.05 versus 
 
114 
 
DISCUSSION 
Uremic toxins are biological agents accumulating in renal failure which may produce 
biological responses deleterious to the human body (7). The uremic toxins have been 
classified and stratified into three groups according to MW and protein binding (8): 1, small 
solutes with no protein binding (< 500 Da) (e.g. urea, Tab. 2); 2, solutes with known or likely 
protein binding (e.g. IS and pCS, Tab. 3); 3, middle molecules (≥ 500 Da) (e.g. β2m, Tab. 4). 
The protein-bound uremic solutes IS (Fig. 1) and pCS (Fig. 3) result from the metabolism of 
the amino acids tryptophan (21) and tyrosine (32), respectively. Both toxins accumulate in 
blood with progression of CKD (23; 36; 37) possibly due to reduced uptake by organic anion 
transporters in the kidney (24; 38). Moreover their deleterious effects on biological systems 
have been proven in vitro (29; 30; 43). Both IS and pCS are related to CKD progression (28) 
and to all-cause and cardiovascular mortality in HD patients (23; 37; 39; 40) contributing to 
the reduced survival probability of dialysis patients which is only 85.9%, 76.0%, and 50.3% 
after 1, 2, and 5 years, respectively (6). PAA largely accumulates in plasma of ESRD patients 
(about 3.4 mM) (10), and is suspected to play a role in bone disorder in CKD by affecting 
proliferation, differentiation, mineralization, and responsiveness to PTH of osteoclasts (48) 
and in immunodeficiency by inhibiting macrophage function (49). 
The clearance of uremic toxins differs between the three toxin groups. Although urea is 
easily removed during HD, protein bound uremic toxins, such as IS and pCS, and middle 
molecules, such as β2m, are only poorly removed (22; 33; 59; 60; 61). In spite of their small 
MW, IS and pCS with a protein binding of about 90% to 95% (22; 35) behave like larger 
molecules since their carrier protein albumin (77; 79) is unable to pass dialysis membranes 
and, therefore, is retained in blood. Only the free, unbound fraction is dialyzed (86). 
Therefore, current diffusive- and convective-based dialysis strategies (PD, HD, HF, and high-
flux HDF) are not effective to remove such molecules (7). 
 
The present thesis was motivated by the development of a hemodialysis method based on 
the transitory modification of the ionic strength in the extracorporeal blood stream to 
increase the removal of non-covalently protein bound uremic toxins. 
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I. Reducing the protein binding of uremic toxins 
 
Main findings: 
• Together with plasma dilution and higher temperature, increasing the [NaCl] is effective to 
reduce the PBF of IS, pCS, and PAA in normal and uremic plasma. 
• The binding affinity of HSA for IS was in the same range as the one of plasma proteins. 
• The binding affinity for IS and pCS can be assessed by Eq. 3 in uremic plasma, and depends 
linearly on the ionic strength, which can be modified by adding NaCl or other salts.  
 
HSA is the most important carrier protein for hydrophobic compounds, such as drugs, fatty 
acids, hormones, and waste products (73; 74; 75; 76). Ligands that bind to site I (such as 
CMPF (77)) of HSA are dicarboxylic acids and/or bulky heterocyclic molecules with a negative 
charge within the molecule, whereas ligands that bind to site II (like IS and pCS (77; 79)) of 
HSA  are aromatic carboxylic acids with a negatively charged acidic group at one end of the 
molecule that is separate from a hydrophobic center. The binding involves interactions with 
the amino acid residues (e.g. Trp214 for site I, Arg410 and Tyr411 for site II) in each binding 
pocket (72). Such intermolecular forces include dipole-dipole forces, hydrogen bonding, and 
London dispersion forces (73; 94). Moreover, the free and bound forms of such ligands are in 
a dynamic equilibrium (83). It is therefore possible to shift the equilibrium by modifying the 
electrochemical environment of the protein (i.e., modifying the ionic strength) and/or by 
changing the charge of the amino acid residues (i.e., modifying the pH). The choice of NaCl 
salt to increase the ionic strength in blood was motivated by: i), electrostatic interactions 
and/or Van der Waals forces are involved in the protein binding of IS and pCS (46; 95); ii), 
increasing its concentration to 0.30 M reduced the binding affinity of both p-cresol and pCS 
in HSA solution (96); iii), its concentration in blood is already high (about 120 mM); and iv), 
NaCl is inexpensive (about 16 €/kg (97)) and well approved for pharmaceutical application in 
human. 
 
1) Validation of frozen plasma 
 
The binding experiments with the uremic toxins IS, pCS, and PAA presented in the present 
thesis have been performed mostly in frozen human plasma. It is known from plasma 
fractionation that freezing of plasma alters the solubility of plasma proteins and leads to 
agglutination of, e.g. fibrinogen (98), thus changing the total protein concentration in the 
sample. Before using frozen plasma the aggregates were removed either by centrifugation or 
filtration. Therefore, it initially was verified if freezing of the plasma samples had an 
influence on both the PBF and the binding ability of uremic toxins in uremic and normal 
plasma (refer to “Effect of storage conditions”). 
 
In uremic plasma samples, the PBF of both IS and pCS was slightly higher (about 1.0%) after 
freezing. The reason for the decreased free toxin concentration after freezing (Fig. 21) may 
be the precipitation of other molecules, such as fatty acids, which are no longer bound to 
 
116 
 
albumin (74). Thus, less competitive reactions for the limited number of binding receptors 
occured after freezing leading to stronger toxin binding in uremic plasma. It is also possible 
that the small difference in both total (4 µM for both IS and pCS, thus representing an error 
of 4% and 2%, respectively) and free (1.4 and 1.9 µM for IS and pCS, respectively, thus 
representing an error of 21% and 26%, respectively) toxin concentrations may be due to 
pipetting. 
Freezing of normal samples revealed that the KD of proteins for IS was constant in plasma (KD 
= 14.3 ± 5.3 and 14.7 ± 7.5 µM before and after freezing, respectively) as well as the albumin 
concentration. However, apart from the limitation that only very few experiments were 
performed (n = 2), the binding capacity of the plasma was reduced because Bm slightly 
decreased after freezing (from 614 ± 47 to 565 ± 33 µM). 
 
Taken together, these experiments demonstrated that freezing of plasma did not 
significantly influence the binding ability of plasma proteins for protein bound uremic toxins, 
such as IS and pCS, allowing the use of this medium for further binding experiments.  
 
2) NaCl decreases the protein binding of uremic toxins 
 
a. Concept validation in pilot experiments 
 
Pilot experiments (Fig. 24 and Fig. 25) on the protein binding of IS, pCS, and PAA in normal 
human plasma were performed mainly by using a cocktail of toxins. Thus, it was possible to 
assess the influence of an increased toxin concentration (Fig. 25) and of the [NaCl] (Fig. 24) 
on the PBF of the toxins.  
As predicted by Eq. 3 and as shown in Fig. 7, increasing the toxin concentration ([LT]) 
decreased the PBF of protein bound toxins (Fig. 25) since the ratio [LT]/Bm increased (73). 
Moreover, since many toxins were added together competitive reactions for the limited 
number of binding sites on HSA (99) and other proteins must be assumed especially at the 
highest concentrations (35; 100). Spiking plasma of HD patients with 100 µM of IS increased 
(P < 0.001) the free fraction of pCS from 6.7% (native uremic plasma) to 8.6%, whereas 
spiking plasma of HD patients with 166 µM of pCS increased (P < 0.001) the free fraction of IS 
from 9.3% (native uremic plasma) to 12.1% (35). This finding was confirmed by the work of 
Watanabe et al. who reported competitive reaction between IS and pCS in HSA solution by a 
Klotz analysis and a spiking experiment (85). The assumption that competition occurs 
between uremic toxins for the limited number of binding sites also explains the stronger 
decrease of the PBF of IS compared to pCS with increasing toxin concentration (Fig. 25) since 
the experiments involving pCS were performed only with the single toxin. Furthermore, to 
estimate the influence of increased [NaCl] on the PBF (Fig. 24), displacement experiments 
were performed with 100 µM of IS and pCS, and 200 µM of PAA with an [NaCl] of 0.15, 0.30, 
0.50, and 1.00 M. Increasing the [NaCl] decreased the PBF of all protein bound toxins under 
investigation, i.e., IS, pCS, and PAA. Using Eq. 3, the possible effect of [NaCl] on KD of plasma 
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proteins for IS and pCS was calculated (Tab. 10). The resulting values at 0.15 M NaCl (IS, 
about 48 µM; pCS, about 18 µM) were unexpectedly different compared to previous report, 
although, they were measured in HSA solution: IS, KD = 0.6 to 1.1 µM (77; 79); pCS: KD = 2.5 
mM (96). Moreover, assuming Bm = 300 µM to assume KD may not reflect the actual binding 
capacity of normal plasma. Therefore, it was interesting to elucidate this difference more 
accurately, i.e., in HSA solution and in normal human plasma by studying a single toxin. 
 
b. Binding of IS to HSA 
 
In order to demonstrate the influence of increased ionic strength on the binding affinity of 
HSA for IS, fatty acid free HSA was used. This material was preferred to albumin solution 
which contains stabilizers interfering with ligand binding (101). Briefly, 65 µM HSA was 
incubated for 30 min at room temperature with PBS pH 7.4 in the presence of IS 
(concentration ranging from 2.5 to 25 µM) and at different ionic strengths (0.15, 0.30, 0.50, 
and 0.75 M NaCl). The PBF was determined by ultrafiltration. The experiments demonstrated 
that KD of albumin for IS positively correlated with the [NaCl] (KD = 8.7 ± 0.6 and 40.8 ± 10.8 
µM at 0.15 and 0.75 M NaCl, respectively; Fig. 26, A), i.e., increasing the [NaCl] decreases the 
binding affinity. This result is in agreement with previous findings which demonstrated that 
increasing the ionic strength to 0.30 M NaCl decreased the binding affinity of HSA for both p-
cresol and pCS (96), which are protein bound toxins like IS. Furthermore, the same was 
shown for the binding of naproxen to bovine serum albumin (102), a drug known to bind to 
Sudlow’s site II (101). The Scatchard plot (Fig. 26, B) demonstrated a single high-affinity 
binding site for IS on HSA, more exactly Sudlow’s site II as already documented by Sakai et al. 
(77). Since IS and pCS share the same binding site (35; 85) and have nearly the same binding 
strength in plasma (22; 33; 35), it can be concluded that the effect of increased ionic 
strength on the binding of IS and pCS is similar. 
The binding experiments of the present study were performed in 4.25 g/L HSA solution 
which is not representative for the physiologically much higher concentration in plasma 
(about 38 g/L) (37; 72). However, this difference should not have influenced the affinity of 
the binding sites. Sakai et al. reported that the binding affinity of HSA for dansylsarcosine, a 
marker ligand of HSA site II, was similar when using 40 or 200 µM HSA (77). The determined 
KD value of HSA for IS at physiologic [NaCl] and room temperature are in the range of 
reported data in the literature: KD ranges from about 1.0 µM (77; 79) to 10 µM (85). The 
experimental conditions may largely influence the results. Watanabe et al., who reported KD 
= 10 µM, had incubated the protein with IS in PBS pH 7.4 at room temperature and used 
ultrafiltration (85), thus, similarly to our method. Although Sakai et al. performed their study 
at room temperature, they used 67 mM phosphate buffer (that did not contain Cl- ions) and 
equilibrium dialysis (77; 79). The lower ionic strength in the solution may explain why Sakai 
et al. found a higher binding affinity (KD = 0.6 and 1.1 µM) as compared to Watanabe et al. 
(85). Ultrafiltration was used because equilibrium dialysis is time consuming (103). Since 
fatty acid free HSA (≥99% purity) was used and IS binds to a single high-affinity binding site 
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(77; 85), it can be considered that the number of binding sites is equal to the HSA 
concentration. Thus, in order to calculate more accurately KD, Bm was estimated to be equal 
to the HSA concentration (65 µM). 
 
c. Binding of IS, pCS, and PAA in normal human plasma 
 
Binding experiments in normal human plasma showed that both IS and pCS were bound 
specifically to one single binding site in normal human plasma as shown on the 
corresponding Scatchard plots (Fig. 29). This binding site has been identified by several 
authors as Sudlow’s site II of albumin in plasma (35; 77; 79). At low concentrations (< 500 
µM), PAA also was bound to a single, but likely different high affinity binding site (Fig. 82). 
When increasing the ionic strength in plasma by addition of NaCl, the results show a positive 
correlation of KD of these uremic toxins with the [NaCl] (Fig. 28, A): IS, KD = 71.2 × [NaCl] + 
5.1; pCS, KD = 82.4 × [NaCl] + 1.9; and PAA, KD = 1007 × [NaCl] + 55.3. The binding affinity of 
plasma proteins for both IS and pCS is similar (0.15 M NaCl, KD = 13.2 ± 3.7 and 16.3 ± 9.0 µM 
for IS and pCS, respectively; 0.50 M NaCl, KD = 43.9 ± 13.2 and 44.6 ± 16.0 µM for IS and pCS, 
respectively), whereas the PAA binding affinity is about tenfold lower (KD = 284 ± 74 and 459 
± 307 µM at 0.15 and 0.50 M NaCl, respectively). The reduction of the binding affinity with 
higher [NaCl], i.e., increased ionic strength, may be attributed to a modification of the 
electrostatic charges within the binding pocket of albumin (94) and/or a modification of the 
protein conformation (104), particularly, because no decrease of Bm was observed in the 
studied [NaCl] range. Thus, increased [NaCl] also positively correlated with the ratio KD/Bm 
(Fig. 28, B: IS, KD/Bm = 0.20 × [NaCl] + 0.03; pCS, KD/Bm = 0.18 × [NaCl] + 0.02; and PAA, KD/Bm 
= 3.19 × [NaCl] - 0.03) which corresponds to a decrease of the PBF (Eq. 3). In contrast, the 
PAA binding strength was not strong, which is in accordance with other reports confirming 
low protein binding (about 30%) (46). Therefore, this toxin can be easily removed by 
standard hemodialysis (105). Consequently, it was decided to not further study PAA since it 
did not fulfill the criteria of an ideal protein bound solute. 
Similarly to the experiments performed in HSA solution, those using human plasma also had 
been performed at room temperature and pH 7.4 as well as by applying ultrafiltration, which 
is closer to clinical dialysis. The measured KD for IS was slightly higher in human plasma than 
in HSA solution. This may be best explained by the presence of a variety of potential 
competing ligands in normal plasma, e.g. fatty acids, which may alter the binding properties 
of albumin by occupying the binding site (81) and/or inducing conformational changes of the 
protein (106). A methodological artifact can be excluded because comparative PBF of IS 
were obtained with both ultrafiltration and equilibrium dialysis (see “Temperature”). 
Together with protein adsorption onto the semi-permeable dialysis membrane (107), 
ultrafiltration of plasma water leads to an increase of the protein concentration in the 
retentate and, thus, a shift in the equilibrium. This phenomenon is well known from clinical 
hemodialysis, especially during post-dilution HDF (52). Previously reported binding affinities 
of HSA for both p-cresol and pCS (96) were largely lower (KD = 2.0 ± 0.1 and 2.5 ± 0.2 mM, 
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respectively) compared to those observed in the present experiments in human plasma, 
thus, being not consistent with the reported high protein binding (33; 35) and similar 
behavior of IS during HD (64). The high variability of KD observed in the present experiments 
using human plasma (Fig. 28, A) reflects the interindividual difference in the ability of plasma 
from different donors to bind toxins. As shown by Scatchard plot (Fig. 29), it is mainly 
determined by the albumin concentration. The albumin concentrations in the plasma 
samples used for the IS experiments considerably varied between 161 and 257 µM. 
Differences in the plasma content of present competing ligands may play an additional role, 
even though, toxins were incubated at low concentration (toxin-albumin ratio ≤ 1) and 
isolated to avoid extensive competitive reactions.  
 
d. Comparison of the PBF in normal and uremic plasma 
 
Synthetic toxins were added to normal human plasma but this method is regarded to not 
being sufficiently adequate to conclude on the effectiveness of increased ionic strength in 
uremic plasma (8). Therefore, the influence of increased [NaCl] also was demonstrated in 
plasma of ESRD patients on maintenance hemodialysis. Since plasma dilution influences the 
PBF (Fig. 31), the same plasma dilution was used to compare the PBF between normal and 
uremic plasma. Increasing the [NaCl] from physiological (0.15 M) to 0.75 M effectively 
decreased the PBF (Fig. 30) of IS and pCS in both normal (IS, from 93 ± 3% to 83 ± 4%; pCS, 
from 94 ± 2% to 89 ± 3% (at 0.50 M NaCl)) and uremic plasma (IS, from 89 ± 3% to 81 ± 3%; 
pCS, from 91 ± 2% to 84 ± 2%) but the PBF in uremic plasma was lower. This difference may 
be due to competition of the multiple uremic toxins for the same albumin binding site in 
ESRD patients (8; 35) while in human plasma from healthy donors, uremic toxins are not 
present (8). Supporting this argument, the mean native IS and pCS concentrations in uremic 
plasma were 69.4 ± 35.5 and 90.2 ± 27.9 µM, respectively. 
Since only the free toxin fraction is removed during HD (86; 105), the present results 
implicated that adding NaCl to plasma would enhance the clearance of the protein bound 
uremic toxins. The blood clearance of protein bound toxins can be estimated by “clearance = 
QB × free toxin fraction” (73). Thus, an increase of the free IS fraction in uremic plasma from 
11% to 19% (at 0.15 and 0.75 M NaCl, respectively) resulting from increased [NaCl] will 
approximately double its clearance (i.e., for QB = 300 mL/min, IS blood clearance should 
increase from ≈ 33 mL/min to ≈ 57 mL/min). To develop a modified dialysis method based on 
increased ionic strength in order to prove this assumption was a rational next step. 
 
e. Estimation of KD in uremic plasma 
 
The binding affinity of uremic plasma proteins for both IS and pCS was determined. This 
problem could have been approached by isolating and purifying some plasma proteins 
known to be involved in ligand binding (e.g., albumin and α1-acid glycoprotein) from uremic 
plasma (72). However, such an approach is time consuming and not representative for the 
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plasma milieu. In the present study, the protein binding was directly assessed in uremic 
plasma (Fig. 83). To note, performing direct binding studies in native uremic plasma is very 
difficult to interpret because competition occurs between the multiple protein bound uremic 
toxins present in plasma and any newly added ligand (46; 77; 79; 80). Alternatively, the free 
and bound toxin concentrations in plasma of a large number of uremic patients could be 
assessed and the binding constants determined from these data. Drawback of this approach 
is the array of required samples and the interindividual variability interfering with accurate 
calculations. 
In a first set, the influence of HD on the binding ability of plasma proteins was shown. Both IS 
and pCS behaved similarly during dialysis (Fig. 23). This finding is in accordance with Meijers 
et al. who settled that these compounds are interchangeable marker molecules to monitor 
protein bound uremic retention solutes during dialysis (35). In the present investigation on a 
cohort of hemodialysis patients (n = 49), the KD and Bm pre- and post-dialysis were estimated 
(Fig. 22). Both KD and Bm decreased over the dialysis treatment (IS, pre-dialysis, KD = 5.3 ± 1.7 
µM and Bm = 217 ± 36 µM; post-dialysis, KD = 3.5 ± 1.5 µM and Bm = 151 ± 37 µM). Nishio et 
al. reported that the free fatty acid concentration is largely increased post dialysis treatment 
which reduces the binding capacity of albumin (more exactly the binding capacity of its 
Sudlow’s site II) (82). Thus, the accumulation of free fatty acids may explain that Bm 
decreased between pre- and post-treatment (Fig. 22). The decrease of KD can be explained 
by the fall of the osmolarity, thus, of the ionic strength (Fig. 28), during hemodialysis (108; 
109). 
In a second set, the influence of a higher ionic strength on the binding constants of IS and 
pCS was studied. Firstly, it was verified if Eq. 3 is suited in normal plasma to allow an 
accurate prediction of the experimental PBF of IS from the binding constants independently 
of the plasma dilution (Tab. 11 and Tab. 12). At low toxin concentrations, the PBF is known 
to directly correlate with the binding affinity KD and the number of binding sites Bm and, 
thus, with the protein concentration (83). Advantageously reflected by Eq. 3, the binding 
affinity can be assessed in uremic plasma when knowing the PBF, the toxin and the receptor 
protein concentrations which all can be determined experimentally. Since albumin was not 
measured in the plasma samples, a mean albumin concentration of 570 µM (38 g/L), which is 
in accordance with previous studies in dialysis patients (35; 37; 39), and also that Bm = [HSA] 
were taken as assumptions for the calculations. Applying Eq. 3 yields that increasing the 
[NaCl] in uremic plasma from 0.15 to 0.75 M NaCl enhances KD for IS from 27.3 ± 8.6 to 55.9 
± 15.3 µM and for pCS from 20.1 ± 5.3 to 39.7 ± 9.4 µM. This estimated binding affinity 
reflects the apparent affinity of uremic plasma for both IS and pCS and is similar to the one 
found in normal plasma (Fig. 28). 
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f. Cumulative effect of plasma dilution 
 
Two to tenfold dilution of plasma also showed to be effective to decrease the PBF of IS (Fig. 
31) which is explained by a decrease of Bm (Fig. 31, B). This effect was additive to increasing 
KD by an increase of ionic strength through elevating the [NaCl] (Fig. 31, A). Both effects 
complement one another and lead to an increase in the ratio KD/Bm and, a fortiori, to a 
reduction of the PBF (Eq. 3). Clinical and experimental observations support this 
phenomenon. Low serum albumin concentrations in uremic patients were found to correlate 
with a higher free fraction of pCS (41). The same authors confirmed this finding by testing 
different bovine serum albumin concentrations in vitro (41), thereby, supporting the data of 
the present study which demonstrated that plasma dilution did not influence KD. Thus, it is 
important to take the protein concentration or plasma dilution into consideration when 
comparing the PBF from different experiments or clinical studies.  
 
g. Cumulative effect of the temperature 
 
Increasing the temperature from room (25 °C) to body temperature (37 °C) also decreased 
the PBF of IS in normal human plasma from 91 ± 2% to 85 ± 2%, respectively. Confirming 
Bergé-Lefranc et al. who reported that enhancing the temperature reduced the affinity (i.e., 
increased KD) of HSA for both p-cresol and pCS without changing of the protein structure in 
this temperature range (96), this finding is in accordance with the Van’t Hoff equation (Eq. 
17). Since toxin unbinding from a protein is an endothermic reaction (∆Ho > 0), i.e., it 
absorbs energy (110), and with T2 > T1, Eq. 17 gives K2 > K1 (111). Consequently (Eq. 3), 
performing experiments at room temperature must have overestimated the PBF and the 
binding affinity of IS, pCS, and PAA in human plasma compared to body temperature. 
Therefore, the influence of increased ionic strength during clinical dialysis, which usually is 
performed at body temperature, should even be greater compared to the results from the 
present experiments.  
 ln !#I" = ∆b  ! 1>I − 1>#" 
Eq. 17: Van’t Hoff equation (111). 
Where K1 and K2 are the equilibrium constants at the temperatures T1 and T2, respectively; ∆Ho is the standard 
enthalpy change for the process; and R is the gas constant with R = 8.31 J/K. 
 
h. Influence of ions and pH 
 
Not only NaCl but also KCl was able to reduce the PBF of IS in uremic plasma (Fig. 34). The 
effect of both salts was similar for comparable ionic strength. Moreover, mixing both salts 
had the same effect as a single salt at the same concentration. Thus, only an increased ionic 
strength affects the protein binding. Since the albumin conformation depends on pH (74), 
some blood purification methods (112; 113; 114) are based on pH shift, such as the heparin-
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induced extracorporeal lipoprotein precipitation (HELP), which primarily is not designated 
for the treatment of renal failure (39; 40). Lowering the pH to 5.4 (112) reduced the PBF of 
native IS (Fig. 34). Collins et al. described a method to improve the clearance of e.g. protein 
bound solutes by modifying the pH (7.8 < pH < 11) in blood upstream the hemodialyzer. In 
this invention, the pH in blood is restored after exposition to standard dialysate (7.0 < pH < 
7.8) (114). However, physiologic pH in blood is very narrow (pH between 7.35 and 7.45). 
Thus, shifting of the pH directly in blood (114) may induce bioincompatibility, which may 
explain that no data on this topic has ever been published so far. In the present work, adding 
NaCl together with reducing pH has the same effect like adding NaCl only. Both effects are 
not cumulative in the concentration range studied (Fig. 34). 
 
 
II. Modification of pre-dilution HDF for increased ionic strength  
 
Main findings: 
• Ionic strength is effectively increased in the blood line by a simple modification of the 
standard pre-dilution HDF setup. 
• Some parameters such as K0A of the hemodialyzer and QB have to be carefully adjusted to 
avoid retention of the NaCl excess in the blood stream. 
• Mini-dialyzer setups revealed that increased ionic strength during dialysis in plasma 
effectively enhances the removal rate of protein bound uremic toxins. 
• Ex vivo HDF with increased ionic strength up to 0.75 M [NaCl]SUB showed acceptable 
hemocompatibility (no hemolysis, no decrease of the WBC count, no activation of the 
complement or coagulation systems) to be transferred to the animal model. 
 
Modification of standard pre-dilution HDF (as drawn in Fig. 8 and Fig. 9) appeared to be the 
dialysis method which most simply allowed the application of increased ionic strength. The 
substitution fluid permits the addition of highly concentrated NaCl solution, which in turn 
injects the NaCl into the blood stream. It is necessary to increase the ionic strength upstream 
the hemodialyzer, i.e., doing pre-dilution, in order to eliminate untied protein bound toxins 
but also to remove the excess NaCl and restore blood osmolarity to a physiological level by 
the downstream dialysis before the blood is flowing back to the patient. Similarly to the 
clearance concept of the human kidney, the solute transport characteristics of a 
hemodialyzer may be expressed as clearance. Clearance represents the volume of fluid (e.g. 
blood or plasma) cleansed from a given substance per unit of time by the device (91). 
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1) Pilot experimentation of increased ionic strength during 
standard pre-dilution HDF  
 
Pilot experiments were performed in aqueous solution on a dialysis machine to assess the 
feasibility of increasing ionic strength using standard high-flux hemodialyzers (1.8 m²). For 
NaCl infusion, a 5.00 M (292.2 g/L) solution was used because it approaches the maximal 
solubility of NaCl in ultrapure water (358 g/L at 20 °C) (97). 
Since measurement of ion concentration by ion specific electrodes is time consuming, it was 
decided to measure instantaneously the conductivity in aqueous solution to estimate the 
ionic strength. The conductivity of a solution is directly proportional to the ion concentration 
(Eq. 8) and its respective molar conductivity. Since H3O
+ and HO- ions have the highest molar 
conductivity (34.95 and 19.86 mS.m²/mol, respectively) compared to Na+ and Cl- (5.01 and 
7.63 mS.m²/mol, respectively), a pH shift may largely influence the conductivity. Measuring 
the conductivity during dialysis was possible because the dialysate composition is constant 
during dialysis and buffered at pH of about 7.4. Therefore, the standard curve of the 
conductivity versus the [NaCl] was generated (Fig. 35).  Surprisingly, in the range of 0.10 to 
5.00 M NaCl, the curve was not linear which is not in accordance with the calculation of 
conductivity according to Kohlrausch’s law (Eq. 8). It could be explained by a saturation of 
the electrode for concentrations greater than 1.00 M. However, the conductivity was nearly 
linear in the most interesting range between 10 and 50 mS/cm and it was possible to 
perform a linear regression between [NaCl] and conductivity in the range of 10 – 35 mS/cm 
(Eq. 15). This information allowed a sufficiently accurate estimate of the [NaCl] from the 
conductivity in this range. 
 
Since saline has a physiological [NaCl] (0.15 M), its infusion at different flow rates (QNaCl) did 
not change the conductivity in the system (Fig. 36). Infusion of 5.00 M NaCl solution to the 
substituate increased the conductivity, i.e., [NaCl] in blood entering the dialyzer (Fig. 38 and 
Fig. 39). Furthermore, a constant NaCl infusion increased the ionic strength to equilibrium 
(Fig. 37). After modifying the external pump (Fig. 9) to synchronously injecting NaCl solution 
and removing dialysate, higher infusion flow rates QNaCl were possible. The previous setup 
was limited by the ultrafiltration flow rate QUF (usually 0 < QUF < 40 mL/min) since no excess 
fluid volume added to the blood reservoir. The modification allowed avoiding this problem. 
QNaCl further was only limited by the substitution flow rate Qinf (usually 0 < Qinf < 160 mL/min 
in pre-dilution HDF). 
Depending on the blood flow rate QB, the NaCl excess was not entirely removed from the 
blood stream (Fig. 40). This observation was predictable by simple models of the clearance 
from blood (Fig. 42 and Eq. 18) taking into account the K0A of urea (MW = 60 Da, i.e., similar 
to Na+ and Cl-: 23 and 35 Da, respectively), QB, and QD. Actually the clearance increases with 
QB, however, the increase is not proportional since the efficiency of diffusion decreases as 
blood flow increases (5). The [NaCl] in the blood entering the dialyzer depends only on the 
dilution factors (= flow rates) of NaCl solution and substituate and of substituate and blood. 
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K0A has the greatest influence on the removal of NaCl (Fig. 43) (5). Thus, high-flux filters 
(with high K0A) were preferred to low-flux filters (rather low K0A) for the application of 
increased ionic strength during HDF because an adequate NaCl balance is mandatory in 
maintenance dialysis patients lacking the renal control of homeostasis (115; 116). Increasing 
QD, as already exposed (5), has only a minor effect on small solute removal (Fig. 40 and Fig. 
43). Furthermore, a low QB (≤ 300 mL/min) is mandatory to remove the excess NaCl in order 
to avoid the retention of NaCl in the blood leaving the dialyzer which is reinfused into the 
patient.  
 
2) Toxin removal increased with higher ionic strength 
 
Mini-dialyzers (membrane surface area reduced to about 250 cm²) with similar high-flux 
membranes like standard dialyzers were used to perform preliminary studies on the removal 
of uremic toxins. Major advantage of such a miniaturized setup is the small filling volume 
(dialyzer + tubing ≈ 30 mL) allowing the use of plasma from reduced blood donation (60 mL) 
of ESRD patients. Since the flow rates had to be adjusted to the membrane surface area, the 
number of plasma/blood runs through the mini-dialyzer was determined (Eq. 7) to compare 
directly to normal setups. It corresponds to the number of times blood passes through the 
hemodialyzer. A clinical reference can be established for a standard dialysis duration of 4 h, a 
QB = 300 mL/min, and a normal patient with about 5.0 L blood. In this respect, blood is 
pumped about 15 times during hemodialysis. 
 
Mini-dialyzers may differ from larger hemodialyzers in term of clearance. Therefore, initially, 
an experiment was designed to assess the clearance of IS in different milieus, namely in 
aqueous solution before and after coating with plasma protein and in human plasma (Fig. 
69). Aqueous clearance of IS was reduced (between 15% and 20%) after coating of the 
membrane with plasma proteins. The protein (albumin, fibrin/fibrinogen) coating effect has 
been described to occur immediately after exposure to blood or plasma because of the 
hydrophobicity of the membrane material (11). Although albumin coating decreases solute 
clearances (11), it improves the hemocompatibility, e.g. by reducing thrombocyte adhesion 
(13). Similarly to standard hemodialyzers (117), increasing QB increased the clearance of the 
mini-dialyzers (Fig. 69) but not proportionally (as expected from Eq. 18). Therefore, 
interpreting the results with respect to the blood runs was preferred. The plasma clearance 
of IS was largely lower compared to the aqueous clearance because newly added IS must 
have bound to plasma proteins and only the free toxin fraction could be removed (86; 105). 
However, the plasma clearance was higher than the aqueous clearance relative to the free 
toxin fraction (calculated by Eq. 12; Fig. 69). It must be considered that removal of IS change 
the binding equilibrium (83) so that bound toxin is released and then removed from plasma 
(86; 105). 
In a consecutive pilot in vitro experiment (Fig. 73), both IS and pCS were demonstrated to be 
completely removed from native uremic undiluted plasma at the same rate. This was the 
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case when long time dialysis (about 9 h) was applied. An [NaCl] in plasma increased to about 
0.32 M was used to accelerate the removal and shorten the experiment duration. 
Mini-dialyzer experiments also revealed that increasing the ionic strength in the substituate 
to 1.00 M NaCl (0.36 M NaCl in plasma) effectively increased the removal rate of IS in normal 
plasma (Fig. 70) (plus 65% and 48% for QB eq = 300 and 400 mL/min, respectively). However, 
compared to HD, plasma dilution as obtained by HDF did not increase the removal rate of IS. 
Since the uremic toxin is diluted to the same proportion as it is released (118) both effects 
oppose themselves without changing the free mass of toxin (Eq. 3). The results also confirm 
that IS is mainly removed by diffusion as demonstrated by recent studies (63; 64). 
Another set of experiments comparing uremic and normal plasma and normal HDF with 
increased ionic strength HDF was done (Fig. 71). Increasing the [NaCl] increased the removal 
rate of both IS and pCS but the statistical power of the trial (n = 3) was too low to reach 
significance (P = 0.36 and P = 0.20 in normal and uremic plasma, respectively). However, the 
results rather confirmed than refuted the observation that IS and pCS behave similarly in 
normal and uremic plasma. Although low serum albumin concentration correlates with a 
higher free fraction of pCS (41), thus potentially with higher clearance (105), the removal 
rate of IS and pCS in human plasma did not significantly (P = 0.07 and P = 0.09 for [NaCl] = 
0.15 and 0.36 M) correlate with albumin concentration (Fig. 72).  
 
3) Ex vivo hemocompatibility of increased ionic strength 
 
The hemocompatibility was assessed in freshly donated heparinized blood from healthy 
volunteers according to ISO 8637:2010. 
 
a. Single contact experiments 
 
In order to illustrate the experimental results of hemolysis and cell count obtained during 
modified pre-dilution HDF, preliminary experiments were carried out by single contact of 
blood with hypertonic solutions (i.e., with increased [NaCl]). Other parameters assessing 
hemocompatibility (i.e., activation of the complement and coagulation systems) are only 
relevant under conditions closed to clinical application (i.e., longer lasting dialysis 
experiments as discussed below). 
Exposition of blood to increased ionic strength (Fig. 46) led to hemolysis when [NaCl]blood > 
0.50 M, which is in accordance with published results reporting a critical level of osmotic 
stress of 1.4 Osm (119; 120; 121). Green et al. also reported a hemolysis level of about 2% in 
1.00 M NaCl solution (120). The transformation of the cell morphology towards hemolysis 
corresponded to the increasing osmolarity (Fig. 48) (122; 123). In hypertonic solution, cells 
lose water through osmosis resulting in significant cell shrinking and appearance of the 
cytoskeleton (122). This is called crenation (124) and RBCs can be observed in form of 
echinocytes (122; 125) already at 0.25 M NaCl (124). If the milieu is excessively hypertonic, 
the cell membrane can no longer support the water loss and disrupts. 
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Interestingly, the resistance of RBC to osmotic changes correlates with the RBC count and 
tHb (Fig. 47). Only few publications are available on this relationship, particularly 
investigating hypotonic media (126; 127; 128). Reddy et al. did not find in tuberculosis 
patients any correlation between tHb or RBC count and osmotic fragility (126). Similarly, in 
human female subjects, the erythrocyte membrane resistance to hypotonic lysis was 
correlated neither with RBC count nor with the cell volume (127). On the opposite, Karai et 
al. found a close relationship between RBC osmotic fragility and both cell volume and tHb in 
workers from lead industry, whereas in healthy controls they found a close relationship 
between RBC osmotic fragility and both cell volume and RBC count (128). These data may 
not reflect the RBC resistance to hypertonic solution as studied here (Fig. 46, Fig. 47, and Fig. 
48) since the water flux is in the opposite direction in hypo- and hypertonic media (124) and 
the osmotic fragility test is performed by exposing RBC to hypotonic solutions (0% to 0.9% 
NaCl) (129). An explanation for the apparently higher RBC resistance in hypertonic media for 
higher RBC counts (Fig. 47) could be that the higher the number of cells, the lower the 
volume loss (i.e., the lower the crenation) in order to equilibrate the osmolarity on both 
sides of the cell membrane. Since the hypertonic milieu is diluted when the cells loose water, 
the osmolarity decreases, especially in the present in vitro conditions. This effect will be of 
interest when selecting a study population suited for the clinical application of modified pre-
dilution HDF. Together with low hemoglobin levels in uremic patients (11.9 ± 1.3 (67) versus 
15.5 ± 2 g/dL in the normal population (130)), the erythrocyte osmotic fragility of both 
diabetic and uremic (on maintenance HD) patients is higher than in healthy humans (131; 
132; 133; 134) because of the decreased deformability of the cells (135; 136). Therefore the 
erythrocytes of uremic patients may be more susceptible to lysis during modified pre-
dilution HDF compared to those of healthy people. 
A difference was seen between blood dilution and dialysis with NaCl solutions (Fig. 46). 
Hemolysis was worse in the latter case. This phenomenon could be attributable to the shear 
stress induced by the passage through the capillaries (internal diameter 215 µm) of the 
dialyzer (137). RBC deformability decreases with both hypo- and hypertonicity (138), which 
plays a significant role in spontaneous hemolysis (137) and cell life span (139; 140). 
Furthermore, the incubation time at increased ionic strength could have also added to the 
observed difference since blood samples were incubated for 1 h under dilution versus 4 h for 
single pass dialysis. 
The hemolysis increased exponentially with the [NaCl] starting at about 0.50 M with both 
single pass dialysis and blood dilution (Fig. 46). The most fragile population of RBC would be 
the first to be damaged by the sudden exposure to hypertonic media (137). Although 
osmotic resistance is used to differentiate old and young RBC because the young human 
erythrocytes are more resistant to hemolysis in hypotonic media compared to older cells 
(141; 142), cellular aging does not produce a gradual increase in osmotic fragility (143). It 
decreases the RBC volume (142) which is correlated with a higher resistance to a 
hyperosmotic milieu since small RBCs are more resistant compared to larger ones (121). 
 
127 
 
The WBC morphology also changed in a similar manner with increased ionic strength (Fig. 
50), i.e., the cellular size decreased with higher tonicity because of osmosis (124). In 
principal, the phenomenon of cellular shrinking is reversible (140; 144) for both RBC and 
WBC (Fig. 49 and Fig. 50) as long as lysis does not occur. Interestingly, WBC seem to be more 
resistant to osmotic changes compared to RBC (134; 145; 146). The median osmotic fragility 
in hypotonic NaCl solution was about 0.25% and 0.39% NaCl for normal lymphocytes (145) 
and erythrocytes (134), respectively. 
 
From these single contact experiments it was concluded that blood cells may support up to 
0.50 M NaCl without sustained damages. Because of the higher susceptibility to osmotic 
changes of the RBC of patients on maintenance hemodialysis and diabetic patients (131; 
132; 133; 134), it would have been an interesting issue to perform similar experiments (Fig. 
46, Fig. 47) on the blood of ESRD patients on maintenance hemodialysis. 
 
b.  Experiments on a dialysis machine and under dynamic 
conditions 
 
A first set of experiments comparing the effect of increased ionic strength ([NaCl]SUB = 1.00 
M and [NaCl]blood = 0.50 M) on the blood volumes between 500 and 1500 mL revealed a 
strong impact of  the blood volume on the hemolysis (Fig. 51, A) and WBC count (Fig. 52, A 
and Fig. 53). It best is explained by the number of stimulations inflicted upon the blood cells. 
Compared to 500 mL blood, blood cells in a larger blood volume (1500 mL) encounter three 
times less often osmotic changes from increased [NaCl] and mechanical stress through the 
blood pump of the circuit. Therefore, Eq. 7 was used to determine the number of blood runs 
τ, corresponding to the number of stimulations, to set the experimental results into 
perspective. When plotting the degree of hemolysis versus τ (Fig. 51, B), no difference 
between 500 and 1500 mL blood could be identified. This finding was of great importance 
for the interpretation of the in vitro results before transferring it into the clinical application. 
Since 15 τ are commonly obtained during clinical hemodialysis of a 70 kg patient with 
approximately 5 L of blood (see above), a hemolysis < 1% in vitro after 30 τ, representing 
twice the standard dialysis duration, is by far on the safe side even after taking into account 
an additional security margin because the hemolysis increased exponentially with the 
mechanical stresses (Fig. 51 and Fig. 55). An Acceptable level of hemolysis for medical 
devices is not defined in standards, such as ISO 10993-4:2002 (147) but a reference value of 
1% hemolysis is used to assess biocompatibility of blood storage materials (137). Moreover, 
free plasma Hb concentrations of 0.3 to 2.1 g/dL (i.e., corresponding to about 2% to 17% 
hemolysis, respectively) were associated with the manifestation of symptomatic illness of 
hemodialysis patients during acute hemolysis (148). 
 
The observed increase of the TMP when using 500 mL blood (Fig. 54, A) may be due to 
membrane clotting because of damaged cell particles. Damaged RBCs during treatment with 
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increased ionic strength will release Hb and cellular organelles (124; 148). The membrane 
pores are obstructed by the cell particles and the membrane surface area is decreased (11). 
Since the QUF is constant, the TMP increases. 
 
Subsequently, the hemocompatibility of increased ionic strength was determined during 
standard pre-dilution HDF at different [NaCl]blood (0.15, 0.36, and 0.50 M). After pilot 
experiments (Fig. 55) had revealed that the [NaCl]SUB plays a role in hemolysis, two different 
[NaCl]SUB, 0.75 and 1.00 M, were compared to obtain a 0.36 M [NaCl]blood. The experiments 
were designed with a QB of 150 mL/min applicable to the planned sheep animal model of 
dialysis (149) and Qinf representative for the clinical application (60) (Qinf was 75 and 50 
mL/min at [NaCl]SUB of 0.75 and 1.00 M, respectively, to reach 0.36 M [NaCl]blood). The 
treatment duration of 120 min was calculated from the blood volume in order to pump 
blood more than 30 times to reach the acceptance criteria for hemolysis. Blood Hct and TP 
were adjusted according to ISO 8637:2010. 
As a main requirement, the [NaCl]VEN (Tab. 16) should not be higher than the control (0.15 
M) in all experiments performed in standard pre-dilution HDF as a measure for a complete 
removal of the NaCl excess by the downstream HD (Eq. 18). The experiments further 
confirmed that the osmotic shock, as defined by the difference between [NaCl]SUB (0.75 and 
1.00 M) and [NaCl]blood (0.36 M), plays the major role for the RBC damage (Fig. 60, A) 
because the hemolysis was significantly more intense with 1.00 M NaCl substituate 
compared with 0.75 M, although, the obtained [NaCl]blood was identical. Furthermore, the 
hemolysis correlated with [NaCl]SUB. Since hemolysis after 30 τ was below 1% (see above) 
only for the 0.75 M NaCl substituate, it was concluded that this setting represents the 
maximum [NaCl]SUB which achieves ex vivo results being acceptable to be transferred into 
the animal model. 
 
Although, post-dialysis hemolysis was high using 1.20 M NaCl substitution fluid (17.6 ± 7.2%, 
P < 0.05), the RBC count did not decrease (range 3.45 ± 0.51 to 4.19 ± 0.65 ×106 cells /mm3 
at the beginning of the dialysis experiments). This observation can be explained as follows. 
When cell membranes disrupted in hypertonic solution, free Hb was released into the 
plasma. Due to hydrophobic interactions, the cell membranes merged few instants later 
resulting in damaged RBCs of nearly the same size as normal (124) not differentiated by the 
automated cell counter (measurement by impedance). Thus, RBC damage should be 
assessed by measuring the Hb release. 
The WBC count was constant over time when increasing the [NaCl]SUB up to 1.00 M (Fig. 61, 
A) and did not differ from physiologic ionic strength. Furthermore, the course of the WBC 
count was similar to that observed in patients during hemodialysis with biocompatible 
membranes (150). Confirming the experiments performed with single contact of blood with 
hypertonic NaCl solutions (see above), the WBC (Fig. 61, A) seemed to be more resistant to 
the osmotic shock compared to RBC (Fig. 60, A) since no difference was observed in the WBC 
count between 0.75 and 1.00 M [NaCl]SUB (Fig. 61, A; 92.4 ± 7.7% versus 89.4 ± 6.5% after 
 
129 
 
120 min dialysis with 0.75 and 1.00 M [NaCl]SUB, respectively). However, they finally 
decreased with 1.20 M [NaCl]SUB (57.7 ± 6.5% after 120 min dialysis; P < 0.05). This finding 
was consistent with the dot plots (Fig. 62, A) and the platelet volume histograms (Fig. 63, A). 
Dead cells or cell fragments appeared only with 1.20 M NaCl substituate. Dot plots (Fig. 62) 
and platelet volume histograms (Fig. 63) were performed after a dialysis duration of 0, 13.3, 
and 27.2 τ corresponding to baseline (0 τ), near to full-time clinical dialysis (15 τ), and 
defined performance criteria (30 τ), respectively. 
In order to assess the activation of the coagulation and complement system by increased 
ionic strength, the course of TAT (MW = 96 kDa (151)) and C5a concentrations, respectively, 
were measured at the different [NaCl]. These parameters are recommended by European 
guidelines to assess the biocompatibility of medical devices in contact with blood (147) 
because thrombin and C5a are activated downstream the coagulation and complement 
cascades, respectively, and are independent of the activation pathways (152; 153). No 
activation of the coagulation system was observed (the TAT concentration remained in the 
range of 6 to 32 µg/L during the dialysis experiments without any influence of the [NaCl]). 
Krieter et al. reported TAT concentrations between 2 to 6 µg/L in vitro for biocompatible 
dialysis membranes (150). Since C5a concentrations were below the detection limit after 15 
min treatment, this 11 kDa protein must have been removed by high-flux hemodialysis as 
shown in previous studies (154). The Cuprophan® membrane, which is classified as 
bioincompatible membrane (155), induces activation of complement with rising of the C5a 
concentration of up to 49 mg/L (154). This is by far higher compared to biocompatible 
polyethersulfone membranes (C5a concentration in the range of 1 to 3 mg/L) (150). Taken 
together increased ionic strength applied in the defined range during pre-dilution HDF 
demonstrated adequate biocompatibility. 
 
 
III. Iterated application of increased ionic strength by serial 
dialyzers HD / HDF 
 
Main findings: 
• Better hemocompatibility of increased ionic strength dialysis is obtained with the SDial 
setup. 
• Transmembrane pre-dilution further improves hemocompatibility by decreasing the [NaCl] 
gradient at the porous membrane. 
• Inadequate flow rates (i.e., Qex << QB) may increase the concentration gradient leading to 
deteriorated hemocompatibility. 
• Both standard pre-HDF and SDial pre-HDF are efficient to increase protein bound uremic 
toxin removal. 
 
To reduce the detrimental effects of osmotic shock, the infusion of the substitution fluid was 
split to several sites of the circuit (see Fig. 14) during a pilot experiment of standard pre-
dilution HDF. This setting did not reduce hemolysis compared to single site infusion (Fig. 55). 
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Alternatively, blood can be dialyzed against a solution with the targeted ionic strength to 
reduce the osmotic shock. Therefore, the SDial setup was developed as an iteration step 
(Fig. 10). In the first cartridge, blood was dialyzed against a solution with elevated [NaCl] to 
increase the concentration in blood. Then, blood passed through a second serial cartridge 
(high-flux hemodialyzer) in which the NaCl excess and toxins were removed.  
The validation of this setting was performed in different steps: control of the ionic strength 
in aqueous solution, ex vivo hemocompatibility, and toxin removal efficacy. 
 
1) Control of the NaCl concentration in aqueous solution 
 
Since the final [NaCl]blood with the SDial setup did not depend directly on the different flow 
rates but also on the semi-permeable membrane properties (11) (i.e., K0A), pilot 
experiments using aqueous solutions were designed. 
First experiments showed that the ionic strength was stable over time at different flow rates 
(Fig. 41). Moreover, the second cartridge effectively removed the NaCl excess ([NaCl]VEN was 
about 137 mM). However, there was still a difference in the [NaCl] between the blood (BM) 
and the dialysate compartment (IN) ([NaCl]IN / [NaCl]BM = 1.45 ± 0.05, 1.38 ± 0.10, and 1.36 ± 
0.05 for Qex = 200, 225, and 250 mL/min, respectively) indicating that Na
+ and Cl- ions did not 
diffuse completely from the dialysate into the blood stream. The difference was reduced by 
increasing the dialysate flow rate of the external closed loop Qex. Using recursion calculation, 
the [NaCl] at the different sites of the setup was simulated (see Fig. 87 and Fig. 44) in order 
to explain the difference between the [NaCl]BM and [NaCl]IN, and to assess the stability of the 
ionic strength over time. The experimental results were well approached by the simulation 
of the [NaCl]BM, [NaCl]IN, and [NaCl]VEN with relative errors of 2.1 ± 2.1%, 11.5 ± 2.0%, and 1.5 
± 0.7%, respectively, whereas [NaCl]OUT was underestimated (relative error of 26.6 ± 5.8%). 
In a consecutive iteration, the concentration gradient, i.e., the osmotic shock, was further 
reduced by performing transmembrane pre-dilution HDF (Fig. 11). Adding convection to 
diffusion increases the mass transfer of NaCl (156) from the dialysate closed loop into the 
blood stream resulting in lower concentration gradients between both sides of the semi-
permeable membrane (Fig. 45) as compared to SDial pre-HDF. 
 
2) Ex vivo hemocompatibility in dynamic conditions 
 
Several pre-dilution HDF experiments with human blood comparing the SDial setup with 
normal and transmembrane substitution were performed. The same flow rates (QB, QD, Qinf) 
and hemodialyzers as with the standard pre-HDF setting were taken in order to allow a 
direct comparison of the results. 
Different [NaCl]blood were studied: 0.15 M in order to validate the influence of the second 
serial cartridge on the hemocompatibility, 0.36 and 0.50 M in order to compare the 
performance of the SDial system to standard pre-HDF of the same [NaCl]blood, and 0.75 M in 
order to verify the maximal admissible [NaCl] in blood. 
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Firstly, adding a second cartridge to the setup did not induce hemolysis ex vivo (Fig. 60, B). 
Secondly, hemolysis did not occur below a [NaCl]blood of 0.50 M. At this concentration, 
hemolysis was largely lower compared to standard pre-HDF at 1.20 M [NaCl]SUB which 
corresponded to the same [NaCl]blood. Therefore, the iteration of the experimental setup in 
form of a second serial dialyzer for infusion of NaCl effectively reduced the osmotic shock as 
indicated by improved hemocompatibility at the highest ionic strength. Thirdly, a 
concentration of 0.75 M NaCl in the blood stream also was tested but, since RBCs were 
severely damaged (71.7% hemolysis post treatment), only a single experiment was 
performed. Although the osmotic shock was reduced with the SDial setup, cells, which were 
not damaged after a single contact (Fig. 46), hemolyzed after repeated osmotic stimulations 
as shown by the increasing hemolysis during dialysis treatment (Fig. 60). 
Compared to the standard pre-HDF at the same [NaCl]blood (0.50 M), survival of WBCs (Fig. 
61, Fig. 62, and Fig. 63) was not improved with the SDial pre-HDF as indicated by an equally 
decreasing WBC count. Therefore, WBCs seem to be particularly sensitive to the [NaCl]blood 
independently of the osmotic shock (in the range of the concentrations studied). Similarly to 
standard pre-HDF, no activation of the coagulation system (TAT) was seen with SDial pre-
HDF. 
Although the [NaCl]blood was higher (535 ± 19 mM versus 474 ± 7 mM, P < 0.01), performing 
SDial pre-HDF using transmembrane substitution to 0.50 M [NaCl]blood further reduced 
hemolysis (Fig. 66, A) compared to SDial pre-HDF. Furthermore, no significant decrease of 
the WBC count was measured (Fig. 66, B). This result was confirmed by the dot plots (Fig. 67) 
and platelet volume histograms (Fig. 68) demonstrating fewer destroyed cells when using 
transmembrane substitution. This was in contrast to the finding mentioned above leading to 
the conclusion that WBCs are even very sensitive to the osmotic shock and SDial pre-HDF 
using transmembrane substitution represents a particularly gentle method of infusing NaCl 
at high concentrations.  
The TMP increased only for the standard pre-HDF with 1.20 M [NaCl]SUB and for the SDial 
pre-HDF 0.75 M [NaCl]blood (Fig. 65) conforming fouling of the dialysis membrane surface 
with the cell fragments as indicated above (see “Experiments on a dialysis machine and 
under dynamic conditions”) (52).  
 
In order to assess the protective effect of the first cartridge of the SDial setup against the 
concentration gradient, a pilot experiment in HD modus (Qinf = 0 mL/min) at 0.50 M 
[NaCl]blood was designed. Two concentration gradients (0.55 and 1.10 M NaCl on the 
dialysate side; see Fig. 80) were compared and a single blood pool was taken allowing a 
better comparison of the biological parameters in only a single experiment. Hemolysis was 
higher with the higher [NaCl] gradient (i.e., 1.10 M NaCl; Fig. 56) reaching 4.0% versus 0.2% 
with 0.55 M NaCl on the dialysate side. Therefore, the porous membrane represents no 
direct physical protection for the blood cells against the hypertonic dialysate. The formation 
of a highly hypertonic aqueous layer in the blood stream next to the porous membrane 
inducing an important osmotic stress onto the RBC may explain the stronger hemolysis 
 obtained with the more concentrated dialysate. The WBC count increased at the beginning 
of the experiment until 30 min, most probably because of insufficient mixing of the blood at 
baseline. Subsequently, it slightly faster decreased with 1.10 M [NaCl] in the 
57) confirming the hypothesis of sensitivity of these cells to the concentration gradient.
 
 
In the second part of the continued experiment, blood was further d
of 5.00 M NaCl solution, thus, [NaCl]
decrease of the [NaCl]blood from about 0.50 to 0.15 M led to no further damage of blood cells 
(Fig. 56, Fig. 57, and Fig. 58). 
stopping the osmotic challenge, blood cells are no more sensitive to mechanical stresses
Interestingly, although HD was performed (Q
M to 0.15 M [NaCl]blood, the TMP in the first cartridge increased about 20 to 25
is in the range of the oncotic pressure 
is osmotically driven into this compartment (TMP <
peritoneal dialysis where the tonicity is obtained by altering the dextrose concentration 
whereas under physiological conditions, the protein concentration drags water into the
blood (TMP > 0 mmHg) (124). 
 
3) Toxin removal efficacy
 
After having demonstrated adequate hemocompatibility 
bound toxin removal was assessed. A pilot experiment was designed with mini
compare the removal of IS from 
and serial dialyzers HD (Fig. 17
using independent dialysate loops compared with standard single dialyzer HD (
0.21 %/run versus 2.81 ± 1.09 %/run), it was tried to further exploit the first hemodialyzer of 
the SDial setup. Additionally to its function as NaCl diffuser, the first cartridge was set up to 
also remove uremic toxins like the second hemodialyzer. Different setups to implement 
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additional hemodialyzer for this function are presented in Tab. 22 illustrating respective 
advantages and drawbacks. The SDial setup with charcoal adsorber was implemented 
because this setup requires a single dialysis machine, the volume of dialysate is not 
increased, the volume of NaCl solution is minimized, and it allows an adjustment of the 
dialysate temperature in the first cartridge. Since activated charcoal is known to adsorb 
hydrophobic compounds, such as fatty acids (157), protein bound uremic toxins (110; 158), 
and also β2m (158; 159), it was decided to add a charcoal adsorber. The adsorber consisted 
of a reservoir filled with activated carbon which was integrated into the dialysate loop to 
remove IS diffusing into the dialysate (Fig. 18). Activated charcoal-based adsorbers are used 
in specific clinical situations since decades. The MARS (160; 161; 162) and the Prometheus 
(163) systems are typical, elaborated representatives, which are applied for the treatment of 
liver failure.  
  
The removal of IS from normal human plasma was studied on a dialysis machine. The setup 
was built in order to switch from one setting to the other but the plasma volume was 
different between standard pre-HDF and SDial pre-HDF because of the additional volume of 
the second cartridge. The removal rate γ of IS was calculated based on the blood runs (Eq. 
13). Therefore, the results were independent from the plasma volume. The same high-flux 
dialyzers (1.7 m²) deriving from the same batch as the hemocompatibility experiments were 
used to avoid variations in the membrane permeability (91). 
Based on removal models (86; 105) and the binding experiments performed in normal 
human plasma at different ionic strength (Fig. 30) , the removal rate of IS should be doubled 
when increasing the ionic strength from 0.15 to 0.50 M NaCl in undiluted normal plasma to 
increase the free IS fraction from about 3% to 7% (Eq. 3 and Fig. 28). Nevertheless, γ of IS 
increased only about 43% and 52% for both the standard pre-HDF and the SDial pre-HDF, 
respectively (Fig. 75). A likely explanation for the difference between the theoretical 
approach (Eq. 3) and the experimental results could be the removal of NaCl within the 
hemodialyzer which leads to a progressively decreasing concentration along the cartridge 
with the consequence of a proportionally reduced free toxin fraction. 
Adding the charcoal adsorber into the closed dialysate loop not significantly increased γ of IS 
of about 13%. The adsorber was tailored with sufficiently activated charcoal (2 g) to bind the 
diffused toxin. Based on a pilot experiment in aqueous solution, which estimated the 
adsorption capacity of charcoal for IS to be about 17 µmol/g, γ of IS with the activated 
charcoal adsorber was expected to be doubled. This estimation by far was not reached, most 
probably, because the dialysate perfusion through the self made charcoal adsorber was 
insufficient. Therefore, the experiment should be repeated with a commercially available 
adsorber to verify the results of the setting. It was not possible to perform this experiment in 
the laboratory because of the expensiveness of such devices. 
 
 Set-up 
Dual dialyzers with dialysate lines 
connected in parallel (164) 
Dual dialyzer
connected in series
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• Both dialyzers independent 
allowing increased dialysis doses. 
• HD, pre- and post-HDF feasible. 
• Adjustment of the dialysate 
temperature possible. 
• Normal dialysate volume.
• Low volume of NaCl solution.
• HD, pre
D
r
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• Requires high volume of 
dialysate. 
• Requires a 2
nd
 dialysis monitor. 
• Requires high volume of NaCl 
solution. 
• QD
in 
Tab. 22: Variations of serial dialyzers HD with increased ionic strength
Advantages and drawbacks are given. 
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s with dialysate lines 
 (164) 
Collins’ set-up (114) 
  
 
 
- and post-HDF feasible. 
• Normal dialysate volume. 
• HD, pre- and post-HDF feasible. 
 split to the dialyzers resulting 
lower clearance. 
• Requires peristaltic pump 
between both dialyzers on the 
dialysate line to control flow 
rates and avoid shunt-flow. 
• Recirculation of toxins removed 
in the 2
nd
 cartridge possible. 
• Requires high volume of NaCl 
solution. 
. 
 
Serial dialyzers with charcoal 
adsorber 
 
• Normal dialysate volume. 
• Low volume of NaCl solution. 
• HD, pre- and post-HDF feasible. 
• Adjustment of the dialysate 
temperature possible. 
 
 
 
• Requires peristaltic pump to 
circulate dialysate in the 1
st
 
cartridge. 
• Requires adsorber to remove 
toxins diffused into the closed 
loop. 
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IV. Transfer of increased ionic strength HDF to the animal model 
 
Main findings: 
• The animal model demonstrated the adequate hemocompatibility of increased ionic 
strength during HDF. 
 
1) Validation of the animal model 
 
Sheep models, which are accepted in the ISO 10993-4, have been used to study the influence 
of hemodialysis membranes on living biological systems in the past (92; 149; 165). Since the 
behavior of blood cells during increased ionic strength HDF and, to a lesser extent, the 
activation of coagulation were the main focus, pilot experiments comparing human and 
ovine RBC at different ionic strengths under static and dynamic conditions were performed. 
 
Under static conditions, ovine RBCs were significantly more resistant to high [NaCl] 
compared to human RBC (Fig. 76), more precisely, the hemolysis level was 0.2 ± 0.1% in 
ovine blood versus 0.5 ± 0.2% (P < 0.05) in human blood. This finding, supported by previous 
studies reporting a higher osmotic resistance of sheep RBC compared to human RBC in both 
hypotonic (166) and hypertonic media (121), may be explained as follows. As mentioned 
above, the osmotic resistance of erythrocytes increases as cell volume decreases (121). 
Moreover, sheep RBC are smaller than human’s (121; 167) (mean cell volume: 29.0 ± 0.41 fL 
versus 89.2 ± 0.59 fL) which correlates with an improved cell deformability (168). The higher 
osmotic resistance of sheep RBC might also be explained by this specie’s evolution. Sheep 
belong to the bovidea family like caprids and antelopes. These animals originate from dry 
geographical regions (169). Therefore, their metabolism is adapted to overcome periods 
without water (170). When retaining mineral salts during insufficient fluid supply, their 
blood cells must be adapted to support high osmolarity, i.e., ovine RBCs are more resistant 
to osmotic changes. 
However, under dynamic conditions using a mini-dialyzer apparatus (Fig. 77), hemolysis was 
similar between human and ovine blood when exposed to the same [NaCl] as well as the 
minor hemolysis induced by the blood pump. Therefore, the choice of sheep for the dialysis 
model of increased ionic strength HDF was justified. 
 
2) Feasibility of increased ionic strength HDF 
 
A low-flux filter was chosen for the first serial cartridge of the SDial setup to avoid as much 
as possible backfiltration as an interfering factor (171). The second dialyzer consisted in a 
high-flux membrane with high K0A in order to remove as much as possible the NaCl excess 
(Fig. 43). Initially, the [NaCl] of the two tested settings, i.e., standard pre-HDF (0.75 M 
[NaCl]SUB) and SDial-TM pre-HDF (0.15 M [NaCl]SUB), was set at 0.36 M [NaCl]blood because 
adverse effects were never previously seen at this concentration ex vivo (Fig. 60 to Fig. 63). 
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The [NaCl]blood was increased after an initial 30 min baseline period to wait for fluid 
equilibration in the setup and to generate baseline data to refer to without running an 
additional, the animal affecting experiment. After 30 min, cell counts, Hct, and tHb in the 
arterial sample were slightly decreased (Tab. 21; P < 0.05) as compared to 0 min because of 
the mixing of blood with the prerinsing fluid in the extracorporeal circuit. Ion concentrations 
(K+, range 3.40 – 3.62 mM versus 4.11 – 4.26 mM; HCO3
-, range 28.1 – 31.1 mM versus 26.6 – 
29.5 mM;  Na+, range 141.6 – 143.9 mM versus 143.5 – 145.3 mM) and the pO2 (range 43.2 – 
44.0 mmHg versus 47.9 – 65.2 mmHg) were slightly decreased (P < 0.05) at baseline 
indicating an equilibration of the blood electrolytes with the dialysate. The stress relaxation 
of the animals after catheter placing for blood access and treatment starting was illustrated 
by the decrease of the heart rate within the first 30 min (0 min, range 100 – 120 beats/min; 
30 min, range 70 – 90 beats/min). 
Increasing the ionic strength after 30 min dialysis increased the [NaCl]BM (Tab. 19; range 
362.0 – 370.2 mM) to the expected concentration (0.36 M). It also slightly increased the 
[NaCl]VEN (range 123.7 – 124.2 mM versus 121.0 mM at baseline, P < 0.05) indicating an 
incomplete removal of the NaCl excess. Both hemolysis (0.2 ± 0.1% after 120 min versus 0.1 
± 0.1% at baseline, P < 0.05) and LDH concentration (490 ± 84 U/L after 120 min versus 449 ± 
80 U/L at baseline, P < 0.05) as an additional clinical marker of hemolysis slightly increased 
only during the standard pre-HDF with 0.36 M [NaCl]blood (Fig. 79). It is however possible that 
the cell damages result partially from the mechanical stress induced by the extracorporeal 
setup itself, which was identical during all treatments (blood pump, passage through the 
hemodialyzer, catheter as blood access) (172; 173; 174; 175). Thus, this very low, but still 
acceptable hemolysis, most probably, was due to the increased ionic strength. Moreover, no 
clinical symptoms of bioincompatibility (hypoxia, collapse, increase of the heart rate, 
tachypnea, etc. (149; 165)) were seen. 
After the results were acceptable with 0.36 M [NaCl]blood, in a next step, the ionic strength 
was increased to the presumed maximal admissible ex vivo level in order to produce minor 
hemolysis. The settings were standard pre-HDF at 0.45 M [NaCl]blood (1.10 M [NaCl]SUB) and 
SDial-TM pre-HDF at 0.60 M [NaCl]blood (0.15 M [NaCl]SUB). The higher [NaCl] for the SDial-TM 
pre-HDF was chosen because ex vivo results were favorably (see above) with this setup 
compared to the standard pre-HDF (Fig. 60 and Fig. 66). As compared to 0.36 M [NaCl]blood 
tested, the PLT count slightly decreased with increased ionic strength (120 min, range 311 – 
336 ×103/mm3; baseline, range 348 – 407 ×103/mm3) with both SDial-TM pre-HDF at 0.60 M 
[NaCl]blood and standard pre-HDF at 0.45 M [NaCl]blood. No adverse event was seen in the 
animal. Blood pressure and heart rate were always constant when increasing the [NaCl]blood. 
Increasing the ionic strength after 30 min dialysis increased the [NaCl]BM (Tab. 19; standard 
pre-HDF, about 475 mM; SDial-TM pre-HDF, about 618 mM) to the expected concentration 
(0.45 and 0.60 M, respectively). Again, the NaCl excess was not entirely removed ([NaCl]VEN 
range 125.4 – 130.4 mM versus 121.0 mM at baseline, P < 0.05). Both hemolysis (0.2 ± 0.1% 
after 120 min versus 0.1 ± 0.1% at baseline, P < 0.05) and LDH concentration (506 ± 24 U/L 
after 120 min versus 462 ± 44 U/L at baseline, P < 0.05) slightly increased only during the 
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SDial-TM pre-HDF with 0.60 M [NaCl]blood (Fig. 79) pointing again at the increased ionic 
strength as the likely reason. 
 
Since animal weighted about 43 kg in average, their blood volume can be estimated to be 
about 2.5 L (176). Hence, their blood had passed about five times through the hemodialyzer 
(Eq. 7). The preliminary ex vivo experiments were performed to reach 30 τ in order to design 
a safe dialysis strategy for the clinical application. It was not possible to dialyze the animals 
comparably long (30 τ would correspond to about 8 h treatment at QB = 150 mL/min, Eq. 7) 
but it provided an idea of an adequate biocompatibility even if a typical normal four hour 
dialysis session in a maintenance dialysis patient (about 15 τ, see above) is not fully 
reflected. 
 
NaCl slightly accumulated in the venous line for all settings because of the increased ionic 
strength (Tab. 19; Na+, range 140.3 – 146.7 mM after 120 min versus 137.3 – 139.3 mM at 
baseline; Cl-, range 107.1 – 110.5 mM after 120 min versus 103.1 – 104.7 mM at baseline). 
Although the [NaCl]VEN after 60 and 120 min did not significantly (P > 0.05) differ between 
the different settings (possibly because of the small population (i.e., n = 4)), the 
accumulation of NaCl seemed to be proportional with the [NaCl]blood (Tab. 19). Retention of 
NaCl must be carefully monitored during a clinical application since its homeostasis in uremic 
patients is crucial (1). Overload of NaCl may lead to hypertension, increased cardiovascular 
risk, and ultimately to death (115; 116; 177). However, all animals were healthy including a 
normal renal function allowing the correction of any electrolyte disturbance. 
 
Increasing the ionic strength in blood changed the coloration of the blood into light red (Fig. 
78). This phenomenon may be explained by the difference of the absorption spectra 
between O2Hb and HHb (178) and the decreased amount of O2Hb (Tab. 20; range 77.3% – 
89.4% at baseline, range 63.5% – 82.7% at 60 min dialysis) to the benefit of HHb (range 8.1% 
– 20.0% at baseline, range 14.9% – 33.8% at 60 min dialysis). Increasing the intracellular Cl- 
concentration may induce the dissociation of oxygen bound to Hb (O2Hb dissociates to HHb) 
(179). HHb in turn would bind HCO3
- ions, thus, reducing its plasma concentration (180) as 
observed in the experiment (range 29.4 – 31.5 mM at baseline versus range 19.9 – 24.7 at 60 
min dialysis). Since carbon monoxide poisoning changes the coloration of the blood into light 
red too (181; 182), the observed coloration change (Fig. 78) arose this question. However, in 
the present experiments, COHb and MetHb levels were not changed because of increased 
ionic strength (Tab. 20). Moreover the modification of O2Hb to HHb because of higher 
[NaCl]blood was reversible. After removal of the excess of NaCl, normal levels of both O2Hb 
and HHb were recovered, and no difference was seen between the arterial (O2Hb; range 
57.0% – 63.4% at baseline versus range 58.7% – 64.8% at 60 min dialysis; HHb accordingly; 
range 34.0% – 41.9% versus range 32.7% – 38.7%) and venous (O2Hb; range 73.9% – 78.5% 
at baseline versus range 70.1% – 78.9%  at 60 min dialysis; HHb accordingly; range 18.9% – 
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23.3% versus range 18.6% – 27.2%) samples. Therefore, the modification of the Hb induced 
by increased ionic strength has no impact on the clinical application of modified pre-HDF. 
 
A single alarming event was observed during SDial-TM pre-HDF. Previously uneventfully 
treated with standard pre-HDF, the TMP of the second hemodialyzer increased immediately 
after beginning of the dialysis experiment before increasing the [NaCl]blood. After restitution 
of the blood from the extracorporeal circuit, it became obvious that the hemodialyzer 
membrane was clotted as already indicated by accumulation of NaCl in the venous line 
([NaCl] = 170 mM). The reason for this event remained unclear because it occurred despite 
correctly administered anticoagulation. From the long lasting experience with the sheep 
dialysis model, it was already known that this species seems to possess a more active 
coagulation compared to human patients (personal communication of unpublished data). 
Nevertheless, this incident underlines a potential hazard of ionic strength HDF which 
requires a fully patent dialyzer not only for toxin elimination but also for restoration of the 
NaCl balance. 
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CONCLUSION 
The present thesis demonstrated that increasing the ionic strength by increasing the [NaCl] 
in human blood was effective to increase the removal of the protein bound uremic toxins IS 
and pCS by decreasing their binding affinity in both normal and uremic plasma. This method 
was applicable during modified pre-dilution HDF with adequate hemocompatibility. The 
hemocompatibility was further improved by developing a serial dialyzers setup which has 
the major advantage to allow HD, pre-dilution HDF, and post-dilution HDF. The SDial setup 
was designed with a closed dialysate loop at the first cartridge to use the same dialysate 
flow rate as for standard treatments and minimize the required volume of NaCl solution. 
This setup may be further developed to fully exploit the first hemodialyzer, which potentially 
could double the normal dialysis dose by adding commercially available adsorbers (183). 
Furthermore, in order to dissociate the protein binding, the temperature in the first 
cartridge may be increased. This must be done with caution to avoid protein denaturation 
and hemolysis. According to the literature, a maximum of 47 °C may be tolerated (52; 184). 
The second cartridge will be used to restore the blood temperature to the desired level. 
 
After the feasibility of the method was demonstrated in an animal model, its clinically safe 
applicability and efficacy has to be proven on the short and the long term by demonstrating 
increased protein bound uremic toxin clearance and, ideally, improved patient outcome. 
Even if the clearance of protein bound toxins is improved, the equilibrium between the 
different compartments of the body, which is proportional to the distribution volume of the 
toxin, will impact on the total elimination and finally on clinical outcomes (1; 185). For long 
term studies, a partnership with dialysis machine manufacturers must be developed in order 
to modify current hemodialysis machines for a safe use in the patient (186). Particularly 
crucial aspects are the control of the flow rates (Qex) to avoid excessive concentration 
gradients at the first cartridge and the prevention of the accumulation of NaCl. In the 
experimental setting, two separate hemodialyzers were applied to perform SDial dialysis. 
Such an arrangement could be integrated in a single device similarly to the Nephros OLpūr™ 
MD hemodiafilter (187) or the Bellco HFR Aequilibrium dialyzer. 
Increasing the QB to comply with clinical practice (QB up to 500 mL/min) correlates with 
decreased clearance of NaCl. Concentrations higher than physiologic may flow back to the 
patients. In order to avoid this problem, an alternative would be to reduce the ionic strength 
in the dialysate similarly to the description of Collins et al. for pH shift (114). The handling of 
the [NaCl] is of great importance in clinical practice because hypernatremia is related to 
hypertension and morbidity in uremic patients (115; 116; 188; 189). Since at the end of 
dialysis the extracorporeal circuit is rinsed with saline to return the blood to the patient (91), 
the infusion of NaCl has to be stopped before completion of the treatment. Clinical 
application requires also the use of sterile and non-pyrogenic NaCl solution which has to be 
manufactured according to pharmacopoiea. 
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Together with ameliorations of the technology, the patient recruitment should be done 
carefully. Patients with low Hb concentration may be at greater risk for hemolysis when 
[NaCl]blood is increased. Moreover, during the first clinical trial, the influence of increased 
ionic strength hemodialysis on the in vivo RBC life span (134) and RBC fragility (134) has to 
be determined. 
 
The present work focused on CKD but protein bound substances also play a role in other 
diseases. Modified ionic strength HDF may be applicable in liver insufficiency or in the 
treatment of intoxications with protein bound drugs. Furthermore, this dialysis strategy may 
be coupled with other methods. Flow rates and larger dialyzers may be adjusted to 
selectively increase the clearance of protein bound uremic toxins (190). The dialysis 
frequency and duration with and without NaCl infusion may be adapted to increase toxin 
removal and improve biocompatibility (191). Moreover, the closed dialysate loop of the 
SDial setup may be filled with an albumin solution and adsorbents similarly to the MARS 
system (162). In such a manner, the clearance of protein bound toxins would be increased in 
the first cartridge while NaCl diffuses into the blood stream. The functional efficacy would be 
restored in the adsorbers. 
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APPENDIX 
I. Additional theoretical aspects 
 
A complete demonstration of the ligand-receptor theory (84) for a single high-affinity 
binding site on the protein surface is proposed as follows. 
 
Abbreviations: 
• [R] free receptor concentration 
• [L] free ligand concentration 
• [RL] complex ligand-receptor concentration 
• [LT] total ligand concentration ([LT] = [RL] + [L]) 
 
The maximal binding capacity Bm (84) is given by 
  =    
 
The binding affinity will be described through the dissociation constant KD of the equilibrium 
(84) 
 
 ↔    
with: 
 = . [][]  
Since [R] = Bm – [RL], then  = & − []). [][]  
The equation can be solved for [RL]: [] = . [] + [] 
 
This equation is for proteins presenting a single type of high affinity binding site. When [L] = 
KD, 50% of the receptors are bound to ligands. It is proposed here to define the protein 
bound fraction PBF as a function of KD and Bm as follows: 
  = [][] + [] = [][] 
 
For that purpose, [RL] has to be expressed depending on [LT]: 
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 = . [] + [] = . &[] − []) + &[] − []) 
 [] = . [] − . [] + [] − []  
 
 
It leads to [].  + []. [] − []# = . [] − . [] 
 [].  + []. [] − []# − . [] + . [] = 0 
 []. & + [] + ) − []# − . [] = 0 
 
This equation is of the type V. d# + e. d + f = 0 and to solve it, its differential ∆ has to be 
calculated with: 
g V = −1e =  + [] + f = −. [] h 
 ∆= e# − 4. V. f = & +  + [])# − 4  &−1)  &−. []) 
 ∆= # + # + []# + 2. .  + 2. . [] + 2. . [] − 4. . [] 
 ∆= # + # + []# + 2.  .  + 2. . [] − 2. . [] 
 
∆ > 0 if [LT] = 0, or if [LT] << KD, or if [LT] << Bm, or if [LT] >> KD, or if [LT] >> Bm. 
 
It means that the equation V. d# + e. d + f = 0 admits two solutions: 
ijk
jldI = −e − √∆2Vd# = −e + √∆2V
h 
 
Since x1 < 0, this solution is not physically possible, thus only x2 remains: 
 [] = −& +  + []) + √∆2  &−1)  
 [] = & +  + []) − √∆2  
 [] =  +  + [] − n& +  + [])# − 4. . []2  
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 So the PBF becomes: 
 
 =  =       n&    )
#  4. . []2. []  
 
The ratio toxin concentration / binding capacity α can be introduced here: 
 o = [] ⇔ [] = o.  
 
Then, the PBF becomes 
  =  + &o + 1).  − n& + &o + 1). )# − 4. o. #2. o.   
  =  + &o + 1). 2. o.  − n& + &o + 1). )# − 4. o. #2. o.   
 
 = p + o + 1q . 2. o.  − & + &o + 1). )# − 4. o. #4. o#. #  
 
 = p + o + 1q . 2. o.  −r
_p + o + 1q . `# − 4. o. #4. o#. #  
 
 = p + o + 1q . 2. o.  −rp
 + o + 1q# . # − 4. o. #4. o#. #  
 
Bm can be eliminated as follows: 
 
 =  + o + 12. o − rp
 + o + 1q# − 4. o4. o#  
 
Finally, the PBF may be described by: 
 
 =
 + o + 1 −  p + o + 1q# − 4. o2. o  
With α = [LT] / Bm. 
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II. Interest of calculating the blood runs through the dialyzer 
 
The concentration reduction of toxin from blood or plasma corresponds to a first-order 
process (11). It is possible to present results on a time t dependant axis or a blood run τ 
dependant axis, with 
5 = 6. 7K8K  
 
Where QB is the blood flow rate [mL/min], and VB the blood volume [mL]; τ is dimensionless. 
 
The concentration is given by (83): s* = *3. QRt.D* = *3. QRS.T h 
 
With β and γ the corresponding slopes. What is the relationship between β and γ ? Since 
 * = *3. QRt.D = *3. QRS.T 
Removing C0, QRt.D = QRS.T 
Finally, u. 6 = v. 5 
It is known that (83): u = K8K  
 
With KB, the blood clearance of the solute [mL/min]. According to the definition of τ and β, 
 u. 6 = v. 6. 7K8K ⇔u = v.7K8K ⇔K8K = v. 7K8K  
leading to v = K7K 
 
Yet, it is known that KB corresponds to the blood flow rate QB times the apparent free 
fraction FFapp of the toxin: v = K7K = Fww. 7K7K = Fww 
 
 
 
 
 To conclude: 
 
Note: further refinement is to describe the apparent free fraction 
corresponds to the actual fraction 
on the binding constants KD and 
(taking into account the diffusion and convection capacity of the dialyzer and restoration of 
the equilibrium). 
 
 
III. Determination of the binding constants 
 
1) Of healthy plasma for PAA
 
The binding affinity of normal human plasma for PAA was assessed at different ionic 
strengths. Different plasma dilutions (final volume 4 mL) were 
with 3.48 mL plasma; 0.40, 0.50, and 0.65 M NaCl was tested with 3.08 mL plasma.
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g * = *3. QRxyMy .D* = *3. QRzz{|| .T h 
FFapp 
removed, from the free toxin fraction 
Bm and the toxin concentration) and the filter permeability 
v = Fww = . } 
KD and Bm 
 
used: 0.15 M NaCl was tested 
 
Fig. 81: Binding of PAA in 
normal human plasma at 
different ionic strengths.
Binding experi
performed in citrate 
from the same donor in 
triplicate (n = 3) at room 
temperature, pH 7.4, and with 
0.15 ( ), 0.40 (
and 0.65 M (
plasma dilution factor was 1.15 
for 0.15 M NaCl and otherwise 
1.30. 
 
of the toxin, which 
FF (depending only 
pi 
 
 
ments were 
plasma 
), 0.50 ( ), 
) NaCl. The 
 Fig. 82: Scatchard plot deriving from the binding studies 
The Scatchard plot is shown for: A, 0.15 M NaCl (
dilution factor was 1.15 (A) and 1.30 (B). These curves indicate two types of binding sites: the first one of high 
affinity and the second one of low affinity corresponding to the specific and nonspecific binding, respectively.
 
2) Of uremic plasma for IS and
 
The binding constants of uremic plasma for IS and 
at different ionic strengths in a population of 15 ESRD patients. As shown below, the 
population was still too small to obtain relevant values for 
 
Fig. 83: Binding of IS and pCS in uremic plasma at different ionic strengths.
Binding experiments were performed in half
with IS (A) and pCS (B) at room temperature, 
NaCl. Binding constants were: for IS, K
247429 µM; for pCS, KD = 11.2, 26.8, 19.3, and 68.1 µM; B
and 0.75 M NaCl, respectively. 
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on PAA in normal human plasma.
); B, 0.40 ( ), 0.50 ( ), and 0.65 M (
 pCS 
pCS (native concentrations) were assessed 
KD and Bm. 
 
-diluted human plasma from 15 different ESRD patients (n = 15) 
pH 7.4, and with 0.15 ( ), 0.30 ( ), 0.50 (
D = 406, 1186, 136219, and 58750 µM; Bm = 3247, 7390, 686137, and 
m = 202, 291, 207, and 445 µM, a
 
 
 
) NaCl. Plasma 
 
 
), and 0.75 M ( ) 
t 0.15, 0.30, 0.50, 
 3) Effect of dilution on the binding ability of plasma for IS
 
The effect of plasma dilution (plasma 1:2
Bm for IS was studied at 0.15 and 0.50 M NaCl at r
curves presented below (Fig. 84
= 3). 
Fig. 84: Binding of IS in normal human plasma 
Binding experiments were performed in human plasma from 3 single donors (n = 3) at 0.15 (
0.50 M NaCl ( , ). Plasma was 1:2
regression using Eq. 2; each curve represents one single donor.
 
 
IV. Simulation of increased ionic strength in aqueous solution on a 
dialysis machine 
 
1) Definitions and notations
 
VB, blood volume [mL]; CNaCl 
concentration in the dialysate [M]; 
dialysate flow rate [mL/min]; 
QD out, dialysate flow rate exiting the hemodialyzer [mL/min]; 
closed loop (serial dialyzers setup only); 
solution) [mL/min]; Qinf, substituate flow rate [mL/min]; 
[mL/min]; K, instantaneous whole blood clearance [mL/min]; and
coefficient over the area [mL/min]. 
 
Eq. 18: Instantaneous blood clearance
Where K is the clearance [mL/min], 
K0A the mass transfer coefficient over the area of urea [mL/min].
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- and 1:10-diluted) on the binding constant 
oom temperature and pH 7.4. The binding 
) were obtained in citrate plasma from three single donors (n
at different plasma dilutions and ionic strengths.
- (A) and 1:10-diluted (B). Data were interpolated by non linear 
 
 
blood, NaCl concentration in blood [M]; 
∆t, time interval [min]; QB, blood flow rate [mL/min]; 
QD in, dialysate flow rate entering the hemodialyzer [mL/min]; 
Qex, dialysate flow rate in the 
QNaCl, infusion flow rate (default: a 5.00 M NaCl 
QUF, ultrafiltration flow rate 
 K0A, the mass transfer 
CNaCl blood and CNaCl dialysate are set to 0.12 M NaCl.
 = 7K. ~
 Qx.pRy.y q  1Qx.pRy.y q  7K7
 
 calculated from the K0A(11). 
QB the blood flow rate [mL/min], QD the dialysate flow rate [mL/min], and 
 
 
 
KD and 
 
 
 
, ) and 
CNaCl dialysate, NaCl 
QD, 
 
 2) Algorithm 
 
a. Standard pre
 
i. Working hypotheses
 
With the dialysis apparatus Bellco Formula 2000
from the dialysate line according to 
during dialysis (whether restored 
equilibrium within the body). Within the hemodialyzer, NaCl removal occurs firstly by 
convection and secondly by diffusion. Therefore, the concentrations on both the blood and 
dialysate side are modified after convection to take into a
counter-current flows. 
 
Fig. 85: Model of NaCl mass balance during standard pre
The following spots are highlighted: A, patient; B, blood line; C, 
removal within the dialyzer (occurring by convection and diffusion); F, dialyzer blood outlet.
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-dilution HDF with the Bellco dialysis machine
 
 (see Fig. 8), Qinf and QUF
QD in = QD – Qinf – QUF. VB is supposed to be constant 
in vitro by an external pump or in 
ccount the mass transfer and 
-dilution HDF with the Bellco dialysis machine.
substituate line; D, dialyzer blood inlet; E, NaCl 
 
 
 are both removed 
vivo through fluid 
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ii. Equations 
 7z = 7<  7z 7K	Fww = 7K  7z 7	< = 7  7z 
 = 7K	Fww. ~
 Qx.!	Ry	{||	.y	{|| " − 1Qx.!	Ry	{||	.y	{|| " − 7K	Fww7	< 
 . ∆6 
 
A - Patient (see Fig. 85): *OFA	wFD<CDD3 = *OFA	@AB ⇒OFA	wFD<CDD3 = *OFA	wFD<CDD3 . 8K OFA	wFD<CDD = OFA	wFD<CDDRI − OFA	@AB	A<CDRI + OFA	CDRI ⇒*OFA	wFD<CDD = OFA	wFD<CDD 8K  
 
B - Blood line before access of the substituate line (see Fig. 85) : *OFA	@AB	A<CD = *OFA	wFD<CDD ⇒ OFA	@AB	A<CD = *OFA	@AB	A<CD . 7K. ∆6 
 
C - Substituate line (see Fig. 85): 
OFA	<D = *OFA	B<FAGHFDC . 7< . ∆6 + 5. 7OFA. ∆6 ⇒ *OFA	<D = OFA	<D7< + 7OFA. ∆6 
 
D - Dialyzer blood inlet (see Fig. 85): OFA	FDD = OFA	<D + OFA	@AB	A<CD ⇒*OFA	FDD = OFA	FDD&7K + 7< + 7OFA). ∆6 
 
E - NaCl removal within the dialyzer (see Fig. 85): OFA	CD<D = &7z + 7OFA). *OFA	FDD . ∆6 
⇒
ijk
jl *′OFA	FDD = OFA	FDD − OFA	CCD<D&7K − 7z). ∆6*′OFA	B<FAGHFDC = *OFA	B<FAGHFDC . 7	<. ∆6 + OFA	CCD<D7 . ∆6
h 
OFA	B<EH<D = . _2. *OFA	FDD + *OFA	FDD3 − 2. *OFA	B<FAGHFDC + *′OFA	B<FAGHFDC3 ` . ∆6 
 
F - Dialyzer blood outlet (see Fig. 85): OFA	CD = OFA	FDD − OFA	CCD<D − OFA	B<EH<D + *OFA	@AB. 7z. ∆6 *OFA	CD = OFA	CD7K. ∆6  
 b. Standard pre
 
i. Working
 
With the dialysis apparatus Nikkiso DBB
the dialysate line according to 
constant during dialysis (whether restored 
fluid equilibrium within the body). Substituate is withdrawn at the same flow rate (
5.00 M NaCl solution is injected. NaCl removal occurs firstly by convection and secondly by 
diffusion. Therefore, the concentrations on both the blood and dialysate side are modified 
after convection to take into account the mass transfer and counter
 
Fig. 86: Model of NaCl mass balance during standard pre
The following spots are highlighted: A, patient; B, blood line; C, substituate line; D, dialyzer blood inlet; E, NaCl 
removal within the dialyzer (occurring by convection and diffusion); F, dialyzer blood outlet.
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-dilution HDF with the Nikkiso dialysis machine
 hypotheses 
-03 (see Fig. 9), Qinf and QUF are
QD in = QD and QD out = QD + Qinf + QUF. VB
in vitro by an external pump or 
-current flows.
-dilution HDF with the Nikkiso 
 
 
 independent from 
 is supposed to be 
in vivo through 
QNaCl) as 
 
 
dialysis machine. 
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ii. Equations 
 7z = 7<  7z 7K	Fww = 7K  7z 
 = 7K	Fww. ~
 Qx.!Ry	{||.y	{||	" − 1Qx.!Ry	{||.y	{|| " − 7K	Fww7 
 . ∆6 
 
A - Patient (see Fig. 86): *OFA	wFD<CDD3 = *OFA	@AB ⇒OFA	wFD<CDD3 = *OFA	wFD<CDD3 . 8K OFA	wFD<CDD = OFA	wFD<CDDRI − OFA	@AB	A<CDRI + OFA	CDRI ⇒*OFA	wFD<CDD = OFA	wFD<CDD 8K  
 
B - Blood line before substituate line (see Fig. 86): *OFAD = *OFA	wFD<CDD ⇒ OFAD = *OFAD . 7K. ∆6 
 
C - Substituate line (see Fig. 86): OFA	<D = *OFA	B<FAGHFDC . 7<. ∆6 + 5 − *OFA	B<FAGHFDC. 7OFA. ∆6 *OFA	<D = OFA	<D7< . ∆6  
 
D - Dialyzer blood inlet (see Fig. 86): OFA	FDD = OFA	<D + OFAD ⇒*OFA	FDD = OFA	FDD&7K + 7<). ∆6 
 
E - NaCl removal within the dialyzer (see Fig. 86): OFA	CD<D
= 7z . *OFA	FDD . ∆6 ⇒ijk
jl *′OFA	FDD = OFA	FDD − OFA	CD<D&7K − 7z). ∆6*′OFA	B<FAGHFDCD = *OFA	B<FAGHFDC . 7. ∆6 + OFA	CD<D&7 + 7z). ∆6
h 
OFA	B<EH<D = . _2. *OFA	FDD + *OFA	FDD3 − 2. *OFA	B<FAGHFDC + *OFA	B<FAGHFDCD3 ` . ∆6 
 
F - Dialyzer blood outlet (see Fig. 86): OFA	CD = OFA	FDD − OFA	CD<D − OFA	B<EH<D + *OFA	@AB. 7z . ∆6 *OFA	CD = OFA	CD7K. ∆6  
 c. Serial dialyzer
 
i. Working 
 
Additionally to the hypotheses described above (see “
Nikkiso dialysis machine”), it is supposed that no convection happens within the first 
hemodialyzer (NaCl transfer through the semi
Number “1” and “2” refer to the first and second dialyzer, respectively (see 
 
Fig. 87: Model of NaCl mass balance during 
The following spots are highlighted: A, patient; B, blood line; C, substituate line; D, 1
dialyzer dialysate inlet; F, NaCl transfer within the 1
dialysate outlet; H, between dialyzers; I, NaCl removal within the 2
diffusion); J, 2
nd
 dialyzer blood outlet.
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s setup in pre-dilution HDF 
hypotheses 
Standard pre-dilution HDF with the 
-permeable membrane is purely diffusive).
SDial pre-dilution HDF with the Nikkiso dialysis machine.
st
 dialyzer blood inlet; E, 1
st
 dialyzer (occurring only by diffusion); G, 1
nd
 dialyzer (occurring by convection and 
 
 
 
Fig. 10). 
 
 
st
 
st
 dialyzer 
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ii. Equations 
 7z = 7<  7z 
s7K	Fww	I = 7K  7<7K	Fww	# = 7K  7z h 
ij
jj
k
jjj
lI = 7K	Fww	I. ~
 Qx.!Ry	{||	.y	{||	 " − 1Qx.!Ry	{||	.y	{||	 " − 7K	Fww	I7C 
 . ∆6
# = 7K	Fww	#. ~
 Qx.!Ry	{||	.y	{||	 " − 1Qx.!Ry	{||	.y	{||	 " − 7K	Fww	#7 
 . ∆6
h 
 
A - Patient (see Fig. 87): *OFA	wFD<CDD3 = *OFA	@AB ⇒OFA	wFD<CDD3 = *OFA	wFD<CDD3 . 8K OFA	wFD<CDD = OFA	wFD<CDDRI − OFA	@AB	A<CDRI + OFA	CDRI ⇒*OFA	wFD<CDD = OFA	wFD<CDD 8K  
 
B - Blood line before substituate line (see Fig. 87): *OFA	@AB	A<CD = *OFA	wFD<CDD ⇒ OFA	@AB	A<CD = *OFA	@AB	A<CD . 7K. ∆6 
 
C - Substituate line (see Fig. 87): 
OFA	<D = *OFA	B<FAGHFDC . 7< . ∆6⇒*OFA	<D = OFA	<D7<. ∆6  
 
D - 1
st
 dialyzer blood inlet (see Fig. 87): OFA	FD	ID = OFA	<D + OFA	@AB	A<CD ⇒*OFA	FD	ID = OFA	FD	ID&7K + 7<). ∆6 
 
E - 1
st
 dialyzer dialysate inlet (see Fig. 87): OFA	O	ID3 = *OFA	B<FAGHFDC . 7C. ∆6 + 5 − *OFA	B<FAGHFDC. 7OFA. ∆6 OFA	O	ID = *OFA		IDRI . 7C. ∆6 + &5 − *OFA		IDRI ). 7OFA. ∆6 ⇒*OFA	O	ID = OFA	O	ID7C. ∆6  
 
F - NaCl transfer through the porous membrane of the 1
st
 dialyzer (see Fig. 87): OFA	CD<	ID = 0 OFA	B<EH<	ID = I. &*OFA	FD	ID − *OFA	O	ID ). ∆6 
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G - 1
st
 dialyzer dialysate outlet (see Fig. 87): 
OFA		ID = OFA	O	ID  OFA	CD<	ID  OFA	B<EH<	ID ⇒*OFA		ID = OFA		ID7C. ∆6  
 
H - 1
st
 dialyzer blood outlet / 2
nd
 dialyzer blood inlet (see Fig. 87): 
OFA	/MD = OFA	FDD − OFA	CD<	ID − OFA	B<EH<	ID ⇒*OFA	/MD = OFA	/MD&7K + 7<). ∆6 
 
I - NaCl removal within the 2
nd
 dialyzer (see Fig. 87): OFA	CD<	#D
= *OFA	/MD . 7z. ∆6 ⇒ijk
jl *′OFA	/MD = OFA	/MD − OFA	CD<	#D&7K − 7z). ∆6*′OFA	O	#D = *OFA	B<FAGHFDC . 7 . ∆6 + OFA	CD<	#D&7 + 7z). ∆6
h 
OFA	B<EH<	#D = #. 2. *OFA	/MD + *OFA	/MD3 − 2. *OFA	B<FAGHFDC + *OFA	O	#D3  . ∆6 
 
J - 2
nd
 dialyzer blood outlet (see Fig. 87): OFA	CD = OFA	/MD − OFA	CD<	#D − OFA	B<EH<	#D + *OFA	@AB. 7z . ∆6 *OFA	CD = OFA	CD7K. ∆6  
 
 
d. Serial dialyzers setup with transmembrane pre-dilution HDF 
 
i. Working hypotheses 
 
See above (“Standard pre-dilution HDF with the Nikkiso dialysis machine”). Number “1” and 
“2” refer to the first and second dialyzer, respectively. The setup is represented in Fig. 11. 
 
 Fig. 88: Model of NaCl mass balance during 
dialysis machine. 
The following spots are highlighted: A, 
inlet; E, NaCl transfer within the 1
outlet; G, between dialyzers; H, NaCl removal within the 2
2
nd
 dialyzer blood outlet. 
 
ii. Equations
 
ij
jj
k
jjj
lI =
# =
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SDial with transmembrane pre-dilution HDF with the 
patient; B, blood line; C, 1
st
 dialyzer blood inlet; D, 1
st
 dialyzer (occurring by convection and diffusion); F, 1
nd
 dialyzer (occurring by convection and diffusion); I, 
 
7z = 7<  7z 
s7K	Fww	I = 7K  7<7K	Fww	# = 7K  7z h 
7K	Fww	I.
~
 Qx.!Ry	{||	.y	{||	 "  1
Qx.!Ry	{||	.y	{||	 "  7K	Fww	I7C 

7K	Fww	#.
~
 Qx.!Ry	{||	.y	{||	 "  1
Qx.!Ry	{||	.y	{||	 "  7K	Fww	#7 

h 
 
 
Nikkiso 
st
 dialyzer dialysate 
st
 dialyzer dialysate 
h
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A - Patient (see Fig. 88): 
*OFA	wFD<CDD3 = *OFA	@AB ⇒OFA	wFD<CDD3 = *OFA	wFD<CDD3 . 8K OFA	wFD<CDD = OFA	wFD<CDDRI − OFA	@AB	A<CDRI + OFA	CDRI ⇒*OFA	wFD<CDD = OFA	wFD<CDD 8K  
 
B - Blood line before substituate line (see Fig. 88): *OFA	@AB	A<CD = *OFA	wFD<CDD ⇒ OFA	@AB	A<CD = *OFA	@AB	A<CD . 7K. ∆6 
 
C - 1
st
 dialyzer blood inlet (see Fig. 88): OFA	FD	ID = OFA	@AB	A<CD ⇒*OFA	FD	ID = OFA	FD	ID7K. ∆6  
 
D - 1
st
 dialyzer dialysate inlet (see Fig. 88): 
 OFA	O	ID3 = *OFA	B<FAGHFDC . 7C. ∆6 + 5 − *OFA	B<FAGHFDC. 7OFA. ∆6 + *OFA	B<FAGHFDC . 7< . ∆6OFA	O	ID = OFA		IDRI + &5 − *OFA		IDRI ). 7OFA. ∆6 + *OFA	B<FAGHFDC . 7<. ∆6 h ⇒*OFA	O	ID = OFA	O	ID&7< + 7C). ∆6 
 
E - NaCl transfer through the porous membrane of the 1
st
 dialyzer (see Fig. 88): 
OFA	CD<	ID = *OFA	O	ID . 7< . ∆6 ⇒ijk
jl*′OFA	FD	ID = OFA	FD	ID + OFA	CD<	ID&7K + 7<). ∆6*′OFA	O	ID = OFA	O	ID − OFA	CD<	ID7C. ∆6
h 
OFA	B<EH<	ID = I. _2. *OFA	FD	ID + *OFA	FD	ID3 − 2. *OFA	O	ID + *OFA	O	ID3 ` . ∆6 
 
F - 1
st
 dialyzer dialysate outlet (see Fig. 88): OFA		ID = OFA	O	ID − OFA	CD<	ID + OFA	B<EH<	ID ⇒*OFA		ID = OFA		ID7C. ∆6  
 
G - 1
st
 dialyzer blood outlet / 2
nd
 dialyzer blood inlet (see Fig. 88): OFA	/MD = OFA	FD	ID + OFA	CD<	ID − OFA	B<EH<	ID ⇒*OFA	/MD= OFA	/MD&7K + 7<). ∆6 
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H - NaCl removal within 2
nd
 dialyzer (see Fig. 88): OFA	CD<	#D
=	*OFA	/MD . 7z. ∆6 ⇒ijk
jl *′OFA	/MD = OFA	/MD − OFA	CD<	#D&7K − 7z). ∆6*′OFA	O	#D = *OFA	B<FAGHFDC . 7 . ∆6 + OFA	CD<	#D&7 + 7z). ∆6
h 
OFA	B<EH<	#D = #. 2. *OFA	/MD + *OFA	/MD3 − 2. *OFA	B<FAGHFDC + *OFA	O	#D3  . ∆6 
 
I - 2
nd
 dialyzer blood outlet (see Fig. 88): OFA	CD = OFA	/MD − OFA	CD<	#D − OFA	B<EH<	#D + *OFA	@AB. 7z . ∆6 
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Design of test protocols (bio- and hemocompatibility, cytotoxicity, 
primary cell cultures, animal studies, simulations), results analysis, and 
research project management (innovative dialysis strategy; orthopedic 
implants with antimicrobial properties). Team management and 
interns supervision. 
10/2009 – 03/2010 R&D design manager within Tornier SAS (Montbonnot, FRANCE). 
Feasibility study (state of the art, competition) of a cruciate retaining 
total knee arthroplasty. 
 
INTERNSHIPS: 
 
02/2009 – 07/2009 R&D internship graduation within Tornier SAS (Montbonnot, FRANCE). 
CE marking file for a polyethylene inlay of total hip replacement; 
technical and industrial feasibility study of a cementless acetabular 
implant with highly crosslinked polyethylene bearing. 
09/2007 – 02/2008 Internship by eXcorLab GmbH (Obernburg, GERMANY). Carrying out of 
experiments on dialysis machines, topic: removal of protein bound 
uremic toxins by hemodiafiltration. 
02/2005 Training as worker by Vinci Technologies (Nanterre, FRANCE). R&D 
activities (study on a capillary viscometer 1000 bars) and pressure 
tests on equipments. 
 
 
 
172 
 
EDUCATION AND QUALIFICATIONS: 
 
Since 04/2011 PhD student of the Julius-Maximilians University of Würzburg, 
deanery of Biology (Würzburg, GERMANY). 
03/2006 – 07/2006 ERASMUS semester in the Fachhochschule Furtwangen, field Medical 
Engineering (Villingen-Schwenningen, GERMANY). 
09/2004 – 09/2009 Engineer degree of the University of Technology of Compiègne 
(Compiègne, FRANCE), field Biological Engineering – Biomechanic and 
Biomaterials. 
 
SKILLS: 
 
Languages English 
French 
German 
Japanese 
fluent 
native speaker 
fluent 
basic knowledge 
Sofwares Pack office 
CAD (ProEngineer, Solidworks) 
Programming (C, Pascal, VBA) 
Data analysis (GraphPad, Minitab) 
 
 
